WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, August 12, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L37	L36 AND 435/325.CCLS.	36
☐	L36	L35 AND porcine	132
☐	L35	(mesencephalon)	509
☐	L34	L33 AND mesencephalon	25
☐	L33	= 1999	2273
☐	L32	L24 AND L25	9568
☐	L31	L30 AND transplantation	52
☐	L30	= 1999	114
☐	L29	(L28) AND (1999)[PD]	0
☐	L28	L27 AND 435/325.CCLS.	1790
☐	L27	L24 AND L25 AND L26	4297
☐	L26	macrophage OR monocyte	46076
☐	L25	fetal OR embryonic	68731
☐	L24	(porcine)	22575
☐	L23	L21 AND monocyte	10
☐	L22	L21 AND monocyte	3
☐	L21	L20 AND macrophage	10
☐	L20	L19 AND ventral mesencephalon	18
☐	L19	L18 AND porcine	4019
☐	L18	435/325.CCLS.	15534
☐	L17	Holgersson.IN.	55
☐	L16	Holgersson-J.IN.	9
☐	L15	Holgersson-Jan.IN.	14
☐	L14	Rasmussen.IN.	5024
☐	L13	Rasmussen-J-Z.IN.	1
☐	L12	Rasmussen-J.IN.	89
☐	L11	Rasmussen-Jens.IN.	6
☐	L10	Rasmussen-J-Zimmer.IN.	0
☐	L9	LRasmussen-J-Zimmer.IN.	0
☐	L8	Rasmussen-Jens-Z.IN.	0
☐	L7	Rasmussen-Jens-Zimmer.IN.	0
☐	L6	Kristensen.IN.	614
☐	L5	Kristensen-T.IN.	14

h e b b cg b chh e f f ff e ch e c ch

☐	L4	Kristensen-Tom.IN.	2
☐	L3	Brevig.IN.	7
☐	L2	Brevig-T.IN.	1
☐	L1	(Brevig-Thomas.IN.)	0

END OF SEARCH HISTORY

h e b b cg b chh e f f ff e ch e c ch

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 52 of 52 returned.

☐ 1. Document ID: US 6001647 A

Using default format because multiple data bases are involved.

L31: Entry 1 of 52 File: USPT Dec 14, 1999

US-PAT-NO: 6001647
DOCUMENT-IDENTIFIER: US 6001647 A
** See image for Certificate of Correction **

TITLE: In vitro growth of functional islets of Langerhans and in vivo uses thereof

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Peck; Ammon B.	Gainesville	FL		
Cornelius; Janet G.	Gainesville	FL		

US-CL-CURRENT: 435/325; 435/383, 435/384, 435/392

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 5993799 A

L31: Entry 2 of 52 File: USPT Nov 30, 1999

US-PAT-NO: 5993799
DOCUMENT-IDENTIFIER: US 5993799 A
** See image for Certificate of Correction **

TITLE: Methods of using genetically engineered cells that produce insulin in response to glucose

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Newgard; Christopher R	Dallas	TX		

US-CL-CURRENT: 424/93.21; 435/320.1, 435/325, 435/455, 435/6

ABSTRACT:

The present disclosure relates to the application of genetic engineering to provide artificial .beta. cells, i.e. cells which can secrete insulin in response to glucose. This is achieved preferably through the introduction of one or more genes selected from the insulin gene, glucokinase gene, and glucose transporter gene, so as to

h e b b g e e e f e f ef b e

provide an engineered cell having all three of these genes in a biologically functional and responsive configuration. Assays for detecting the presence of diabetes-associated antibodies in biological samples using these and other engineered cells expressing diabetes-associated epitopes are described. Also disclosed are methods for the large-scale production of insulin by perfusing artificial .beta. cells, grown in liquid culture, with glucose-containing buffers.

36 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

3. Document ID: US 5976849 A

L31: Entry 3 of 52 File: USPT Nov 2, 1999

US-PAT-NO: 5976849
DOCUMENT-IDENTIFIER: US 5976849 A

TITLE: Human E3 ubiquitin protein ligase

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hustad; Carolyn Marziasz	Wilmington	DE		
Ghildyal; Namit	Kennett Square	PA		

US-CL-CURRENT: 435/183; 435/243, 435/254.2, 435/320.1, 435/325, 435/410, 435/455, 536/23.1, 536/23.2, 536/24.3, 536/24.31, 536/24.33

ABSTRACT:

A novel human E3 ubiquitin protein ligase is provided as well as a nucleic acid structural region which encodes the polypeptide and the amino acid residue sequence of the human biomolecule. Methods are provided to identify compounds that modulate the biological activity of the molecule and hence regulate cellular and tissue physiology.

7 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

4. Document ID: US 5962325 A

L31: Entry 4 of 52 File: USPT Oct 5, 1999

US-PAT-NO: 5962325
DOCUMENT-IDENTIFIER: US 5962325 A

TITLE: Three-dimensional stromal tissue cultures

h e b b g e e e f e f ef b e

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Naughton; Gail K.	La Jolla	CA		
Naughton; Brian A.	El Cajon	CA		

US-CL-CURRENT: 435/395; 424/529, 424/530, 424/534, 424/572, 424/574, 435/1.1, 435/325, 435/402, 435/405

ABSTRACT:

The present invention relates to a method of stimulating the proliferation and appropriate cell maturation of a variety of different cells and tissues in three-dimensional cultures in vitro using TGF-.beta. in the culture medium. In accordance with the invention, stromal cells, including, but not limited to, chondrocytes, chondrocyte-progenitors, fibroblasts, fibroblast-like cells, umbilical cord cells or bone marrow cells from umbilical cord blood are inoculated and grown on a three-dimensional framework in the presence of TGF-.beta.. Stromal cells may also include other cells found in loose connective tissue such as endothelial cells, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma, etc. The stromal cells and connective tissue proteins naturally secreted by the stromal cells attach to and substantially envelope the framework composed of a biocompatible non-living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells. The living stromal tissue so formed provides the support, growth factors, and regulatory factors necessary to sustain long-term active proliferation of cells in culture and/or cultures implanted in vivo. When grown in this three-dimensional system, the proliferating cells mature and segregate properly to form components of adult tissues analogous to counterparts in vivo.

20 Claims, 40 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 26

☐ 5. Document ID: US 5961972 A

L31: Entry 5 of 52 File: USPT Oct 5, 1999

US-PAT-NO: 5961972
DOCUMENT-IDENTIFIER: US 5961972 A
**** See image for Certificate of Correction ****

TITLE: Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Bookline	MA		

US-CL-CURRENT: 424/93.7; 435/325

ABSTRACT:

h e b b g e e e f e f ef b e

Isolated porcine pancreatic cells, isolated populations of such cells and methods for isolating and using the cells to treat subjects with diseases characterized by insufficient insulin activity are described. The porcine pancreatic cells are preferably non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject, such as a human subject. Such cells include embryonic porcine pancreatic cells obtained from embryonic pigs between about day 31 and day 35 of gestation. The porcine pancreatic cells can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof). The isolated porcine pancreatic cells of the invention can be used to treat diseases characterized by insufficient insulin activity, e.g., Type I and Type II diabetes, by administering the cells to a subject having such a disease.

15 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

6. Document ID: US 5958404 A

L31: Entry 6 of 52 File: USPT Sep 28, 1999

US-PAT-NO: 5958404
DOCUMENT-IDENTIFIER: US 5958404 A
**** See image for Certificate of Correction ****

TITLE: Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Selawry; Helena P.	Rileyville	VA		

US-CL-CURRENT: 424/93.7; 435/325, 435/373, 435/404

ABSTRACT:

A method of treating a disease is provided that results from a deficiency of a biological factor which comprises administering to a mammal Sertoli cells and cells that produce the biological factor. A method of treating diabetes mellitus is carried out by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A method of creating an immunologically privileged site and providing cell stimulatory factors in a mammal for transplants is also carried out. A method of co-localizing islet cells with Sertoli cells and the use of the co-localized product for treating diabetes mellitus is further provided. Further described is a method of creating systemic tolerance to foreign antigens. A method of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is also provided. In addition, a pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is provided.

h e b b g e e e f e f ef b e

50 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 7. Document ID: US 5945577 A

L31: Entry 7 of 52 File: USPT Aug 31, 1999

US-PAT-NO: 5945577
DOCUMENT-IDENTIFIER: US 5945577 A

TITLE: Cloning using donor nuclei from proliferating somatic cells

DATE-ISSUED: August 31, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stice; Steven L.	Belchertown	MA		
Cibelli; Jose	Amherst	MA		
Robl; James	Belchertown	MA		
Golueke; Paul	Belchertown	MA		
Ponce de Leon; F. Abel	Amherst	MA		
Jerry; D. Joseph	Shutesbury	MA		

US-CL-CURRENT: 800/24; 435/325, 800/14, 800/15, 800/16, 800/17

ABSTRACT:

An improved method of nuclear transfer involving the transplantation of donor differentiated cell nuclei into enucleated oocytes of the same species as the donor cell is provided. The resultant nuclear transfer units are useful for multiplication of genotypes and transgenic genotypes by the production of fetuses and offspring, and for production of isogenic CICM cells, including human isogenic embryonic or stem cells. Production of genetically engineered or transgenic mammalian embryos, fetuses and offspring is facilitated by the present method since the differentiated cell source of the donor nuclei can be genetically modified and clonally propagated.

24 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 8. Document ID: US 5925564 A

L31: Entry 8 of 52 File: USPT Jul 20, 1999

US-PAT-NO: 5925564
DOCUMENT-IDENTIFIER: US 5925564 A

TITLE: Expression vector systems and method of use

h e b b g e e e f e f ef b e

DATE-ISSUED: July 20, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schwartz; Robert J.	Houston	TX		
DeMayo; Franco J.	Houston	TX		
O'Malley; Bert W.	Houston	TX		

US-CL-CURRENT: 435/325; 435/320.1

ABSTRACT:

This invention relates to gene therapy by using vectors which encode stable MRNA and methods of using such vectors. In particular, this invention relates to vectors which establish controlled expression of recombinant genes within tissues at certain levels. The vector includes a 5' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a 3' flanking region including a 3' UTR and/or 3' NCR which stabilizes mRNA expressed from the nucleic acid cassette, and a linker which connects the 5' flanking region to a nucleic acid sequence. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. The 3' flanking region is 3' to the position for inserting the nucleic acid cassette. The expression vectors of the present invention can also be regulated by a regulatory system and/or constructed with a coating.

3 Claims, 30 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 30

☐ 9. Document ID: US 5919702 A

L31: Entry 9 of 52 File: USPT Jul 6, 1999

US-PAT-NO: 5919702
DOCUMENT-IDENTIFIER: US 5919702 A

TITLE: Production of cartilage tissue using cells isolated from Wharton's jelly

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Purchio; Anthony F.	La Jolla	CA		
Naughton; Brian A.	El Cajon	CA		
San Roman; Julia	San Diego	CA		

US-CL-CURRENT: 435/378; 424/93.1, 435/325, 435/366, 435/377

ABSTRACT:

The invention relates to the isolation and use of pre-chondrocytes from the umbilical cord, specifically from Wharton's jelly, that give rise to chondrocytes which produce cartilage. The isolated pre-chondrocytes, or the chondrocytes to which they give rise, can be mitotically expanded in culture and used in the production of new

h e b b g e e e f e f ef b e

cartilage tissue for therapeutic use. "Banks" of pre-chondrocytes or chondrocytes can be stored frozen, and thawed and used to produce new cartilage tissue as needed.

6 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Des

---

☐ 10. Document ID: US 5919652 A

L31: Entry 10 of 52 File: USPT Jul 6, 1999

US-PAT-NO: 5919652
DOCUMENT-IDENTIFIER: US 5919652 A

TITLE: Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pang; Shen	Van Nuys	CA		
Belldegrun; Arie S.	Los Angeles	CA		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/366, 536/24.1

ABSTRACT:

The present invention provides isolated or purified nucleic acid molecules comprising a prostate specific antigen (PSA) promoter alone or in combination with a cytomegalovirus (CMV) promoter.

13 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Des

---

☐ 11. Document ID: US 5919449 A

L31: Entry 11 of 52 File: USPT Jul 6, 1999

US-PAT-NO: 5919449
DOCUMENT-IDENTIFIER: US 5919449 A

TITLE: Porcine cardiomyocytes and their use in treatment of insufficient cardiac function

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

h e b b g e e e f e f ef b e

Dinsmore; Jonathan Brookline MA

US-CL-CURRENT: 424/93.7; 424/569, 435/325

ABSTRACT:

Porcine cardiomyocytes and methods for using the cardiomyocytes to treat disorders characterized by insufficient cardiac function are described. The porcine cardiomyocytes are preferably embryonic porcine cardiomyocytes. The porcine cardiomyocytes can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine cardiomyocytes can be modified such that an antigen (e.g., an MHC class I antigen) on the cardiomyocyte surface which is capable of stimulating an immune response against the cardiomyocytes in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cardiomyocyte when introduced into the subject. In one embodiment, the porcine cardiomyocytes are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine cardiomyocytes of the present invention can be used to treat disorders characterized by insufficient cardiac function, e.g., congestive heart failure, in a xenogeneic subject by administering the cardiomyocytes to the subject.

11 Claims, 3 Drawing figures
Exemplary Claim Number: 5
Number of Drawing Sheets: 2

☐ 12. Document ID: US 5914121 A

L31: Entry 12 of 52 File: USPT Jun 22, 1999

US-PAT-NO: 5914121
DOCUMENT-IDENTIFIER: US 5914121 A

TITLE: Formation of human bone in vivo using ceramic powder and human marrow stromal fibroblasts

DATE-ISSUED: June 22, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Robey; Pamela Gehron	Bethesda	MD		
Bianco; Paolo	Rome			IT
Kuznetsov; Sergei	Bethesda	MD		
Rowe; David	West Hartford	CT		
Krebsbach; Paul	Bethesda	MD		
Mankani; Mahesh H.	Bethesda	MD		

US-CL-CURRENT: 424/423; 424/422, 424/426, 424/489, 424/93.7, 435/325, 435/366, 435/372, 435/395

ABSTRACT:

An in vivo model for human bone metabolism. Human marrow stromal fibroblasts are isolated, expanded in culture, combined with ceramic powder (hydroxyapatite) delivery

h e b b g e e e f e f ef b e

vehicles with or without fibrin glue and implanted into a mammal. This protocol results in the formation of self-maintained human bone which supports hematopoiesis. This model system can be used to screen compounds which inhibit or stimulate bone formation. The marrow stromal fibroblast delivery vehicles can be implanted into humans to augment bone implants or to repair bone defects.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 13. Document ID: US 5902741 A

L31: Entry 13 of 52 File: USPT May 11, 1999

US-PAT-NO: 5902741
DOCUMENT-IDENTIFIER: US 5902741 A

TITLE: Three-dimensional cartilage cultures

DATE-ISSUED: May 11, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Purchio; Anthony F.	La Jolla	CA		
Zimber; Michael	La Jolla	CA		
Dunkelman; Noushin	La Jolla	CA		
Naughton; Gail K.	La Jolla	CA		
Naughton; Brian A.	El Cajon	CA		

US-CL-CURRENT: 435/325; 424/572, 424/574, 435/1.1, 435/366, 435/371, 435/395, 435/396, 435/399, 435/405, 435/406

ABSTRACT:

The present invention relates to a method of stimulating the proliferation and appropriate cell maturation of a variety of different cells and tissues in three-dimensional cultures in vitro using TGF-.beta. in the culture medium. In accordance with the invention, stromal cells, including, but not limited to, chondrocytes, chondrocyte-progenitors, fibroblasts, fibroblast-like cells, umbilical cord cells or bone marrow cells from umbilical cord blood are inoculated and grown on a three-dimensional framework in the presence of TGF-.beta.. Stromal cells may also include other cells found in loose connective tissue such as endothelial cells, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma, etc. The stromal cells and connective tissue proteins naturally secreted by the stromal cells attach to and substantially envelope the framework composed of a biocompatible non-living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells. The living stromal tissue so formed provides the support, growth factors, and regulatory factors necessary to sustain long-term active proliferation of cells in culture and/or cultures implanted in vivo. When grown in this three-dimensional system, the proliferating cells mature and segregate properly to form components of adult tissues analogous to counterparts in vivo.

36 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 26

h e b b g e e e f e f ef b e

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

☐ 14. Document ID: US 5897987 A

L31: Entry 14 of 52 File: USPT Apr 27, 1999

US-PAT-NO: 5897987
DOCUMENT-IDENTIFIER: US 5897987 A

TITLE: Use of arabinogalactan in cell cryopreservation media

DATE-ISSUED: April 27, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Oliver; Sylvia Adams	Spokane	WA		
Ellington; Joanna E.	Valleyford	WA		

US-CL-CURRENT: 435/1.3; 435/243, 435/260, 435/325, 435/404, 536/123.1

ABSTRACT:

Methods and compositions for cryopreserving somatic cells are provided. In one embodiment, a cell cryopreservation medium is provided which includes an effective amount of arabinogalactan to maintain the viability of cells upon freezing, storage and thawing. The cells may be cooled or frozen during storage to a temperature about or below 4.degree. C., for example, to about -196.degree. C. In one preferred embodiment, ultrarefined arabinogalactan is provided in the cryopreservation medium, optionally in combination with a second cryopreservation agent, such as dimethyl sulfoxide. The medium can be used for the cryopreservation of a wide variety of different cell types from different sources. For example, mammalian cells, including porcine, canine, human, equine, rodent and bovine cells can be cryopreserved in the medium. The presence of arabinogalactan in the medium protects the viability of cells in the medium during the process of freezing, storage and thawing.

22 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

☐ 15. Document ID: US 5891645 A

L31: Entry 15 of 52 File: USPT Apr 6, 1999

US-PAT-NO: 5891645
DOCUMENT-IDENTIFIER: US 5891645 A

TITLE: Porcine E-selectin

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

h e b b g e e e f e f ef b e

Rollins; Scott	Monroe	CT
Rother; Russell P.	Cheshire	CT
Matis; Louis A.	Southport	CT
Evans; Mark J.	Cheshire	CT

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 536/23.5

ABSTRACT:

A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as to prevent and treat such transplant rejection.

6 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

16. Document ID: US 5888816 A

L31: Entry 16 of 52 File: USPT Mar 30, 1999

US-PAT-NO: 5888816
DOCUMENT-IDENTIFIER: US 5888816 A

TITLE: Cell cultures of and cell culturing method for nontransformed pancreatic, thyroid, and parathyroid cells

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; Hayden G.	Gaithersburg	MD		
Ambesi-Impiombato; Francesco Saverio	Tricesimo			IT
Curcio; Francesco	Pagnacco			IT

US-CL-CURRENT: 435/366; 435/325, 435/378, 435/382, 435/383, 435/391, 435/392, 435/404, 435/408

ABSTRACT:

The present invention provides a method for producing an expanded, enriched, non-transformed human cell culture of human pancreatic, thyroid or parathyroid endocrine cells and other types of cells which comprises (1) preparing partially purified, minced tissue that includes a desired type of cells; (2) concentrating the desired cells; (3) resuspending the concentrated cells in a growth medium which selects in favor of the desired cells and in which those cells are proliferated without being transformed and differentiated functions are retained through periodic passaging; (4) culturing the resuspended cells in the growth medium to effect sustained cell division; and (5) passaging the cultured cells periodically to expand the culture. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture and procedures to form matrix-embedded aggregated and non-aggregated cells for providing pseudotissues and products such as matrix-embedded

h e b b g e e e f e f ef b e

pancreatic islets (pseudoislets). Growth medium and conditioned medium is provided for the culturing of the cells and clonal strains, the growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, serum and other ingredients, which growth medium selects in favor of desired human cells and against passenger cells including fibroblast, macrophage, and capillary endothelial cells such that the desired cells are selectively proliferated without being transformed and an expanded cell culture is provided of functionally differentiated, expanded, non-transformed human cells that is substantially free of such passenger cells.

34 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 17. Document ID: US 5885803 A

L31: Entry 17 of 52 File: USPT Mar 23, 1999

US-PAT-NO: 5885803
DOCUMENT-IDENTIFIER: US 5885803 A

TITLE: Disease associated protein kinases

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA		
Hillman; Jennifer L.	Mountain View	CA		
Corley; Neil C.	Mountain View	CA		
Guegler; Karl J.	Menlo Park	CA		
Lal; Preeti	Santa Clara	CA		
Goli; Surya K.	Sunnyvale	CA		
Shah; Purvi	Sunnyvale	CA		

US-CL-CURRENT: 435/69.1; 435/194, 435/252.3, 435/320.1, 435/325, 536/23.2

ABSTRACT:

The invention provides human disease associated protein kinases and polynucleotides (collectively designated DAPK) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human disease associated protein kinases.

9 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

h e b b g e e e f e f ef b e

☐ 18. Document ID: US 5876708 A

L31: Entry 18 of 52 File: USPT Mar 2, 1999

US-PAT-NO: 5876708
DOCUMENT-IDENTIFIER: US 5876708 A

TITLE: Allogeneic and xenogeneic transplantation

DATE-ISSUED: March 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sachs; David H.	Newton	MA		

US-CL-CURRENT: 424/93.1; 435/325

ABSTRACT:

Methods of inducing tolerance including administering to the recipient a short course of help reducing treatment or administering a short course and methods of prolonging the acceptance of a graft by administering a short course of an immunosuppressant.

79 Claims, 14 Drawing figures
Exemplary Claim Number: 1,26,51
Number of Drawing Sheets: 4

☐ 19. Document ID: US 5866119 A

L31: Entry 19 of 52 File: USPT Feb 2, 1999

US-PAT-NO: 5866119
DOCUMENT-IDENTIFIER: US 5866119 A
**** See image for Certificate of Correction ****

TITLE: Human ribonuclease

DATE-ISSUED: February 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA		
Lal; Preeti	Sunnyvale	CA		
Corley; Neil C.	Mountain View	CA		

US-CL-CURRENT: 424/94.6; 435/199, 435/252.3, 435/320.1, 435/325, 435/419, 435/6, 536/23.2

ABSTRACT:

This invention relates to nucleic acid and amino acid sequences of a new human ribonuclease and to the use of these sequences in the diagnosis, prevention and treatment of inflammation and disorders associated with cell proliferation and apoptosis.

h e b b g e e e f e f ef b e

14 Claims, 6 Drawing figures
Exemplary Claim Number: 11
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 20. Document ID: US 5853997 A

L31: Entry 20 of 52 File: USPT Dec 29, 1998

US-PAT-NO: 5853997
DOCUMENT-IDENTIFIER: US 5853997 A
**** See image for Certificate of Correction ****

TITLE: Human protein phosphatase

DATE-ISSUED: December 29, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA		
Goli; Surya K.	Sunnyvale	CA		
Lal; Preeti	Sunnyvale	CA		
Corley; Neil C.	Mountain View	CA		
Zhang; Hong	Pleasant Hills	CA		

US-CL-CURRENT: 435/6; 435/196, 435/252.3, 435/254.11, 435/320.1, 435/325, 435/410, 536/23.2

ABSTRACT:

The invention provides a human protein phosphatase (PROPHO) and polynucleotides which identify and encode PROPHO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PROPHO.

11 Claims, 11 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 21. Document ID: US 5849584 A

L31: Entry 21 of 52 File: USPT Dec 15, 1998

US-PAT-NO: 5849584
DOCUMENT-IDENTIFIER: US 5849584 A

TITLE: Cell cultures of and cells culturing method for nontransformed parotid cells

DATE-ISSUED: December 15, 1998

h e b b g e e e f e f ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; Hayden G.	Gaithersburg	MD		
Ambesi-Impiombato; Francesco Saverio	Tricesimo			IT
Curcio; Francesco	Pagnacco			IT

US-CL-CURRENT: 435/366; 435/325, 435/378, 435/382, 435/383, 435/391

ABSTRACT:

The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of parotid cells and other glandular cells such as pancreatic, thyroid, and parathyroid, and cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells. The nontransformed cells are cultured in a growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, and serum.

17 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 22. Document ID: US 5849285 A

L31: Entry 22 of 52 File: USPT Dec 15, 1998

US-PAT-NO: 5849285
DOCUMENT-IDENTIFIER: US 5849285 A
**** See image for Certificate of Correction ****

TITLE: Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Selawry; Helena P.	Memphis	TN		

US-CL-CURRENT: 424/93.7; 435/325, 435/347, 435/354

ABSTRACT:

The present invention describes a method of treating a disease that results from a deficiency of a biological factor which comprises administering to a mammal Sertoli cells and cells that produce the biological factor. In particular, the present invention describes a method of treating diabetes mellitus by transplanting

h e b b g e e e f e f ef b e

pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A method of creating an immunologically privileged site and providing cell stimulatory factors in a mammal for transplants is further described by the present invention. The present invention further describes a method of creating systemic tolerance to foreign antigens. A method of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is further provided. A pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is also provided. In addition treatment of an autoimmune disease via the transplantation of Sertoli cells alone into a transplant site other than the testes is disclosed. The dosage amount of Sertoli cells administered ranges from 10.sup.5 to 10.sup.10 cells. Also an in vitro method of accelerating the maturation and increasing the proliferation and functional capacity of proliferating mammalian cells via the co-culturing of the mammalian cells with Sertoli cells is disclosed.

7 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

☐ 23. Document ID: US 5843723 A

L31: Entry 23 of 52 File: USPT Dec 1, 1998

US-PAT-NO: 5843723
DOCUMENT-IDENTIFIER: US 5843723 A
**** See image for Certificate of Correction ****

TITLE: Alphavirus vector constructs

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubensky, Jr.; Thomas W.	Rancho Sante Fe	CA		
Polo; John M.	San Diego	CA		
Ibanez; Carlos E.	San Diego	CA		
Chang; Stephen M. W.	San Diego	CA		
Jolly; Douglas J.	Leucadia	CA		
Driver; David A.	San Diego	CA		
Belli; Barbara A.	San Diego	CA		

US-CL-CURRENT: 435/69.3; 435/235.1, 435/320.1, 435/325

ABSTRACT:

The present invention provides compositions and method,, for utilizing recombinant alphavirus vectors.

47 Claims, 37 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 30

h e b b g e e e f e f ef b e

☐ 24. Document ID: US 5843697 A

L31: Entry 24 of 52 File: USPT Dec 1, 1998

US-PAT-NO: 5843697
DOCUMENT-IDENTIFIER: US 5843697 A

TITLE: Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pestka; Sidney	North Caldwell	NJ		
Kotenko; Serguei V.	Highland Park	NJ		

US-CL-CURRENT: 435/29; 435/320.1, 435/325, 435/7.21, 536/23.5

ABSTRACT:

The present invention relates to the identification of intracellular signal transduction function for a putative cytokine receptor subunit. In particular, the invention relates to the identification of the signal transduction protein for the interleukin (IL)-10 receptor. Accordingly, the present invention relates to preparing recombinant cells that express the IL-10 receptor and the newly identified IL-10 signal transduction protein, e.g., for use in screening libraries of compounds for IL-10 agonists and antagonists; to restoring IL-10 function to cells in vivo, e.g., via gene therapy; and in addition to chimeric proteins comprising this signal transduction protein to agonize IL-10 activity. In specific examples, cells transfected with both the first chain of the IL-10R and the presently identified second chain, termed herein CRFB4, were able to transduce a signal in response to contact with IL-10.

16 Claims, 17 Drawing figures
Exemplary Claim Number: 6,11
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 25. Document ID: US 5840495 A

L31: Entry 25 of 52 File: USPT Nov 24, 1998

US-PAT-NO: 5840495
DOCUMENT-IDENTIFIER: US 5840495 A

TITLE: Methods for diagnosis of conditions associated with elevated levels of telomerase activity

DATE-ISSUED: November 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

h e b b g e e e f e f ef b e

West; Michael D.	Belmont	CA
Shay; Jerry	Dallas	TX
Wright; Woodring	Arlington	TX

US-CL-CURRENT: 435/6; 435/325, 435/375, 514/44, 536/23.1, 536/24.1, 536/24.3, 536/24.5

ABSTRACT:

Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to inhibit telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity.

27 Claims, 16 Drawing figures
Exemplary Claim Number: 7
Number of Drawing Sheets: 14

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

---

☐ 26. Document ID: US 5837507 A

L31: Entry 26 of 52 File: USPT Nov 17, 1998

US-PAT-NO: 5837507
DOCUMENT-IDENTIFIER: US 5837507 A

TITLE: Hox-induced enhancement of in vivo and in vitro proliferative capacity and gene therapeutic methods

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Largman; Corey	Berkley	CA		
Lawrence; Hugh Jeffrey	Lafayette	CA		
Humphries; R. Keith	Vancouver			CA
Sauvageau; Guy	Montreal, P.O.			CA

US-CL-CURRENT: 424/93.21; 435/325, 435/372, 435/456, 435/458

ABSTRACT:

Stem cells transduced with HOXB4 exhibit enhanced in vitro and in vivo ability for self-regeneration and generate higher-numbers of tranplantable pluripotent hematopoietic stem cells relative to control and nonmanipulated cells.

18 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

h e b b g e e e f e f ef b e

27. Document ID: US 5837236 A

L31: Entry 27 of 52 File: USPT Nov 17, 1998

US-PAT-NO: 5837236
DOCUMENT-IDENTIFIER: US 5837236 A

TITLE: Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 424/93.7; 435/325

ABSTRACT:

Isolated porcine pancreatic cells, isolated populations of such cells and methods for isolating and using the cells to treat subjects with diseases characterized by insufficient insulin activity are described. The porcine pancreatic cells are preferably non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject, such as a human subject. Such cells include embryonic porcine pancreatic cells obtained from embryonic pigs between about day 31 and day 35 of gestation. The porcine pancreatic cells can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof). The isolated porcine pancreatic cells of the invention can be used to treat diseases characterized by insufficient insulin activity, e.g., Type I and Type II diabetes, by administering the cells to a subject having such a disease.

35 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

28. Document ID: US 5834308 A

L31: Entry 28 of 52 File: USPT Nov 10, 1998

US-PAT-NO: 5834308
DOCUMENT-IDENTIFIER: US 5834308 A

TITLE: In vitro growth of functional islets of Langerhans

DATE-ISSUED: November 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

h e b b g e e e f e f ef b e

Peck; Ammon B.	Gainesville	FL
Cornelius; Janet G.	Gainesville	FL

US-CL-CURRENT: 435/325; 435/354, 435/366, 435/371, 435/41, 435/70.1, 435/70.3

ABSTRACT:

The subject invention concerns new methods which make it possible, for the first time, to grow functional islet cells in in vitro cultures. The ability to grow these cells opens up important new avenues for research and therapy relating to diabetes.

10 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

29. Document ID: US 5830705 A

L31: Entry 29 of 52 File: USPT Nov 3, 1998

US-PAT-NO: 5830705
DOCUMENT-IDENTIFIER: US 5830705 A
**** See image for Certificate of Correction ****

TITLE: Method for recombinant production of human pluripotent granulocyte colony-stimulating factor

DATE-ISSUED: November 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Souza; Lawrence M.	Witherspoon	CA		

US-CL-CURRENT: 435/69.5; 435/325, 435/363, 435/365.1, 536/23.5, 536/24.1

ABSTRACT:

Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.

4 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

h e b b g e e e f e f ef b e

☐ 30. Document ID: US 5824509 A

L31: Entry 30 of 52 File: USPT Oct 20, 1998

US-PAT-NO: 5824509
DOCUMENT-IDENTIFIER: US 5824509 A

TITLE: Recombinant lymphotoxin cDNA and variants

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aggarwal; Bharat B.	San Mateo	CA		
Gray; Patrick W.	San Francisco	CA		
Nedwin; Glenn E.	Guilford	CT		

US-CL-CURRENT: 435/69.5; 435/252.3, 435/252.33, 435/254.11, 435/320.1, 435/325, 530/351, 536/23.5

ABSTRACT:

Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10.times.10.sup.7 units/mg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.

20 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 31. Document ID: US 5821108 A

L31: Entry 31 of 52 File: USPT Oct 13, 1998

US-PAT-NO: 5821108
DOCUMENT-IDENTIFIER: US 5821108 A

TITLE: Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker

DATE-ISSUED: October 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Akashi; Koichi	Palo Alto	CA		
Weissman; Irving	Redwood City	CA		

h e b b g e e e f e f ef b e

US-CL-CURRENT: 435/372.3; 424/140.1, 424/143.1, 424/154.1, 424/93.71, 435/325, 435/355, 435/372, 435/7.24, 530/388.75

ABSTRACT:

A subpopulation in the CD4.sup.+ 8.sup.+ (DP) thymic blast population is identified that is the precursor for thymic T cells. All such progenitors are c-kit.sup.+. The c-kit.sup.+ subset expresses lower levels of CD4 and CD8 than the large and small DP c-kit- cells. These DP.sup.int c-kit.sup.+ cells differentiate to thymic T cells rapidly on heterogenous thymic stromal cell cultures. Similar maturation takes place in vivo over 4 days. A method for isolating the cells which are c-kit.sup.+ and which express intermediate or low levels of CD4+/CD8+ is also disclosed.

8 Claims, 11 Drawing figures
Exemplary Claim Number: 2
Number of Drawing Sheets: 9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

☐ 32. Document ID: US 5811517 A

L31: Entry 32 of 52 File: USPT Sep 22, 1998

US-PAT-NO: 5811517
DOCUMENT-IDENTIFIER: US 5811517 A
**** See image for Certificate of Correction ****

TITLE: ICAM-related protein variants

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gallatin; W. Michael	Seattle	WA		
Vazeux; Rosemay	Seattle	WA		

US-CL-CURRENT: 530/350; 435/252.3, 435/320.1, 435/325, 435/69.1, 435/69.7, 536/23.1, 536/23.4

ABSTRACT:

DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.

8 Claims, 39 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 34

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

h e b b g e e e f e f ef b e

33. Document ID: US 5795570 A

L31: Entry 33 of 52 File: USPT Aug 18, 1998

US-PAT-NO: 5795570
DOCUMENT-IDENTIFIER: US 5795570 A

TITLE: Method of containing core material in microcapsules

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weber; Collin J.	Atlanta	GA		
Ayres-Price; Jennifer	Mooresville	NC		

US-CL-CURRENT: 424/93.7; 264/4, 264/4.3, 264/4.32, 424/424, 424/572, 428/402.2, 428/402.24, 435/178, 435/182, 435/325, 435/363, 435/366, 435/382

ABSTRACT:

A core material such as animal tissue or cells is contained within a semipermeable vessel which may be a microcapsule, hollow fiber or plastic membrane having a semipermeable wall by a method that prevents the core material from incorporation into the wall of the vessel. This is accomplished by suspending the core material in a solution of polysaccharide gum such as an alkali metal alginate in an amount between about 0.2% and about 0.5%, removing and washing the core material to remove all but a thin layer of polysaccharide gum, and gelling the polysaccharide gum with multivalent cations or other means to form a pretreated core material. The pretreated core material is contained within a semipermeable vessel such as by suspending the pretreated core material in a solution of alkali metal alginate, forming the suspension into droplets, gelling the droplets to form temporary shape-retaining capsules and treating the capsules with a polymeric material having groups that react with and crosslink acid groups of the capsules to form a permanent semipermeable membrane around the capsules. A second permanent semipermeable membrane may be formed around the capsules to form double-walled microcapsules by further treating the capsules with the polymeric material. The semipermeable vessel may be impermeable to immune factors. Cells or tissue can be transplanted from a donor to a subject such as by using pancreatic islet tissue or cells as the core material of the double-walled microcapsules and transplanting the microcapsules by intraperitoneal injection into a diabetic subject.

25 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

34. Document ID: US 5792656 A

L31: Entry 34 of 52 File: USPT Aug 11, 1998

US-PAT-NO: 5792656
DOCUMENT-IDENTIFIER: US 5792656 A

TITLE: Methods of preparing genetically engineered cells that produce insulin in response to glucose

h e b b g ee e f e f ef b e

DATE-ISSUED: August 11, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Newgard; Christopher B.	Dallas	TX		

US-CL-CURRENT: 435/325; 435/382, 435/395, 435/6

ABSTRACT:

The present disclosure relates to the application of genetic engineering to provide artificial .beta. cells, i.e. cells which can secrete insulin in response to glucose. This is achieved preferably through the introduction of one or more genes selected from the insulin gene, glucokinase gene, and glucose transporter gene, so as to provide an engineered cell having all three of these genes in a biologically functional and responsive configuration. Assays for detecting the presence of diabetes-associated antibodies in biological samples using these and other engineered cells expressing diabetes-associated epitopes are described. Also disclosed are methods for the large-scale production of insulin by perfusing artificial .beta. cells, grown in liquid culture, with glucose-containing buffers.

50 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 35. Document ID: US 5789245 A

L31: Entry 35 of 52 File: USPT Aug 4, 1998

US-PAT-NO: 5789245
DOCUMENT-IDENTIFIER: US 5789245 A

TITLE: Alphavirus structural protein expression cassettes

DATE-ISSUED: August 4, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubensky, Jr.; Thomas W.	Rancho Sante Fe	CA		
Polo; John M.	San Diego	CA		
Ibanez; Carlos E.	San Diego	CA		
Chang; Stephen M. W.	San Diego	CA		
Jolly; Douglas J.	Leucadia	CA		
Driver; David A.	San Diego	CA		

US-CL-CURRENT: 435/320.1; 435/325, 435/69.1, 536/23.72

ABSTRACT:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

h e b b g e e e f e f ef b e

29 Claims, 35 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 30

☐ 36. Document ID: US 5780299 A

L31: Entry 36 of 52 File: USPT Jul 14, 1998

US-PAT-NO: 5780299
DOCUMENT-IDENTIFIER: US 5780299 A

TITLE: Method of altering blood sugar levels using non-transformed human pancreatic cells that have been expanded in culture

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; Hayden G.	Gaithersburg	MD		
Ambesi-Impiombato; Francesco Saverio	Tricesimo			IT
Curcio; Francesco	Pagnacco			IT

US-CL-CURRENT: 435/366; 435/325, 435/382, 435/383, 435/391

ABSTRACT:

The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

14 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 37. Document ID: US 5756349 A

L31: Entry 37 of 52 File: USPT May 26, 1998

US-PAT-NO: 5756349
DOCUMENT-IDENTIFIER: US 5756349 A
** See image for Certificate of Correction **

h e b b g e e e f e f ef b e

TITLE: Production of erythropoietin

DATE-ISSUED: May 26, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lin; Fu-Kuen	Thousand Oaks	CA		

US-CL-CURRENT: 435/325; 435/358, 435/365

ABSTRACT:

Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin ("EPO") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Illustratively, genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g., the immunological properties and in vitro and in vivo biological activities of EPO of human or monkey species origins. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of EPO. Also disclosed are improved methods for the detection of specific single stranded polynucleotides in a heterologous cellular or viral sample prepared from, e.g., DNA present in a plasmid or viralborne cDNA or genomic DNA "library".

7 Claims, 27 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 27

☐ 38. Document ID: US 5756264 A

L31: Entry 38 of 52 File: USPT May 26, 1998

US-PAT-NO: 5756264
DOCUMENT-IDENTIFIER: US 5756264 A
**** See image for Certificate of Correction ****

TITLE: Expression vector systems and method of use

DATE-ISSUED: May 26, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schwartz; Robert J.	Houston	TX		
DeMayo; Franco J.	Houston	TX		
O'Malley; Bert W.	Houston	TX		

US-CL-CURRENT: 424/93.2; 424/93.21, 435/252.3, 435/320.1, 435/325, 435/349, 435/455, 435/465, 435/6, 514/44, 536/24.1

h e b b g e e e f e f ef b e

ABSTRACT:

This invention relates to gene therapy by using vectors which encode stable MRNA and methods of using such vectors. In particular, this invention relates to vectors which establish controlled expression of recombinant genes within tissues at certain levels. The vector includes a 5' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a 3' flanking region including a 3' UTR and/or 3' NCR which stabilizes mRNA expressed from the nucleic acid cassette, and a linker which connects the 5' flanking region to a nucleic acid sequence. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. The 3' flanking region is 3' to the position for inserting the nucleic acid cassette. The expression vectors of the present invention can also be regulated by a regulatory system and/or constructed with a coating.

26 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

☐ 39. Document ID: US 5747325 A

L31: Entry 39 of 52 File: USPT May 5, 1998

US-PAT-NO: 5747325
DOCUMENT-IDENTIFIER: US 5747325 A

TITLE: Devices comprising genetically engineered .beta.cells

DATE-ISSUED: May 5, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Newgard; Christopher B.	Dallas	TX		

US-CL-CURRENT: 435/325; 424/425, 424/520, 435/372.2, 435/6, 435/69.1, 530/303, 530/350, 530/397, 604/891.1

ABSTRACT:

The present disclosure relates to the application of genetic engineering to provide artificial .beta. cells, i.e. cells which can secrete insulin in response to glucose. This is achieved preferably through the introduction of one or more genes selected from the insulin gene, glucokinase gene, and glucose transporter gene, so as to provide an engineered cell having all three of these genes in a biologically functional and responsive configuration. Assays for detecting the presence of diabetes-associated antibodies in biological samples using these and other engineered cells expressing diabetes-associated epitopes are described. Also disclosed are methods for the large-scale production of insulin by perfusing artificial .beta. cells, grown in liquid culture, with glucose-containing buffers.

29 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

h e b b g e e e f e f ef b e

☐ 40. Document ID: US 5733336 A

L31: Entry 40 of 52 File: USPT Mar 31, 1998

US-PAT-NO: 5733336
DOCUMENT-IDENTIFIER: US 5733336 A

TITLE: Ported tissue implant systems and methods of using same

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Neuenfeldt; Steven	Vernon Hills	IL		
Brauker; James	Lake Ville	IL		
Clarke; Robert	Libertyville	IL		

US-CL-CURRENT: 435/325; 128/898

ABSTRACT:

A method and apparatus for implanting cells in a host is provided. In an embodiment, an implant assembly for a host tissue is provided comprising wall means defining a chamber for holding cells for implantation, the wall means including means for forming a porous boundary between the host tissue and the implanted cells in the chamber, the pore size of the boundary being sufficient to isolate the implanted cells from the immune response of the host tissue, and port means for providing selective access to the chamber.

16 Claims, 34 Drawing figures
Exemplary Claim Number: 1,15
Number of Drawing Sheets: 10

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 41. Document ID: US 5679340 A

L31: Entry 41 of 52 File: USPT Oct 21, 1997

US-PAT-NO: 5679340
DOCUMENT-IDENTIFIER: US 5679340 A

TITLE: Cells with multiple altered epitopes on a surface antigen for use in transplantation

DATE-ISSUED: October 21, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chappel; Scott C.	Milton	MA		

US-CL-CURRENT: 424/93.1; 435/325, 435/366, 435/368, 435/370, 435/371, 435/372

h e b b g ee e f e f ef b e

ABSTRACT:

Cells suitable for transplantation which have at least two different epitopes on a surface antigen altered prior to transplantation to inhibit rejection of the cells following transplantation into an allogeneic or xenogeneic recipient are disclosed. These cells are more successfully transplanted than cells which have only a single epitope on the surface antigen altered. Preferably, the antigen on the cell surface which is altered is an MHC class I antigen. Two different epitopes on an MHC class I antigen can be altered by contacting the cell with two molecules, such as antibodies or fragments thereof (e.g., F(ab').sub.2 fragments), which bind to two different epitopes on the antigen. Preferred epitopes on human MHC class I antigens to be altered are epitopes recognized by the monoclonal antibodies W6/32 and PT85. Improved methods for transplantation utilizing cells which have at least two different epitopes on a surface antigen altered prior to transplantation are also disclosed.

28 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 42. Document ID: US 5677174 A

L31: Entry 42 of 52 File: USPT Oct 14, 1997

US-PAT-NO: 5677174
DOCUMENT-IDENTIFIER: US 5677174 A

TITLE: Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity

DATE-ISSUED: October 14, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 435/325

ABSTRACT:

Isolated porcine pancreatic cells, isolated populations of such cells and methods for isolating and using the cells to treat subjects with diseases characterized by insufficient insulin activity are described. The porcine pancreatic cells are preferably non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject, such as a human subject. Such cells include embryonic porcine pancreatic cells obtained from embryonic pigs between about day 31 and day 35 of gestation. The porcine pancreatic cells can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof). The isolated porcine pancreatic cells of the invention can be used to treat diseases characterized by insufficient insulin activity, e.g., Type I and Type II diabetes, by administering the cells to a subject having such a disease.

50 Claims, 4 Drawing figures

h e b b g ee e f e f ef b e

Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Desc

☐ 43. Document ID: US 5658780 A

L31: Entry 43 of 52 File: USPT Aug 19, 1997

US-PAT-NO: 5658780
DOCUMENT-IDENTIFIER: US 5658780 A

TITLE: Rel a targeted ribozymes

DATE-ISSUED: August 19, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stinchcomb; Dan T.	Boulder	CO		
Draper; Kenneth G.	Boulder	CO		
McSwiggen; James	Boulder	CO		

US-CL-CURRENT: 435/366; 435/320.1, 435/325, 435/6, 435/91.31, 514/44, 536/23.1, 536/23.2, 536/24.5

ABSTRACT:

Enzymatic RNA molecules which cleave rel A mRNA.

13 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Desc

☐ 44. Document ID: US 5646042 A

L31: Entry 44 of 52 File: USPT Jul 8, 1997

US-PAT-NO: 5646042
DOCUMENT-IDENTIFIER: US 5646042 A
** See image for Certificate of Correction **

TITLE: C-myb targeted ribozymes

DATE-ISSUED: July 8, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stinchcomb; Dan T.	Boulder	CO		
Draper; Kenneth	Boulder	CO		
McSwiggen; James	Boulder	CO		

h e b b g e e e f e f ef b e

Jarvis; Thale Boulder CO

US-CL-CURRENT: 435/366; 435/320.1, 435/325, 435/353, 435/6, 435/91.31, 514/44, 536/23.1, 536/23.2, 536/24.5

ABSTRACT:

Enzymatic nucleic acid molecules which cleave c-myb RNA or other RNAs associated with restenosis or cancer.

220 Claims, 29 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Des

☐ 45. Document ID: US 5641670 A

L31: Entry 45 of 52 File: USPT Jun 24, 1997

US-PAT-NO: 5641670
DOCUMENT-IDENTIFIER: US 5641670 A
**** See image for Certificate of Correction ****

TITLE: Protein production and protein delivery

DATE-ISSUED: June 24, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Treco; Douglas A.	Arlington	MA		
Heartlein; Michael W.	Boxborough	MA		
Selden; Richard F.	Wellesley	MA		

US-CL-CURRENT: 435/325; 435/254.11, 435/320.1, 435/326, 435/366, 435/367, 435/371, 435/372, 435/372.2, 435/372.3, 435/419

ABSTRACT:

The invention relates to constructs comprising: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) an unpaired splice-donor site. The invention further relates to a method of producing protein in vitro or in vivo comprising the homologous recombination of a construct as described above within a cell. The homologously recombinant cell is then maintained under conditions which will permit transcription and translation, resulting in protein expression. The present invention further relates to homologously recombinant cells, including primary, secondary, or immortalized vertebrate cells, methods of making the cells, methods of homologous recombination to produce fusion genes, methods of altering gene expression in the cells, and methods of making a protein in a cell employing the constructs of the invention.

30 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

h e b b g e e e f e f ef b e

☐ 46. Document ID: US 5629194 A

L31: Entry 46 of 52 File: USPT May 13, 1997

US-PAT-NO: 5629194
DOCUMENT-IDENTIFIER: US 5629194 A

TITLE: Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity

DATE-ISSUED: May 13, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 435/325; 424/152.1, 436/548

ABSTRACT:

Isolated porcine pancreatic cells, isolated populations of such cells and methods for isolating and using the cells to treat subjects with diseases characterized by insufficient insulin activity are described. The porcine pancreatic cells are preferably non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject, such as a human subject. Such cells include embryonic porcine pancreatic cells obtained from embryonic pigs between about day 31 and day 35 of gestation. The porcine pancreatic cells can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof). The isolated porcine pancreatic cells of the invention can be used to treat diseases characterized by insufficient insulin activity, e.g., Type I and Type II diabetes, by administering the cells to a subject having such a disease.

14 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 47. Document ID: US 5624823 A

L31: Entry 47 of 52 File: USPT Apr 29, 1997

US-PAT-NO: 5624823
DOCUMENT-IDENTIFIER: US 5624823 A

TITLE: DNA encoding procine interleukin-10

DATE-ISSUED: April 29, 1997

h e b b g e e e f e f ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sachs; David H.	Newton	MA		
Leguern; Christian A.	Newton	MA		
Sykes; Megan	Charlestown	MA		
Blancho; Gilles JF.	Cambridge	MA		

US-CL-CURRENT: 435/69.52; 435/252.3, 435/320.1, 435/325, 435/365.1, 536/23.5

ABSTRACT:

Purified DNA encoding porcine IL-10, porcine IL-10, and methods of inducing immunological tolerance and inhibiting graft versus host disease.

27 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

48. Document ID: US 5618698 A

L31: Entry 48 of 52 File: USPT Apr 8, 1997

US-PAT-NO: 5618698
DOCUMENT-IDENTIFIER: US 5618698 A
**** See image for Certificate of Correction ****

TITLE: Production of erythropoietin

DATE-ISSUED: April 8, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lin; Fu-Kuen	Thousand Oaks	CA		

US-CL-CURRENT: 435/69.4; 435/325, 435/69.6, 536/23.51

ABSTRACT:

Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin ("EPO") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Illustratively, genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g., the immunological properties end in vitro and in vivo biological activities of EPO of human or monkey species origins. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of EPO. Also disclosed are improved methods for the detection of specific single stranded polynucleotides in a heterologous cellular or viral sample prepared from, e.g., DNA present in a plasmid or viral-borne cDNA or genomic DNA "library".

h e b b g e e e f e f ef b e

9 Claims, 21 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 27

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 49. Document ID: US 5593673 A

L31: Entry 49 of 52 File: USPT Jan 14, 1997

US-PAT-NO: 5593673
DOCUMENT-IDENTIFIER: US 5593673 A

TITLE: Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity

DATE-ISSUED: January 14, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 424/93.7; 435/325, 514/866

ABSTRACT:

Isolated porcine pancreatic cells, isolated populations of such cells and methods for isolating and using the cells to treat subjects with diseases characterized by insufficient insulin activity are described. The porcine pancreatic cells are preferably non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject, such as a human subject. Such cells include embryonic porcine pancreatic cells obtained from embryonic pigs between about day 31 and day 35 of gestation. The porcine pancreatic cells can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof). The isolated porcine pancreatic cells of the invention can be used to treat diseases characterized by insufficient insulin activity, e.g., Type I and Type II diabetes, by administering the cells to a subject having such a disease.

23 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 50. Document ID: US 5547856 A

L31: Entry 50 of 52 File: USPT Aug 20, 1996

US-PAT-NO: 5547856
DOCUMENT-IDENTIFIER: US 5547856 A

h e b b g e e e f e f ef b e

TITLE: Hepatocyte growth factor variants

DATE-ISSUED: August 20, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Godowski; Paul J.	Burlingame	CA		
Lokker; Natalie A.	San Francisco	CA		
Mark; Melanie R.	Burlingame	CA		

US-CL-CURRENT: 435/69.4; 435/320.1, 435/325, 530/399, 536/23.51

ABSTRACT:

The invention concerns hepatocyte growth factor (HGF) amino acid sequence variants. The preferred variants are resistant to proteolytic cleavage by enzymes capable of in vivo conversion of HGF into its two-chain form and/or contain a mutation within the protease domain of HGF.

20 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

☐ 51. Document ID: US 5545223 A

L31: Entry 51 of 52 File: USPT Aug 13, 1996

US-PAT-NO: 5545223
DOCUMENT-IDENTIFIER: US 5545223 A

TITLE: Ported tissue implant systems and methods of using same

DATE-ISSUED: August 13, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Neuenfeldt; Steven	Vernon Hills	IL		
Brauker; James	Lake Ville	IL		
Clarke; Robert	Libertyville	IL		

US-CL-CURRENT: 435/325; 424/422, 424/424, 623/902

ABSTRACT:

A method and apparatus for implanting cells in a host is provided. In an embodiment, an implant assembly for a host tissue is provided comprising wall means defining a chamber for holding cells for implantation, the wall means including means for foxing a porous boundary between the host tissue and the implanted cells in the chamber, the pore size of the boundary being sufficient to isolate the implanted cells from the immune response of the host tissue, and port means for providing selective access to the chamber.

9 Claims, 34 Drawing figures

h e b b g e e e f e f ef b e

Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

☐ 52. Document ID: US 5256560 A

L31: Entry 52 of 52 File: USPT Oct 26, 1993

US-PAT-NO: 5256560
DOCUMENT-IDENTIFIER: US 5256560 A

TITLE: Primitive cell colony stimulating factors and lymphohematopoietic progenitor cells

DATE-ISSUED: October 26, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lawman; Michael J. P.	Gainsville	FL		
Ohmann; Helle B.	Saskatchewan			CA
Attah-Poku; Samuel K.	Saskatchewan			CA
Heise-Qualtiere; Janette	Saskatchewan			CA

US-CL-CURRENT: 435/325; 435/372

ABSTRACT:

The invention derives from the discovery of cells, non-adherent (NA) cells, which have properties indicating that they may be pluripotent lymphohematopoietic progenitor cells. These cells, and the stromal cells derived from bone marrow cultures, produce factors which stimulate the growth of primitive cell colonies, as reflected in their stimulation of the growth of colonies of NA cells. These primitive cell colony stimulating factors (PC-CSFs) may be useful in the treatment of disorders which can be alleviated by the proliferation of desired cells. In addition, the NA cells and/or PC-CSF(s) may provide an alternative and/or supplementary method to bone marrow transplantation to alleviate hematopoietic disorders.

8 Claims, 9 Drawing figures
Exemplary Claim Number: 1,2
Number of Drawing Sheets: 9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L30 AND transplantation	52

Display Format: - Change Format

h e b b g e e e f e f ef b e

Previous Page Next Page Go to Doc#

h e b b g e e e f e f ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 25 of 25 returned.

☐ 1. Document ID: US 6004924 A

Using default format because multiple data bases are involved.

L34: Entry 1 of 25 File: USPT Dec 21, 1999

US-PAT-NO: 6004924
DOCUMENT-IDENTIFIER: US 6004924 A

TITLE: Protein sequences of serrate gene products

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ish-Horowicz; David	Oxford			GB
Henrique; Domingos Manuel Pinto	Oxford			GB
Lewis; Julian Hart	Oxford			GB
Myat; Anna Mary	Oxford			GB
Fleming; Robert J.	Rochester	NY		
Artavanis-Tsakonas; Spyridon	Hamden	CT		
Mann; Robert S.	Hamden	CT		
Gray; Grace E.	New Haven	CT		

US-CL-CURRENT: 514/2; 514/13, 514/15, 530/300, 530/326, 530/328, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 5989920 A

L34: Entry 2 of 25 File: USPT Nov 23, 1999

US-PAT-NO: 5989920
DOCUMENT-IDENTIFIER: US 5989920 A

TITLE: Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gerald; Christophe P. G.	Ridgewood	NJ		
Weinshank; Richard L.	Teaneck	NJ		
Walker; Mary W.	Elmwood Park	NJ		
Branchek; Theresa	Teaneck	NJ		

h e b b g e e e f e f ef b e

US-CL-CURRENT: 436/501; 435/7.2, 435/7.21, 436/503

ABSTRACT:

This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.

15 Claims, 47 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 42

3. Document ID: US 5989834 A

L34: Entry 3 of 25 File: USPT Nov 23, 1999

US-PAT-NO: 5989834
DOCUMENT-IDENTIFIER: US 5989834 A
**** See image for Certificate of Correction ****

TITLE: Uses of nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors nucleic acid encoding

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gerald; Christophe	Ridgewood	NJ		
Walker; Mary W.	Elmwood Park	NJ		
Branchek; Theresa	Teaneck	NJ		
Weinshank; Richard L.	Teaneck	NJ		

US-CL-CURRENT: 435/7.2; 435/7.1, 435/7.21

ABSTRACT:

This invention provides isolated nucleic acid molecules encoding a human and a rat Y2 receptor, an isolated protein which is a human or rat Y2 receptor, vectors comprising an isolated nucleic acid molecule encoding a human or rat Y2 receptors, mammalian cells comprising such vectors, antibodies directed to the human or rat Y2 receptor, nucleic acid probes useful for detecting nucleic acid encoding human or rat Y2 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human or rat Y2 receptor, pharmaceutical compounds related to human or rat Y2 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human or rat Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human or rat Y2 receptor.

h e b b g e e e f e f ef b e

14 Claims, 48 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 35

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 4. Document ID: US 5968819 A

L34: Entry 4 of 25 File: USPT Oct 19, 1999

US-PAT-NO: 5968819
DOCUMENT-IDENTIFIER: US 5968819 A

TITLE: DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gerald; Christophe P. G.	Ridgewood	NJ		
Weinshank; Richard L.	Teaneck	NJ		
Walker; Mary W.	Elmwood Park	NJ		
Branchek; Theresa	Teaneck	NJ		

US-CL-CURRENT: 435/325; 435/320.1, 536/23.5

ABSTRACT:

This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

22 Claims, 45 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 40

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 5. Document ID: US 5942437 A

L34: Entry 5 of 25 File: USPT Aug 24, 1999

US-PAT-NO: 5942437
DOCUMENT-IDENTIFIER: US 5942437 A

TITLE: Method and media for enhancing viability maturation, and cryopreservation of

h e b b g e e e f e f ef b e

cells

DATE-ISSUED: August 24, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sanberg; Paul R.	Spring Hill	FL		
Othberg; Agneta	Tampa	FL		
Cameron; Don F.	Lutz	FL		
Saporta; Samuel	Tampa	FL		
Borlongan; Cesario V.	Silver Springs	MD		

US-CL-CURRENT: 435/374; 424/93.7, 435/1.3, 435/325, 435/347

ABSTRACT:

A method to increase viability, number, survival and maturation of cells for transplantation or cryopreservation by culturing the cells with Sertoli cells or with sertoli-cell conditioned media (SCM) prior to transplantation (pre-culturing) or cryopreservation.

5 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

6. Document ID: US 5912005 A

L34: Entry 6 of 25 File: USPT Jun 15, 1999

US-PAT-NO: 5912005
DOCUMENT-IDENTIFIER: US 5912005 A

TITLE: Methods of use of uncoated gel particles

DATE-ISSUED: June 15, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lanza; Robert P.	Natick	MA		
Kuhtreiber; Willem M.	Shrewsbury	MA		
Chick; William L.	Wellesley	MA		

US-CL-CURRENT: 424/424; 424/422, 424/423, 435/174, 435/177, 435/243, 435/382, 514/866, 514/885, 514/907, 514/953

ABSTRACT:

The invention covers a method of implanting a living donor cell into a host animal without inflammatory response or rejection of the donor cell by the host animal, by obtaining an uncoated particle of a biocompatible, temperature-independent gel that encapsulates the living donor cell, wherein the uncoated particle provides a molecular weight cutoff that prevents host animal immune cells from entering the particle, yet does not have to prevent entry of host animal IgG and complement into

h e b b g e e e f e f ef b e

the particle, and implanting the uncoated particle into the host animal.

64 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 7. Document ID: US 5911704 A

L34: Entry 7 of 25 File: USPT Jun 15, 1999

US-PAT-NO: 5911704
DOCUMENT-IDENTIFIER: US 5911704 A
**** See image for Certificate of Correction ****

TITLE: Implantable device and uses therefor

DATE-ISSUED: June 15, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Humes; H. David	Ann Arbor	MI		

US-CL-CURRENT: 604/93.01; 604/891.1

ABSTRACT:

Disclosed is an implantable device for delivering a pre-selected molecule, for example, a hormone, into a mammal's systemic circulation. The device comprises a blood permeable element that can be anchored to an inner wall of an intact blood vessel. The device also comprises a capsule that is held in place within the blood vessel by the anchored blood permeable element. The capsule encloses viable cells which produce and secrete the preselected molecule into blood passing the capsule. The invention also provides a minimally invasive method for percutaneously introducing into a preselected blood vessel the device of the invention.

47 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 8. Document ID: US 5891477 A

L34: Entry 8 of 25 File: USPT Apr 6, 1999

US-PAT-NO: 5891477
DOCUMENT-IDENTIFIER: US 5891477 A

TITLE: Non-steroidal anti-inflammatory agents inhibition of fibrotic response to an implanted device

DATE-ISSUED: April 6, 1999

h e b b g e e e f e f ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lanza; Robert P.	Clinton	MA		
Chick; William L.	Wellesley	MA		

US-CL-CURRENT: 424/501; 424/426, 424/502, 435/180, 435/182

ABSTRACT:

Methods for inhibition of fibrotic rejection of implanted devices which contain cells by administering to the recipient of the devices an amount of a non-steroidal anti-inflammatory agent (NSAID) sufficient to inhibit fibrotic inactivation of the device. Most NSAID's are carboxylic acids (R--COOH) or enolic acids (R--COH).

30 Claims, 0 Drawing figures
Exemplary Claim Number: 1

9. Document ID: US 5880260 A

L34: Entry 9 of 25 File: USPT Mar 9, 1999

US-PAT-NO: 5880260
DOCUMENT-IDENTIFIER: US 5880260 A

TITLE: Dopamine receptors and genes

DATE-ISSUED: March 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Civelli; Olivier	Portland	OR		
Bunzow; James R.	Portland	OR		
Grandy; David K.	Portland	OR		
Machida; Curtis A.	Portland	OR		

US-CL-CURRENT: 530/350; 435/69.1, 536/23.5

ABSTRACT:

A mammalian D.sub.2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.

8 Claims, 59 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 47

h e b b g e e e f e f ef b e

☐ 10. Document ID: US 5877399 A

L34: Entry 10 of 25 File: USPT Mar 2, 1999

US-PAT-NO: 5877399
DOCUMENT-IDENTIFIER: US 5877399 A

TITLE: Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease

DATE-ISSUED: March 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hsiao; Karen	North Oaks	MN		
Borchelt; David R.	Baltimore	MD		
Sisodia; Sangram S.	Baltimore	MD		

US-CL-CURRENT: 800/3; 424/9.2, 800/12, 800/9

ABSTRACT:

Provided is a transgenic non-human eukaryotic animal whose germ cells and somatic cells contain the amyloid precursor protein sequence introduced into the animal, or an ancestor of the animal, at an embryonic stage. In mice, an age-related CNS disorder characterized by agitation, neophobia, seizures, inactivity, diminished cerebral glucose utilization, cortico-limbic gliosis, and death, develops. An acceleration of this disorder occurs in transgenic mice expressing human and mouse Alzheimer amyloid precursor proteins (APP) produced using a hamster prion protein gene-derived cosmid vector that confers position-independent, copy number-dependent expression. In transgenic mice the disorder develops in direct relationship to brain levels of transgenic APP, but mutant APP confers the phenotype at lower levels of expression than wild-type APP. The disorder occurs in the absence of extracellular amyloid deposition, indicating that some pathogenic activities of APP are dissociated from amyloid formation.

13 Claims, 41 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 11. Document ID: US 5869282 A

L34: Entry 11 of 25 File: USPT Feb 9, 1999

US-PAT-NO: 5869282
DOCUMENT-IDENTIFIER: US 5869282 A
**** See image for Certificate of Correction ****

TITLE: Nucleotide and protein sequences of the serrate gene and methods based thereon

DATE-ISSUED: February 9, 1999

h e b b g e e e f e f ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ish-Horowicz; David	Oxford			GB2
Henrique; Domingos Manuel Pinto	Oxford			GB2
Lewis; Julian Hart	Oxford			GB2
Myat; Anna Mary	Oxford			GB2
Fleming; Robert J.	Rochester	NY		
Artavanis-Tsakonas; Spyridon	Hamden	CT		
Mann; Robert S.	Hamden	CT		
Gray; Grace E.	New Haven	CT		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 530/300, 530/350, 536/23.1, 536/24.3

ABSTRACT:

The present invention relates to nucleotide sequences of Serrate genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the Serrate protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Serrate which comprise one or more domains of the Serrate protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, cysteine rich domain, transmembrane region, membrane-associated region, or one or more EGF-like repeats of a Serrate protein, or any combination of the foregoing. Antibodies to Serrate, its derivatives and analogs, are additionally provided. Methods of production of the Serrate proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided. In specific examples, isolated Serrate genes, from Drosophila, chick, mouse, Xenopus and human, are provided.

109 Claims, 51 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 36

☐ 12. Document ID: US 5864020 A

L34: Entry 12 of 25 File: USPT Jan 26, 1999

US-PAT-NO: 5864020
DOCUMENT-IDENTIFIER: US 5864020 A

TITLE: HTK ligand

DATE-ISSUED: January 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; Brian D.	Pacifica	CA		
Matthews; William	Woodside	CA		

US-CL-CURRENT: 530/388.24; 435/188, 530/387.1, 530/391.1, 530/391.3

ABSTRACT:

h e b b g e e e f e f ef b e

A novel hepatoma transmembrane kinase receptor ligand (Htk ligand) which binds to, and activates, the Htk receptor is disclosed. As examples, mouse and human Htk ligands have been identified in a variety of tissues using a soluble Htk-Fc fusion protein. The ligands have been cloned and sequenced. The invention also relates to nucleic acids encoding the ligand, methods for production and use of the ligand, and antibodies directed thereto.

10 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

---

☐ 13. Document ID: US 5704910 A

L34: Entry 13 of 25 File: USPT Jan 6, 1998

US-PAT-NO: 5704910
DOCUMENT-IDENTIFIER: US 5704910 A
**** See image for Certificate of Correction ****

TITLE: Implantable device and use therefor

DATE-ISSUED: January 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Humes; H. David	Ann Arbor	MI		

US-CL-CURRENT: 604/502; 604/891.1

ABSTRACT:

Disclosed is an implantable device for delivering a pre-selected molecule, for example, a hormone, into a mammal's systemic circulation. The device comprises a blood permeable element that can be anchored to an inner wall of an intact blood vessel. The device also comprises a capsule that is held in place within the blood vessel by the anchored blood permeable element. The capsule encloses viable cells which produce and secrete the pre-selected molecule into blood passing the capsule. The invention also provides a minimally invasive method for percutaneously introducing into a preselected blood vessel the device of the invention.

8 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

---

☐ 14. Document ID: US 5651980 A

L34: Entry 14 of 25 File: USPT Jul 29, 1997

US-PAT-NO: 5651980
DOCUMENT-IDENTIFIER: US 5651980 A

h e b b g e e e f e f ef b e

TITLE: Methods of use of uncoated gel particles

DATE-ISSUED: July 29, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lanza; Robert P.	Natick	MA		
Kuhtreiber; Willem M.	Shewsbury	MA		
Chick; William L.	Wellesley	MA		

US-CL-CURRENT: 424/424; 424/422, 424/423, 435/174, 435/177, 435/243, 435/382, 514/866, 514/885, 514/907, 514/953

ABSTRACT:

The invention covers a method of implanting a living donor cell into a host animal without inflammatory response or rejection of the donor cell by the host animal, by obtaining an uncoated particle of a biocompatible, temperature-independent gel that encapsulates the living donor cell, wherein the uncoated particle provides a molecular weight cutoff that prevents host animal immune cells from entering the particle, yet does not have to prevent entry of host animal IgG and complement into the particle, and implanting the uncoated particle into the host animal.

64 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

15. Document ID: US 5624899 A

L34: Entry 15 of 25 File: USPT Apr 29, 1997

US-PAT-NO: 5624899
DOCUMENT-IDENTIFIER: US 5624899 A

TITLE: Method for using Htk ligand

DATE-ISSUED: April 29, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; Brian D.	Pacifica	CA		
Matthews; William	Woodside	CA		

US-CL-CURRENT: 514/12; 514/2, 530/350

ABSTRACT:

A novel hepatoma transmembrane kinase receptor ligand (Htk ligand) which binds to, and activates, the Htk receptor is disclosed. As examples, mouse and human Htk ligands have been identified in a variety of tissues using a soluble Htk-Fc fusion protein. The ligands have been cloned and sequenced. The invention also relates to nucleic acids encoding the ligand, methods for production and use of the ligand, and antibodies directed thereto.

h e b b g e e e f e f ef b e

2 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 16. Document ID: US 5610011 A

L34: Entry 16 of 25 File: USPT Mar 11, 1997

US-PAT-NO: 5610011
DOCUMENT-IDENTIFIER: US 5610011 A

TITLE: Virulence-encoding DNA sequences of Strepococcus suis and related products and methods

DATE-ISSUED: March 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Smith; Hilda E.	Cz Lelystad			NL
Vecht; Uri	As Ermelo			NL

US-CL-CURRENT: 435/6; 435/252.3, 435/320.1, 435/885, 435/975, 536/23.1, 536/23.7, 536/24.32

ABSTRACT:

The invention provides DNA sequences which code for polypeptides which are characteristic for the virulence of the pathogenic bacterium Streptococcus suis and parts thereof, and polypeptides and antibodies derived therefrom. The sequences code for a polypeptide of 90,000-120,000 daltons or a polypeptide of higher molecular weight containing such a polypeptide, and for a polypeptide of 135,000-136,000 daltons (muramidase released protein), or parts thereof. The sequences themselves, and also the polypeptides and antibodies derived therefrom, are used for diagnosis of and protection against infection by S. suis in mammals, including man.

9 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 17. Document ID: US 5602024 A

L34: Entry 17 of 25 File: USPT Feb 11, 1997

US-PAT-NO: 5602024
DOCUMENT-IDENTIFIER: US 5602024 A
**** See image for Certificate of Correction ****

TITLE: DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof

h e b b g e e e f e f ef b e

DATE-ISSUED: February 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gerald; Christophe P. G.	Ridgewood	NJ		
Walker; Mary W.	Elmwood Park	NJ		
Branchek; Theresa	Teaneck	NJ		
Weinshank; Richard L.	New York	NY		

US-CL-CURRENT: 435/325; 435/252.3, 435/254.11, 435/320.1, 435/348, 435/365, 435/369, 536/23.5

ABSTRACT:

This invention provides an isolated nucleic acid molecule encoding a human Y5 receptor, an isolated protein which is a human Y5 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y5 receptor, mammalian cells comprising such vectors, antibodies directed to the human Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y5 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y5 receptor, pharmaceutical compounds related to human Y5 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y5 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y5 receptor.

30 Claims, 28 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 28

☐ 18. Document ID: US 5512661 A

L34: Entry 18 of 25 File: USPT Apr 30, 1996

US-PAT-NO: 5512661
DOCUMENT-IDENTIFIER: US 5512661 A

TITLE: Multitrophic and multifunctional chimeric neurotrophic factors

DATE-ISSUED: April 30, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shooter; Eric M.	Portola Valley	CA		
Suter; Ulrich	Menlo Park	CA		
Ip; Nancy P.	Hong Kong			HK
Squinto; Stephen P.	Irvington	NY		
Furth; Mark E.	Chapel Hill	NC		
Lindsay; Ronald M.	Briarcliff Manor	NY		

US-CL-CURRENT: 530/399; 530/350, 530/839, 930/120

ABSTRACT:

h e b b g e e e f e f ef b e

The present invention relates to chimeric neurotrophic factors which comprise at least a portion of a naturally occurring cellular factor and a portion of at least one other molecule such that the resulting chimeric molecule has neurotrophic activity. It is based, in part, on the discovery that chimeric molecules comprising portions of both NGF and BDNF are likely to possess neurotrotrophic activity, and in some cases exhibit a spectrum of activity larger than that of either parent molecule. It is further based on the discovery that chimeric molecules comprising neurotrophic factor sequences as well as additional peptide sequences may retain neurotrophic activity, and in some cases may exhibit a more potent activity than the parent factor. The chimeric neurotrophic factor molecules of the invention provide a number of advantages relative to naturally occurring neurotrophic factors. Chimeric neurotrophic factors may be used to provide, for example, the activity of two neurotrophic factors in a single molecule, or may serve as superagonists of an endogenous neurotrophic factor, thereby enabling an increased biological response at lower doses.

32 Claims, 28 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 25

☐ 19. Document ID: US 5487739 A

L34: Entry 19 of 25 File: USPT Jan 30, 1996

US-PAT-NO: 5487739
DOCUMENT-IDENTIFIER: US 5487739 A

TITLE: Implantable therapy systems and methods

DATE-ISSUED: January 30, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aebischer; Patrick	Barrington	RI		
Goddard; Moses	Tiverton	RI		
Moldauer; John G.	Brooklyn	NY		
Mulhauser; Paul J.	New York	NY		
Rathbun; Anne M.	Providence	RI		
Sanberg; Paul R.	Greenwich	RI		
Vasconcellos; Alfred V.	Cranston	RI		
Warner; Nicholas F.	Belmont	MA		

US-CL-CURRENT: 604/890.1; 424/424, 604/265, 604/93.01

ABSTRACT:

Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a debilitating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as

h e b b g ee e f e f ef b e

polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway. A pusher can be inserted within the cannula, behind the vehicle (40), to position the proximal end of the vehicle at the distal end of the cannula (20b). Once the vehicle (40) is positioned near the distal end of the cannula (20), the cannula is removed from the passageway, followed by the pusher, leaving the vehicle (40) positioned at the treatment site (12).

20 Claims, 23 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

☐ 20. Document ID: US 5453361 A

L34: Entry 20 of 25 File: USPT Sep 26, 1995

US-PAT-NO: 5453361
DOCUMENT-IDENTIFIER: US 5453361 A

TITLE: Method for producing biologically active human brain derived neurotrophic factor

DATE-ISSUED: September 26, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yancopoulos; George	New York	NY		
Barde; Yves-Alain	Munich			DE
Thoenen; Hans	Munich			DE
Lottspeich; Friedrich	Neuried			DE
Leibrock; Joachim	Gauting			DE

US-CL-CURRENT: 435/69.1; 435/252.1, 435/252.3, 435/252.33, 435/252.8, 435/320.1, 435/365.1, 530/350, 536/23.1, 536/23.5

ABSTRACT:

The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NGF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention provides a method for identifying and isolating additional members of this gene family.

26 Claims, 26 Drawing figures
Exemplary Claim Number: 1

h e b b g e e e f e f ef b e

Number of Drawing Sheets: 26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

☐ 21. Document ID: US 5438121 A

L34: Entry 21 of 25 File: USPT Aug 1, 1995

US-PAT-NO: 5438121
DOCUMENT-IDENTIFIER: US 5438121 A

TITLE: Brain derived neurotrophic factor

DATE-ISSUED: August 1, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barde; Yves-Alain	Munich			DE
Leibrock; Joachim	Gauting			DE
Lottspeich; Friedrich	Neuried			DE
Edgar; David	Liverpool			GB2
Yancopoulos; George	New York	NY		
Thoenen; Hans	Munich			DE

US-CL-CURRENT: 530/399; 435/69.1, 530/350, 530/387.9, 530/389.2, 536/23.51

ABSTRACT:

The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. In a specific embodiment, BDNF may be used to promote the survival of substantia nigra dopaminergic neurons and basal forebrain cholinergic neurons, thereby providing a method for treating, respectively, Parkinson's disease and Alzheimer's disease. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NGF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention provides a method for identifying and isolating additional members of this gene family.

11 Claims, 68 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 52

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

☐ 22. Document ID: US 5411883 A

L34: Entry 22 of 25 File: USPT May 2, 1995

h e b b g e e e f e f ef b e

US-PAT-NO: 5411883
DOCUMENT-IDENTIFIER: US 5411883 A
**** See image for Certificate of Correction ****

TITLE: Proliferated neuron progenitor cell product and process

DATE-ISSUED: May 2, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Boss; Barbara D.	Alameda	CA		
Spector; Dennis H.	Oakland	CA		

US-CL-CURRENT: 435/29; 435/325, 435/368, 435/378

ABSTRACT:

This invention is based on the development of procedures for isolation and proliferation of neuron progenitor cells and is directed to growth, storage, production and implantation of proliferated neuron progenitor cells. The isolation and culture methods are designed to proliferate mammalian ventral mesencephalon neuron progenitor cells in vitro to produce a culture which differentiates to produce dopamine-producing cells. The products of this invention include a culture containing neuron progenitor cells, preferably, grown as aggregates in suspension cultures. The process of this invention for preparing neuron progenitor cells comprises obtaining ventral mesencephalon tissue from a donor at the appropriate stage of embryonic development; dissociation of the tissue to obtain single cells and small cell clusters for culture; culturing the neuron progenitor cells in an initial culture medium which selects for a novel cell culture containing neuron progenitor cells and growing the cells for a period of time in a second medium, during which the neuron progenitor cells proliferate.

16 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 23. Document ID: US 5229500 A

L34: Entry 23 of 25 File: USPT Jul 20, 1993

US-PAT-NO: 5229500
DOCUMENT-IDENTIFIER: US 5229500 A

TITLE: Brain derived neurotrophic factor

DATE-ISSUED: July 20, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barde; Yves-Alain	Graefelfing			DE
Leibrock; Joachim	Pfungstadt			DE
Lottspeich; Friedrich	Neuried			DE
Edgar; David	Liverpool			GB2
Yancopoulos; George	Briarcliff Manor	NY		

h e b b g e e e f e f ef b e

Thoenen; Hans Munich DE

US-CL-CURRENT: 514/12; 435/69.1, 530/350, 530/387.9, 530/389.2, 530/399, 530/412, 530/413

ABSTRACT:

The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. In a specific embodiment, BDNF may be used to promote the survival of substantia nigra dopaminergic neurons and basal forebrain cholinergic neurons, thereby providing a method for treating, respectively, Parkinson's disease and Alzheimer's disease. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NGF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention provides a method for identifying and isolating additional members of this gene family.

9 Claims, 66 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 51

☐ 24. Document ID: US 5180820 A

L34: Entry 24 of 25 File: USPT Jan 19, 1993

US-PAT-NO: 5180820
DOCUMENT-IDENTIFIER: US 5180820 A

TITLE: Brain-derived neurotrophic factor

DATE-ISSUED: January 19, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barde; Yves-Alain	Munich 70			DE
Leibrock; Joachim	Gauting			DE
Lottspeich; Friedrich	Neuried			AT
Yancopoulos; George	New York	NY	10032	
Thoenen; Hans	Munich 2			DE

US-CL-CURRENT: 536/23.51; 435/320.1, 435/69.1, 435/69.3, 530/399, 530/412

ABSTRACT:

The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF,

h e b b g e e e f e f ef b e

having provided, for the first time, the ability to generate sufficient quantities of substantially pure BDNF for clinical use. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NGF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention provides a method for identifying an disolating additional members of this gene family.

1 Claims, 26 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 26

25. Document ID: US 5169764 A

L34: Entry 25 of 25 File: USPT Dec 8, 1992

US-PAT-NO: 5169764
DOCUMENT-IDENTIFIER: US 5169764 A

TITLE: Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras

DATE-ISSUED: December 8, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shooter; Eric M.	Portola Valley	CA		
Suter; Ulrich	Menlo Park	CA		
Ip; Nancy	Stamford	CT		
Squinto; Stephen P.	Irvington	NY		
Furth; Mark E.	Pelham	NY		
Lindsay; Ronald M.	Briarcliff Manor	NY		
Yancopoulos; George D.	Briarcliff Manor	NY		

US-CL-CURRENT: 435/69.7; 435/320.1, 514/12, 530/399, 530/402, 530/839

ABSTRACT:

The present invention relates to chimeric neurotrophic factors which comprise at least a portion of a naturally occurring cellular factor and a portion of at least one other molecule such that the resulting chimeric molecule has neurotrophic activity. It is based, in part, on the discovery that chimeric molecules comprising portions of both NGF and BDNF are likely to possess neurotrotrophic activity, and in some cases exhibit a spectrum of activity larger than that of either parent molecule. It is further based on the discovery that chimeric molecules comprising neurotrophic factor sequences as well as additional peptide sequences may retain neurotrophic activity, and in some cases may exhibit a more potent activity than the parent factor. The chimeric neurotrophic factor molecules of the invention provide a number of advantages relative to naturally occurring neurotrophic factors. Chimeric neurotrophic factors may be used to provide, for example, the activity of two neurotrophic factors in a single molecule, or may serve as superagonists of an endogenous neurotrophic factor, thereby enabling an increased biological response at lower doses. Nucleic acids and plasmids encoding the chimeras are disclosed.

h e b b g e e e f e f ef b e

34 Claims, 26 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 25

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L33 AND mesencephalon	25

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e f ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 36 of 36 returned.

☐ 1. Document ID: US 20040142418 A1

Using default format because multiple data bases are involved.

L37: Entry 1 of 36 File: PGPB Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040142418
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040142418 A1

TITLE: Novel neurotrophic factors

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sah, Dinah W. Y.	Boston	MA	US	
Johansen, Teit E.	Horsholm	MA	DK	
Rossomando, Anthony	South Grafton		US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/351, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 2. Document ID: US 20040106125 A1

L37: Entry 2 of 36 File: PGPB Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040106125
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040106125 A1

TITLE: Neurotransmission-associated proteins

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Duggan, Brendan M	Sunnyvale	CA	US	
Honchell, Cynthia D	San Carlos	CA	US	
Ison, Craig H	San Jose	CA	US	
Thangavelu, Kavitha	Sunnyvale	CA	US	
Lu, Dyung Aina M	San Jose	CA	US	
Baughn, Mariah R	Los Angeles	CA	US	
Lal, Preeti G	Santa Clara	CA	US	
Yue, Henry	Sunnyvale	CA	US	

h e b b g e e e f e f ef b e

Tang, Y Tom	San Jose	CA	US
Warren, Bridget A	San Marcos	CA	US
Lee, Ernestine A	Castro Valley	CA	US
Griffin, Jennifer A	Fremont	CA	US
Forsythe, Ian J	Edmonton	CA	CA
Chawla, Narinder K	Union City	CA	US
Jiang, Xin	Saratoga	CA	US
Jackson, Alan A	Los Gatos		US

US-CL-CURRENT: 435/6; 424/143.1, 435/320.1, 435/325, 435/69.1, 530/350, 530/388.22

ABSTRACT:

The invention provides human neurotransmission-associated proteins (NTRAN) and polynucleotides which identify and encode NTRAN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of NTRAN.

☐ 3. Document ID: US 20040029220 A1

L37: Entry 3 of 36 File: PGPB Feb 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040029220
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040029220 A1

TITLE: Novel proteins and nucleic acids encoding same

PUBLICATION-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vernet, Corine A.M.	North Branford	CT	US	
Fernandes, Elma R.	Branford	CT	US	
Gerlach, Valerie	Branford	CT	US	
Shimkets, Richard A.	West Haven	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Boldog, Ferenc L.	North Haven	CT	US	
Zerhusen, Bryan D.	Branford	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Majumder, Kumud	Stamford	CT	US	
Tchernev, Velizar T.	Branford	CT	US	
Padigaru, Muralidhara	Branford	CT	US	
Patturajan, Meera	Branford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	
Gangolli, Esha A.	Branford	CT	US	
Smithson, Glennda	Branford	CT	US	
Rastelli, Luca	Guilford	CT	US	
MacDougall, John R.	Hamden	CT	US	

h e b b g e e e f e f ef b e

Taupier, Raymond J. JR.	East Haven	CT	US
Grosse, William M.	Branford	CT	US
Szekeres, Edward S. JR.	Wallingford	CT	US
Alsobrook, John P. II	Madison	CT	US
Anderson, David W.	Branford	CT	US
Guo, Xiaojia (Sasha)	Branford	CT	US
Li, Li	Branford	CT	US
Zhong, Mei	Branford	CT	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

☐ 4. Document ID: US 20030215823 A1

L37: Entry 4 of 36 File: PGPB Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215823
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030215823 A1

TITLE: Uses of galanin GALR2 receptors

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Smith, Kelli E.	Wayne	NJ	US	
Linemeyer, David	Guilford	CT	US	
Gerald, Christophe P. G.	Ridgewood	NJ	US	
Branchek, Theresa	Teaneck	NJ	US	
Weinshank, Richard L.	Teaneck	NJ	US	
Forray, Carlos	Paramus	NJ	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman

h e b b g e e e f e f ef b e

transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

5. Document ID: US 20030162944 A1

L37: Entry 5 of 36 File: PGPB Aug 28, 2003

PGPUB-DOCUMENT-NUMBER: 20030162944
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030162944 A1

TITLE: Nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors and uses thereof

PUBLICATION-DATE: August 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gerald, Christophe	Ridgewood	NJ	US	
Walker, Mary W.	Elmwood Park	NJ	US	
Branchek, Theresa	Teaneck	NJ	US	
Weinshank, Richard L.	Teaneck	NJ	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.

6. Document ID: US 20030143729 A1

L37: Entry 6 of 36 File: PGPB Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143729
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030143729 A1

TITLE: DNA encoding taurine and GABA transporters and uses thereof

h e b b g e e e f e f ef b e

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Smith, Kelli E.	Wayne	NJ	US	
Borden, Laurence A.	Hackensack	NJ	US	
Weinshank, Richard L.	Teaneck	NJ	US	
Hartig, Paul R.	Pennington	NJ	US	

US-CL-CURRENT: 435/320.1; 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters; methods of isolating these nucleic acid molecules and vectors comprising such nucleic acid molecules as well as mammalian cells comprising such vectors. Nucleic acid probes for detecting nucleic acid molecules encoding mammalian or human GABA transporters, or mammalian or human taurine transporters; antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian GABA or taurine transporter or human GABA or taurine transporter; and antibodies to the mammalian GABA or taurine transporters, or human GABA or taurine transporters are provided. Pharmaceutical compounds related to mammalian GABA or taurine transporters and to human GABA or taurine transporters are provided. Nonhuman transgenic animals which express DNA encoding normal or mutant mammalian GABA or taurine transporters, or normal or mutant human GABA or taurine transporters are provided. Further provided are methods for determining substrate binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with mammalian GABA or taurine transporters, or human GABA or taurine transporters.

☐ 7. Document ID: US 20030139590 A1

L37: Entry 7 of 36 File: PGPB Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030139590
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030139590 A1

TITLE: DNA encoding SNORF25 receptor

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bonini, James A.	Oakland	NJ	US	
Borowsky, Beth E.	Montclair	NJ	US	
Adham, Nika	Ridgewood	NJ	US	
Boyle, Noel	Cliffside Park	NJ	US	
Thompson, Thelma O.	Passaic Park	NJ	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

h e b b g e e e f e f ef b e

This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 8. Document ID: US 20030129702 A1

L37: Entry 8 of 36 File: PGPB Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129702
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030129702 A1

TITLE: DNA encoding galanin GALR2 receptors and uses thereof

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Smith, Kelli E.	Wayne	NJ	US	
Gerald, Christophe P.G.	Ridgewood	NJ	US	
Weinshank, Richard L.	Teaneck	NJ	US	
Linemeyer, David	Guilford	CT	US	
Branchek, Theresa	Teaneck	NJ	US	
Forray, Carlos	Paramus	NJ	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 9. Document ID: US 20030083244 A1

h e b b g e e e f e f ef b e

L37: Entry 9 of 36 File: PGPB May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083244
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030083244 A1

TITLE: Novel proteins and nucleic acids encoding same

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vernet, Corine A.M.	North Branford	CT	US	
Fernandes, Elma R.	Branford	CT	US	
Gerlach, Valerie	Branford	CT	US	
Shimkets, Richard A.	West Haven	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Boldog, Ferenc L.	North Haven	CT	US	
Zerhusen, Bryan D.	Branford	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Majumder, Kumud	Stamford	CT	US	
Tchernev, Velizar T.	Branford	CT	US	
Padigaru, Muralidhara	Branford	CT	US	
Patturajan, Meera	Branford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	
Gangolli, Esha A.	Madison	CT	US	
Smithson, Glennda	Guilford	CT	US	
Rastelli, Luca	Guilford	CT	US	
MacDougall, John R.	Hamden	CT	US	
Taupier, Raymond J. JR.	East Haven	CT	US	
Grosse, William M.	Branford	CT	US	
Szekeres, Edward S. JR.	Branford	CT	US	
Alsobrook, John P. II	Madison	CT	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

☐ 10. Document ID: US 20020132293 A1

L37: Entry 10 of 36 File: PGPB Sep 19, 2002

h e b b g e e e f e f ef b e

PGPUB-DOCUMENT-NUMBER: 20020132293
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020132293 A1

TITLE: Mammalian neuralized family transcriptional regulators and uses therefor

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Palm, Kaia	Santa Monica	CA	US	
Timmusk, Tonis	Helsinki		FI	

US-CL-CURRENT: 435/69.1; 435/195, 435/325, 435/7.1, 530/388.1

ABSTRACT:

The disclosure relates to isolated polynucleotides and purified polypeptides of the Neu family of proteins, which have been shown to demonstrate transcriptional regulatory activity. For example, the purified polynucleotide can encode a Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. A purified Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. Antibodies capable of specifically binding to the disclosed Neu polypeptides are disclosed. Vectors expressing the disclosed Neu protein coding regions and host cells containing the vectors are disclosed. Methods of making the Neu proteins disclosed are also provided, as are method of identifying binding partners that interact with a Neu protein family member.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 11. Document ID: US 20020127205 A1

L37: Entry 11 of 36 File: PGPB Sep 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020127205
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020127205 A1

TITLE: CELLS EXPRESSING IMMUNOREGULATORY MOLECULES AND USES THEREFOR

PUBLICATION-DATE: September 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
EDGE, ALBERT	CAMBRIDGE	MA	US	

US-CL-CURRENT: 424/93.2; 424/93.21, 435/320.1, 435/325

ABSTRACT:

Compositions comprising genetically modified cells which express at least one immunoregulatory molecule and methods for using the genetically modified cells are described. The immunoregulatory molecule expressed by the cell(s) are capable of inhibiting T cell activation and/or natural killer cell-mediated immune response

h e b b g e e e f e f ef b e

against the cell upon transplantation into a recipient subject. The cells of the invention can express an immunoregulatory molecule on the surface of the cells or secrete the immunoregulatory molecule in soluble form. The cells of the invention can be transplanted into a recipient subject such that immune rejection of the cell is inhibited. In addition, non-human transgenic animals which contain cells which are genetically modified to express at least one immunoregulatory molecule are described.

☐ 12. Document ID: US 20020123096 A1

L37: Entry 12 of 36 File: PGPB Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020123096
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020123096 A1

TITLE: Dopamine receptors and genes

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Civelli, Olivier	Portland	OR	US	
Bunzow, James R.	Portland	OR	US	
Grandy, David K.	Portland	OR	US	
Machida, Curtis A.	Portland	OR	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

A mammalian D.sub.2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.

☐ 13. Document ID: US 20020045251 A1

L37: Entry 13 of 36 File: PGPB Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020045251
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020045251 A1

TITLE: COMMON NEURAL PROGENITOR FOR THE CNS AND PNS

h e b b g e e e f e f ef b e

PUBLICATION-DATE: April 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
RAO, MAHENDRA S.	SALT LAKE CITY	UT	US	
MUJTABA, TAHMINA	SANDY	UT	US	

US-CL-CURRENT: 435/325; 435/368, 435/373, 435/377, 435/383, 435/384, 435/387, 435/391, 435/395, 435/402

ABSTRACT:

A method of generating neural crest stem cells involves inducing neuroepithelial stem cells to differentiate in vitro into neural crest stem cells. Differentiation can be induced by replating the cells on laminin, withdrawing mitogens, or adding dorsalizing agents to the growth medium. Derivatives of the peripheral nervous system can be generated by inducing the neural crest stem cells to differentiate in vitro.

☐ 14. Document ID: US 20020031497 A1

L37: Entry 14 of 36 File: PGPB Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031497
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020031497 A1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fraser, Thomas	Newton	MA	US	
Dinsmore, Jonathan	Brookline	MA	US	

US-CL-CURRENT: 424/93.7; 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma,

h e b b g e e e f e f ef b e

stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

☐ 15. Document ID: US 20020009461 A1

L37: Entry 15 of 36 File: PGPB Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020009461
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020009461 A1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Isacson, Ole	Cambridge	MA	US	
Dinsmore, Jonathan	Brookline	MA	US	

US-CL-CURRENT: 424/193.1; 424/93.7, 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

---

☐ 16. Document ID: US 20020006660 A1

L37: Entry 16 of 36 File: PGPB Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006660
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020006660 A1

TITLE: GENETICALLY-MODIFIED NEURAL PROGENITORS AND USES THEREOF

h e b b g e e e f e f ef b e

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
SABATE, OLIVIER	PARIS		FR	
HORELLOU, PHILIPPE	PARIS		FR	
BUC-CARON, MARIE-HELENE	PARIS		FR	
MALLET, JACQUES	PARIS		FR	

US-CL-CURRENT: 435/325; 514/44

ABSTRACT:

The invention concerns human neural progenitor cells containing introduced genetic material encoding a product of interest, and their use for the treatment of neurodegenerative diseases.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 17. Document ID: US 20010039667 A1

L37: Entry 17 of 36 File: PGPB Nov 8, 2001

PGPUB-DOCUMENT-NUMBER: 20010039667
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010039667 A1

TITLE: Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease

PUBLICATION-DATE: November 8, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Stice, Steven L.	Belchertown	MA	US	
Cibelli, Jose	Amherst	MA	US	
Robl, James M.	Belchertown	MA	US	

US-CL-CURRENT: 800/15; 424/93.21, 435/325

ABSTRACT:

Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 18. Document ID: US 6743780 B1

h e b b g e e e f e f ef b e

L37: Entry 18 of 36 File: USPT Jun 1, 2004

US-PAT-NO: 6743780
DOCUMENT-IDENTIFIER: US 6743780 B1

TITLE: Plasmid stabilization

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanak; Julian A. J.	Macclesfield			GB
Williams; Steven G.	Near Crewe			GB
Gorman; Scott D.	Witney			GB
Sherratt; David J.	Witney			GB

US-CL-CURRENT: 514/44; 435/325, 435/375, 435/41, 435/6, 536/24.1

ABSTRACT:

A system is described which utilizes a novel system of repressor titration for maintenance of a plasmid useful in gene therapy and production of a recombinant protein. The system utilizes a transformed host cell containing a plasmid including an operator susceptible to binding by a repressor expressed in trans, a first chromosomal gene encoding the repressor, and a second chromosomal gene that is functionally associated with an operator and essential for cell growth, wherein the plasmid is present in the cell in sufficient numbers to titrate the repressor such that the essential gene is expressed, thereby permitting cell growth.

7 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

19. Document ID: US 6709831 B1

L37: Entry 19 of 36 File: USPT Mar 23, 2004

US-PAT-NO: 6709831
DOCUMENT-IDENTIFIER: US 6709831 B1

TITLE: DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof

DATE-ISSUED: March 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gerald; Christophe P. G.	Ridgewood	NJ		
Jones; Kenneth A.	Bergenfield	NJ		
Bonini; James A.	Oakland	NJ		
Borowsky; Beth E.	Montclair	NJ		
Craig; Douglas A.	Emerson	NJ		

h e b b g e e e f e f ef b e

US-CL-CURRENT: 435/7.2; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

23 Claims, 39 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 33

☐ 20. Document ID: US 6685934 B1

L37: Entry 20 of 36 File: USPT Feb 3, 2004

US-PAT-NO: 6685934
DOCUMENT-IDENTIFIER: US 6685934 B1

TITLE: Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)

DATE-ISSUED: February 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mallet; Jacques	Paris			FR
Perricaudet; Michel	Ecrosnes			FR
Vigne; Emmanuelle	Ivry sur Seine			FR
Revah; Frederic	Paris			FR
Abitbol; Marc	Paris			FR
Roustan; Paul	Les Ulis			FR

US-CL-CURRENT: 424/93.1; 435/235.1, 435/325

ABSTRACT:

Recombinant adenoviruses comprising a heterologous DNA sequence coding for basic blast growth factors (bFGF), preparation and uses thereof for the treatment and/or prevention of neurodegenerative diseases.

21 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

h e b b g e e e f e f ef b e

☐ 21. Document ID: US 6593133 B1

L37: Entry 21 of 36 File: USPT Jul 15, 2003

US-PAT-NO: 6593133
DOCUMENT-IDENTIFIER: US 6593133 B1

TITLE: Neurotrophic factors

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johansen; Teit E.	Horsholm			DK
Blom; Nikolaj	Copenhagen			DK
Hansen; Claus	Holbaek			DK

US-CL-CURRENT: 435/325; 435/252.1, 435/252.3, 435/320.1, 435/455, 435/471, 435/69.1, 435/91.1, 435/91.3, 530/350, 530/351, 536/23.1, 536/23.5

ABSTRACT:

The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.

22 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 22. Document ID: US 6468756 B1

L37: Entry 22 of 36 File: USPT Oct 22, 2002

US-PAT-NO: 6468756
DOCUMENT-IDENTIFIER: US 6468756 B1

TITLE: Methods of identifying compounds that bind to SNORF25 receptors

DATE-ISSUED: October 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bonini; James A.	Oakland	NJ		
Borowsky; Beth E.	Montclair	NJ		
Adham; Nika	Ridgewood	NJ		
Boyle; Noel	Cliffside Park	NJ		
Thompson; Thelma O.	Passaic Park	NJ		

US-CL-CURRENT: 435/7.1; 435/325, 435/348, 435/354, 435/356, 435/357, 435/361, 435/365, 435/369, 435/7.2, 530/350, 536/23.5

h e b b g e e e f e f ef b e

ABSTRACT:

This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

10 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 23. Document ID: US 6364907 B1

L37: Entry 23 of 36 File: USPT Apr 2, 2002

US-PAT-NO: 6364907
DOCUMENT-IDENTIFIER: US 6364907 B1

TITLE: Method to prevent xenograft transplant rejection

DATE-ISSUED: April 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Obochi; Modestus O. K.	Vancouver			CA
Margaron; Philippe Maria Clotaire	Burnaby			CA
Honey; Christopher Richard	Vancouver			CA
Yip; Stephen	Vancouver			CA
Levy; Julia G.	Vancouver			CA

US-CL-CURRENT: 623/11.11; 128/898, 435/325

ABSTRACT:

Donor material from a xenogeneic source is modified to enhance its survival time in a recipient by treating the donor material using low-dose photodynamic therapy (PDT). The donor material, such as an organ or cell suspension, is treated with a photosensitizer and irradiated in a low-dose protocol before transplantation into a xenogeneic recipient.

20 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

h e b b g e e e f e f ef b e

24. Document ID: US 6294383 B1

L37: Entry 24 of 36 File: USPT Sep 25, 2001

US-PAT-NO: 6294383
DOCUMENT-IDENTIFIER: US 6294383 B1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: September 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Isacson; Ole	Cambridge	MA		
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 435/379; 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

8 Claims, 49 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

25. Document ID: US 6277591 B1

L37: Entry 25 of 36 File: USPT Aug 21, 2001

US-PAT-NO: 6277591
DOCUMENT-IDENTIFIER: US 6277591 B1
** See image for Certificate of Correction **

TITLE: Dopamine receptors and genes

DATE-ISSUED: August 21, 2001

h e b b g e e e f e f ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Civelli; Olivier	Portland	OR		
Bunzow; James R.	Portland	OR		
Grandy; David K.	Portland	OR		
Machida; Curtis A.	Portland	OR		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/455, 530/350, 536/23.5

ABSTRACT:

A mammalian D.sub.2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.

48 Claims, 59 Drawing figures
Exemplary Claim Number: 7
Number of Drawing Sheets: 47

☐ 26. Document ID: US 6277372 B1

L37: Entry 26 of 36 File: USPT Aug 21, 2001

US-PAT-NO: 6277372
DOCUMENT-IDENTIFIER: US 6277372 B1
**** See image for Certificate of Correction ****

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: August 21, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fraser; Thomas	Newton	MA		
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 424/93.7; 424/93.1, 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic

h e b b g e e e f e f ef b e

subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

10 Claims, 43 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

27. Document ID: US 6258353 B1

L37: Entry 27 of 36 File: USPT Jul 10, 2001

US-PAT-NO: 6258353
DOCUMENT-IDENTIFIER: US 6258353 B1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: July 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Isacson; Ole	Cambridge	MA		
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 424/93.1; 424/130.1, 424/143.1, 424/809, 424/93.7, 435/325, 435/368

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

26 Claims, 62 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 24

h e b b g e e e f e f ef b e

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

☐ 28. Document ID: US 6214615 B1

L37: Entry 28 of 36 File: USPT Apr 10, 2001

US-PAT-NO: 6214615
DOCUMENT-IDENTIFIER: US 6214615 B1

TITLE: Cloned genes for human dopamine D2 receptors and cell lines expressing same

DATE-ISSUED: April 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brann; Mark R.	Bethesda	MD		
Stormann; Thomas M.	Bethesda	MD		

US-CL-CURRENT: 435/361; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

Disclosed herein is an isolated or essentially pure DNA sequence encoding a human Dopamine D2 receptor, the protein comprising the receptor, vectors for transforming or transfecting host cells with such DNA so that the cells express the DNA, methods of obtaining the DNA and preparing the transformed or transfected cells and cell lines, and methods of using the cells and cell lines in assays for the determination of human dopamine D2 receptor antagonists or agonists.

11 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

☐ 29. Document ID: US 6204053 B1

L37: Entry 29 of 36 File: USPT Mar 20, 2001

US-PAT-NO: 6204053
DOCUMENT-IDENTIFIER: US 6204053 B1
**** See image for Certificate of Correction ****

TITLE: Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: March 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 435/325; 424/93.7, 435/374

h e b b g e e e f e f ef b e

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

16 Claims, 49 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 19

☐ 30. Document ID: US 6140116 A

L37: Entry 30 of 36 File: USPT Oct 31, 2000

US-PAT-NO: 6140116
DOCUMENT-IDENTIFIER: US 6140116 A
**** See image for Certificate of Correction ****

TITLE: Isolated and modified porcine cerebral cortical cells

DATE-ISSUED: October 31, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 435/325; 424/93.7, 435/374

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration

h e b b g e e e f e f ef b e

in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

27 Claims, 40 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

☐ 31. Document ID: US 6036951 A

L37: Entry 31 of 36 File: USPT Mar 14, 2000

US-PAT-NO: 6036951
DOCUMENT-IDENTIFIER: US 6036951 A

TITLE: Sertoli cells as neurorecovery inducing cells for neurodegenerative disorders

DATE-ISSUED: March 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sanberg; Paul R.	Springhill	FL		
Cameron; Don F.	Lutz	FL		
Borlongan; Cesario V.	Lutz	FL		

US-CL-CURRENT: 424/93.1; 424/93.21, 435/325

ABSTRACT:

A method of generating in situ trophic factor production by transplanting Sertoli cells into a tissue in need of trophic factors of a mammal, the cells creating trophic factors in situ.

4 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 32. Document ID: US 5968819 A

L37: Entry 32 of 36 File: USPT Oct 19, 1999

US-PAT-NO: 5968819
DOCUMENT-IDENTIFIER: US 5968819 A

TITLE: DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

h e b b g e e e f e f ef b e

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gerald; Christophe P. G.	Ridgewood	NJ		
Weinshank; Richard L.	Teaneck	NJ		
Walker; Mary W.	Elmwood Park	NJ		
Branchek; Theresa	Teaneck	NJ		

US-CL-CURRENT: 435/325; 435/320.1, 536/23.5

ABSTRACT:

This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

22 Claims, 45 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 40

33. Document ID: US 5942437 A

L37: Entry 33 of 36 File: USPT Aug 24, 1999

US-PAT-NO: 5942437
DOCUMENT-IDENTIFIER: US 5942437 A

TITLE: Method and media for enhancing viability maturation, and cryopreservation of cells

DATE-ISSUED: August 24, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sanberg; Paul R.	Spring Hill	FL		
Othberg; Agneta	Tampa	FL		
Cameron; Don F.	Lutz	FL		
Saporta; Samuel	Tampa	FL		
Borlongan; Cesario V.	Silver Springs	MD		

US-CL-CURRENT: 435/374; 424/93.7, 435/1.3, 435/325, 435/347

ABSTRACT:

A method to increase viability, number, survival and maturation of cells for transplantation or cryopreservation by culturing the cells with Sertoli cells or with sertoli-cell conditioned media (SCM) prior to transplantation (pre-culturing) or

h e b b g e e e f e f ef b e

cryopreservation.

5 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

34. Document ID: US 5869282 A

L37: Entry 34 of 36 File: USPT Feb 9, 1999

US-PAT-NO: 5869282
DOCUMENT-IDENTIFIER: US 5869282 A
**** See image for Certificate of Correction ****

TITLE: Nucleotide and protein sequences of the serrate gene and methods based thereon

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ish-Horowicz; David	Oxford			GB2
Henrique; Domingos Manuel Pinto	Oxford			GB2
Lewis; Julian Hart	Oxford			GB2
Myat; Anna Mary	Oxford			GB2
Fleming; Robert J.	Rochester	NY		
Artavanis-Tsakonas; Spyridon	Hamden	CT		
Mann; Robert S.	Hamden	CT		
Gray; Grace E.	New Haven	CT		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 530/300, 530/350, 536/23.1, 536/24.3

ABSTRACT:

The present invention relates to nucleotide sequences of Serrate genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the Serrate protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Serrate which comprise one or more domains of the Serrate protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, cysteine rich domain, transmembrane region, membrane-associated region, or one or more EGF-like repeats of a Serrate protein, or any combination of the foregoing. Antibodies to Serrate, its derivatives and analogs, are additionally provided. Methods of production of the Serrate proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided. In specific examples, isolated Serrate genes, from Drosophila, chick, mouse, Xenopus and human, are provided.

109 Claims, 51 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 36

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

h e b b g e e e f e f ef b e

☐ 35. Document ID: US 5602024 A

L37: Entry 35 of 36 File: USPT Feb 11, 1997

US-PAT-NO: 5602024
DOCUMENT-IDENTIFIER: US 5602024 A
**** See image for Certificate of Correction ****

TITLE: DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof

DATE-ISSUED: February 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gerald; Christophe P. G.	Ridgewood	NJ		
Walker; Mary W.	Elmwood Park	NJ		
Branchek; Theresa	Teaneck	NJ		
Weinshank; Richard L.	New York	NY		

US-CL-CURRENT: 435/325; 435/252.3, 435/254.11, 435/320.1, 435/348, 435/365, 435/369, 536/23.5

ABSTRACT:

This invention provides an isolated nucleic acid molecule encoding a human Y5 receptor, an isolated protein which is a human Y5 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y5 receptor, mammalian cells comprising such vectors, antibodies directed to the human Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y5 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y5 receptor, pharmaceutical compounds related to human Y5 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y5 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y5 receptor.

30 Claims, 28 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 28

☐ 36. Document ID: US 5411883 A

L37: Entry 36 of 36 File: USPT May 2, 1995

US-PAT-NO: 5411883
DOCUMENT-IDENTIFIER: US 5411883 A
**** See image for Certificate of Correction ****

TITLE: Proliferated neuron progenitor cell product and process

DATE-ISSUED: May 2, 1995

h e b b g e e e f e f ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Boss; Barbara D.	Alameda	CA		
Spector; Dennis H.	Oakland	CA		

US-CL-CURRENT: 435/29; 435/325, 435/368, 435/378

ABSTRACT:

This invention is based on the development of procedures for isolation and proliferation of neuron progenitor cells and is directed to growth, storage, production and implantation of proliferated neuron progenitor cells. The isolation and culture methods are designed to proliferate mammalian ventral mesencephalon neuron progenitor cells in vitro to produce a culture which differentiates to produce dopamine-producing cells. The products of this invention include a culture containing neuron progenitor cells, preferably, grown as aggregates in suspension cultures. The process of this invention for preparing neuron progenitor cells comprises obtaining ventral mesencephalon tissue from a donor at the appropriate stage of embryonic development; dissociation of the tissue to obtain single cells and small cell clusters for culture; culturing the neuron progenitor cells in an initial culture medium which selects for a novel cell culture containing neuron progenitor cells and growing the cells for a period of time in a second medium, during which the neuron progenitor cells proliferate.

16 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Terms	Documents
L36 AND (435/325).CCLS.	36

h e b b g e e e f e f ef b e

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, August 12, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L8	= 1999	178
☐	L7	L6 AND 435/325.CCLS.	2603
☐	L6	L3 AND L4 AND L5	8764
☐	L5	macrophage OR microglia	38652
☐	L4	pig OR porcine	189797
☐	L3	fetal OR embryonic	68731
☐	L2	L1 AND mesencephalon	53
☐	L1	(microglia)	1398

END OF SEARCH HISTORY

h e b b cg b chh e b f ff e ch e c ch

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 53 of 53 returned.

☐ 1. Document ID: US 20040151701 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 53 File: PGPB Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040151701
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040151701 A1

TITLE: Method for differentiating mesenchymal stem cells into neural cells

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kim, Hyun-Soo	Suwon-si, Kyungki-do		KR	
Yoon, Hae-Hoon	Incheon		KR	

US-CL-CURRENT: 424/93.7; 435/368

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 2. Document ID: US 20040106125 A1

L2: Entry 2 of 53 File: PGPB Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040106125
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040106125 A1

TITLE: Neurotransmission-associated proteins

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Duggan, Brendan M	Sunnyvale	CA	US	
Honchell, Cynthia D	San Carlos	CA	US	
Ison, Craig H	San Jose	CA	US	
Thangavelu, Kavitha	Sunnyvale	CA	US	
Lu, Dyung Aina M	San Jose	CA	US	
Baughn, Mariah R	Los Angeles	CA	US	
Lal, Preeti G	Santa Clara	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Tang, Y Tom	San Jose	CA	US	

h e b b g e e e f e b ef b e

Warren, Bridget A	San Marcos	CA	US
Lee, Ernestine A	Castro Valley	CA	US
Griffin, Jennifer A	Fremont	CA	US
Forsythe, Ian J	Edmonton	CA	CA
Chawla, Narinder K	Union City	CA	US
Jiang, Xin	Saratoga	CA	US
Jackson, Alan A	Los Gatos		US

US-CL-CURRENT: 435/6; 424/143.1, 435/320.1, 435/325, 435/69.1, 530/350, 530/388.22

ABSTRACT:

The invention provides human neurotransmission-associated proteins (NTRAN) and polynucleotides which identify and encode NTRAN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of NTRAN.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 3. Document ID: US 20040076613 A1

L2: Entry 3 of 53 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040076613
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040076613 A1

TITLE: Vector system

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mazarakis, Nicholas	Oxford		GB	
Azzouz, Mimoun	Oxford		GB	
Kingsman, Susan Mary	Oxford		GB	

US-CL-CURRENT: 424/93.2; 435/456

ABSTRACT:

Provided is a method of treating motor neuron disease using a lentiviral vector system to transduce a target site, wherein the vector system is or comprises at least part of a rabies G envelope protein or a mutant, variant, homologue or fragment thereof, and a nucleotide of interest (NOI), and wherein the target site is at least part of the central nervous system.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 4. Document ID: US 20040071675 A1

h e b b g e e e f e b ef b e

L2: Entry 4 of 53 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040071675
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040071675 A1

TITLE: Vector system

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mazarakis, Nicholas	Oxford		GB	
Azzouz, Mimoun	Oxford		GB	

US-CL-CURRENT: 424/93.21; 435/368, 435/455

ABSTRACT:

There is provided the use of a vector system comprising at least part of a rabies g protein, to transduce a TH positive neuron. There is also provided the use of a rabies G vector system to transduce a target site, in which the vector system travels to the target site by retrograde transport, which may comprise the step of administration of the vector system to an administration site which is distant from the target site.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 5. Document ID: US 20040063674 A1

L2: Entry 5 of 53 File: PGPB Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063674
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040063674 A1

TITLE: Tetracycline compounds having target therapeutic activities

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Levy, Stuart B.	Boston	MA	US	
Draper, Michael	Plaistow	NH	US	
Nelson, Mark L.	Wellesley	MA	US	
Jones, Graham	Needham	MA	US	

US-CL-CURRENT: 514/152

ABSTRACT:

Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.

h e b b g e e e f e b ef b e

☐ 6. Document ID: US 20040058871 A1

L2: Entry 6 of 53 File: PGPB Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058871
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040058871 A1

TITLE: Human immunosuppressive protein

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sanberg, Paul R.	Spring Hill	FL	US	
Engelman, Robert W.	Tampa	FL	US	
Gower, William R.	Seffner	FL	US	

US-CL-CURRENT: 514/12; 530/350

ABSTRACT:

A method for purifying an immunosuppressant protein (HISP) has the steps of obtaining supernatant from hNT cells; exposing the supernatant to preparative polyacrylamide gel electrophoresis to produce 20 isoelectric fractions, including active isoelectric fraction #10; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting the free fraction containing the concentrated, isolated HISP. Also disclosed is a method of treating inflammation, using an effective amount of an HISP. The HISP is anionic, has a molecular weight of 40-100 kDa, an isoelectric point of about 4.8 and is obtained from the supernatant of hNT cells, but not from NCCIT embryonal carcinoma cells, T98G glioblastoma cells or THP-1 monocytic leukemia cells. HISP can maintain T cells in a quiescent G.sub.0/G.sub.1 state without lowering their viability. HISP loses activity when treated with heat, pH2, pH11, or mixed with trypsin or carboxypeptidase, but not with neuraminidase. HISP can suppress proliferation of responder peripheral blood mononuclear cells in allogeneic mixed lymphocyte cultures; HISP can suppress T-cell proliferation and IL-2 production in response to phorbol 12-myristate 13-acetate (PMA), ionomycin and concanavalin-A. HISP does not bind to heparin-sepharose CL-B gel; or to albumin-binding resin Blue Sepharose. HISP is concentrated with YM10 ultrafiltration. HISP does not act through the T-cell receptor-CD3 complex or via altered accessory signal cells. A method of treating inflammation comprises administering an effective amount of hNT neuronal cells.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 7. Document ID: US 20040048373 A1

L2: Entry 7 of 53 File: PGPB Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048373
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040048373 A1

h e b b g e e e f e b ef b e

TITLE: Method for production of neuroblasts

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gage, Fred H.	La Jolla	CA	US	
Ray, Jasodhara	San Diego	CA	US	

US-CL-CURRENT: 435/368

ABSTRACT:

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

8. Document ID: US 20040035433 A1

L2: Entry 8 of 53 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040035433
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040035433 A1

TITLE: Apparatus for simulating traumatic brain injury and method for inducing spinal cord injury

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meythaler, Jay M.	Birmingham	AL	US	
Peduzzi-Nelson, Jean D.	Chelsea	AL	US	
Eleftheriou, Evangelos	Hoover	AL	US	

US-CL-CURRENT: 128/897

ABSTRACT:

This invention is an apparatus for simulating human traumatic injury in an animal, said apparatus comprising a support having an aperture having end walls and side walls disposed therein; a sliding element slidingly engaged with said side walls of said aperture, said sliding element having a retainer disposed thereon for receiving an animal holder having a hinged first end therein; and a crank arm operatively connected to both said sliding element, and an actuator mechanism. The apparatus allows animal head motion simulative of hyperflexural trauma associated with actual injuries.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

h e b b g e e e f e b ef b e

☐ 9. Document ID: US 20030162734 A1

L2: Entry 9 of 53 File: PGPB Aug 28, 2003

PGPUB-DOCUMENT-NUMBER: 20030162734
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030162734 A1

TITLE: Modulation of DENN-MADD expression and interactions for treating neurological disorders

PUBLICATION-DATE: August 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Miller, Carol A.	San Marino	CA	US	
Villar, Keith Del	Los Angeles	CA	US	

US-CL-CURRENT: 514/44; 514/341, 514/410

ABSTRACT:

The invention describes methods for treating neurodegenerative diseases by modulating the expression of DENN in neuronal cells. It has been observed that neurodegenerative disease states are characterized by abnormal expression of DENN. The overexpression of DENN induces cell death in neuronal cells. However, reduced expression of DENN also characterizes neural tissue affected by neurodegenerative disease. Also disclosed are methods for treating neurodegenerative diseases by inhibiting the interaction of DENN-MADD (Differentially Expressed in Normal versus Neoplastic/MAPK Activating Death Domain containing)protein, also referred to herein as DENN, with c-Jun N-terminal kinases (JNKs). The invention further describes methods for treating neurodegenerative diseases by inhibiting the interaction of DENN-MADD with the p55 tumor necrosis factor receptor I (TNFRI).

☐ 10. Document ID: US 20030100508 A1

L2: Entry 10 of 53 File: PGPB May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100508
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030100508 A1

TITLE: Carbohydrate epitope mimic compounds and uses thereof

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Simon, Maryline	Baar	NY	CH	
Schachner, Melitta	Hamburg	NY	DE	
Neuberger, Timothy J.	Dobbs Ferry		US	

h e b b g e e e f e b ef b e

Herzberg, Uri Yorktown Heights US

US-CL-CURRENT: 514/14; 530/326

ABSTRACT:

This invention provides carbohydrate epitope mimic compounds, particularly peptides, and analogs and variants thereof. In particular, the compounds and peptides of the present invention mimic the carbohydrate epitope GlcA.beta.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc or sulfate - 3GlcA.beta.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc, or the L2/HNK1 carbohydrate epitope. This invention provides an isolated peptide comprising an amino acid sequence of a carbohydrate epitope mimic peptide in which the amino acid sequence is set forth in any of SEQ ID NOS: 1-8, 27-38, 39, 40 and 41, including variants, analogs and active fragments thereof. The invention further provides an isolated nucleic acid encoding a peptide comprising an amino acid sequence of a carbohydrate epitope mimic peptide. This invention provides pharmaceutical compositions and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids, particularly in modulating or mediating cell-cell adhesion and viral infection and the processes and events mediated thereby. Assays for compounds which mimic, alter or inactivate the polypeptides of the present invention for use in therapy are also provided.

☐ 11. Document ID: US 20030036509 A1

L2: Entry 11 of 53 File: PGPB Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036509
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036509 A1

TITLE: TGF-alpha polypeptides, functional fragments and methods of use therefor

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Twardzik, Daniel R.	Bainbridge Island	WA	US	
Pernet, Andre	Lake Forest	IL	US	
Felker, Thomas S.	Vashon	WA	US	
Paskell, Stefan	Bainbridge Island	WA	US	
Reno, John M.	Brier	WA	US	

US-CL-CURRENT: 514/12; 530/399

ABSTRACT:

Disclosed are TGF-60 mimetics that PEGylated TGF-.alpha. polypeptides and PEGylated TGF-60 related polypetides or fragments thereof.

---

h e b b g e e e f e b ef b e

☐ 12. Document ID: US 20030032589 A1

L2: Entry 12 of 53 File: PGPB Feb 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030032589
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030032589 A1

TITLE: NGF for the prevention of demyelination in the nervous system

PUBLICATION-DATE: February 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartke, Ilse	Mannhein	CA	DE	
Unger, Jurgen	Landshut	CA	DE	
Genain, Claude	Mill Valley		US	
Hauser, Stephen	Ross		US	

US-CL-CURRENT: 514/12

ABSTRACT:

This invention pertains to the discovery that nerve growth factor (NGF) is capable of preventing further demyelination of nervous tissue in pathologies characterized by the demyelination of nervous tissue (e.g. multiple sclerosis). In one embodiment, this invention provides a method for inhibiting demyelination in a subject having an inflammatory disease of a nervous tissue. The method involves administering an effective amount of NGF, an NGF analogue, or an active fragment of NGF where the effective amount is sufficient to downregulate the production of interferon .lambda. by T cells infiltrating the central nervous system and/or to upregulate IL-10 production by glial cells.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 13. Document ID: US 20030003087 A1

L2: Entry 13 of 53 File: PGPB Jan 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030003087
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030003087 A1

TITLE: Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system

PUBLICATION-DATE: January 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Eglitis, Martin A.	Indianapolis	IN	US	
Mezey, Eva	Rockville	MD	US	
Mouradian, Mary Maral	Bethesda	MD	US	

US-CL-CURRENT: 424/93.21; 435/372, 435/455

h e b b g e e e f e b ef b e

ABSTRACT:

The present disclosure relates to a method for introducing a hematopoietic cell into the brain of a mammal, by administering bone marrow-derived progenitor cells into the body of the mammal by intravenous injection. The bone marrow-derived cell is preferably a cell that differentiates into a glial cell.

The disclosure also relates to a method for delivery of therapeutic protein molecules into the brain of a mammal, by administering to a mammal an effective amount of bone marrow-derived progenitor cells which contain a gene having a nucleic acid sequence that encodes a functional therapeutic protein.

Isolated recombinant cells and a pharmaceutical composition are also provided.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 14. Document ID: US 20020193301 A1

L2: Entry 14 of 53 File: PGPB Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020193301
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020193301 A1

TITLE: TGF-alpha polypeptides, functional fragments and methods of use therefor

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Twardzik, Daniel R.	Bainbridge Island	WA	US	
Pernet, Andre	Lake Forest	IL	US	
Felker, Thomas S.	Vashon	WA	US	
Paskell, Stefan	Bainbridge Island	WA	US	

US-CL-CURRENT: 514/12

ABSTRACT:

Disclosed are TGF-.alpha. polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 15. Document ID: US 20020169131 A1

L2: Entry 15 of 53 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169131
PGPUB-FILING-TYPE: new

h e b b g e e e f e b ef b e

DOCUMENT-IDENTIFIER: US 20020169131 A1

TITLE: TGF-alpha polypeptides, functional fragments and methods of use therefor

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Twardzik, Daniel R.	Bainbridge Island	WA	US	
Paskell, Stefan	Bainbridge Island	WA	US	
Felker, Thomas S.	Vashon	WA	US	

US-CL-CURRENT: 514/15; 530/328

ABSTRACT:

Disclosed are peptides related to human TGF-.alpha., having TGF-.alpha. biological activity, which are useful for many of the indications that full-length TGF-.alpha. polypeptide is useful. Also provided are methods of use of such peptides, as well as human TGF-.alpha. and biologically related polypeptides. For example, methods for treating or preventing cachexia in subjects are provided as well as methods for stimulating hematopoiesis in patients undergoing cytotoxic chemotherapy. In addition, the use of TGF-.alpha. related peptides to related neurodengenerative diseases is also provided. Methods of the invention also provide protection for patients undergoing cytotoxic therapy from side effects such as gastrointestinal (GI) mucositis.

☐ 16. Document ID: US 20020169119 A1

L2: Entry 16 of 53 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169119
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169119 A1

TITLE: TGF-alpha polypeptides, functional fragments and methods of use therefor

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Twardzik, Daniel R.	Bainbridge Island	WA	US	
Pernet, Andre	Lake Forest	IL	US	
Felker, Thomas S.	Vashon	WA	US	
Paskell, Stefan	Bainbridge Island	WA	US	

US-CL-CURRENT: 514/12

ABSTRACT:

Disclosed are TGF-.alpha. polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury

h e b b g e e e f e b ef b e

as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.

☐ 17. Document ID: US 20020123465 A1

L2: Entry 17 of 53 File: PGPB Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020123465
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020123465 A1

TITLE: TGF-alpha polypeptides, functional fragments and methods of use therefor

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Twardzik, Daniel R.	Bainbridge Island	WA	US	
Pernet, Andre	Lake Forest	IL	US	
Felker, Thomas S.	Vashon	WA	US	
Paskell, Stefan	Bainbridge Island	WA	US	

US-CL-CURRENT: 514/12

ABSTRACT:

Disclosed are TGF-.alpha. polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 18. Document ID: US 20020099008 A1

L2: Entry 18 of 53 File: PGPB Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020099008
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020099008 A1

TITLE: METHOD FOR STIMULATING HEMATOPOIESIS USING TGF-ALPHA

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
TWARDZIK, DANIEL R.	BAINBRIDGE ISLAND	WA	US	

h e b b g e e e f e b ef b e

FELKER, THOMAS S.	VASHON	WA	US
PASKELL, STEFAN L.	BAINBRIDGE ISLAND	WA	US

US-CL-CURRENT: 514/12; 514/2, 530/351

ABSTRACT:

There is disclosed a novel genus of small peptides, much smaller than TGF.alpha., was discovered as having TGF.alpha. biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGF.alpha. polypeptide. There is further disclosed that TGF.alpha. and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.

☐ 19. Document ID: US 20020039789 A1

L2: Entry 19 of 53 File: PGPB Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039789
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039789 A1

TITLE: Method for production of neuroblasts

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gage, Fred H.	La Jolla	CA	US	
Ray, Jasodhara	San Diego	CA	US	

US-CL-CURRENT: 435/368

ABSTRACT:

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

☐ 20. Document ID: US 20020031497 A1

L2: Entry 20 of 53 File: PGPB Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031497
PGPUB-FILING-TYPE: new

h e b b g e e e f e b ef b e

DOCUMENT-IDENTIFIER: US 20020031497 A1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fraser, Thomas	Newton	MA	US	
Dinsmore, Jonathan	Brookline	MA	US	

US-CL-CURRENT: 424/93.7; 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

21. Document ID: US 20020028199 A1

L2: Entry 21 of 53 File: PGPB Mar 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020028199
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020028199 A1

TITLE: Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC)

PUBLICATION-DATE: March 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Griffin, John H.	Del Mar	CA	US	
Zlokovic, Berislav Y.	Rochester	NY	US	

US-CL-CURRENT: 424/94.63; 514/165, 514/262.1

ABSTRACT:

h e b b g e e e f e b ef b e

The present invention provides methods for treating subjects having or at risk of having a neuropathological disorder or brain inflammatory diseases with and without vascular involvement, and systemic inflammatory vascular disease by administering a therapeutically effective amount of Activated Protein C (APC) to the subject. Brain disorders and brain inflammatory vascular diseases that can be treated by the invention method include all neurodegenerative diseases with different types of neuronal dysfunction, including stroke, Alzheimer's disease, Parkinson's disease, Huntington disease, neuroimmunological disorders such as multiple scelrosis and Gullian-Barre, encephalitis, meningitis, as well as other peripheral vascular diseases, such as diabetes, hypertension, artheriosclerosis. Also included are methods of treatment using APC in combination with a co-factor, such as Protein S.

☐ 22. Document ID: US 20020009461 A1

L2: Entry 22 of 53 File: PGPB Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020009461
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020009461 A1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Isacson, Ole	Cambridge	MA	US	
Dinsmore, Jonathan	Brookline	MA	US	

US-CL-CURRENT: 424/193.1; 424/93.7, 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

h e b b g e e e f e b ef b e

☐ 23. Document ID: US 20020004039 A1

L2: Entry 23 of 53 File: PGPB Jan 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020004039
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020004039 A1

TITLE: Methods for treating neurological deficits

PUBLICATION-DATE: January 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Reid, James Steven	Berkeley	CA	US	
Fallon, James H.	Irvine	CA	US	

US-CL-CURRENT: 424/93.7; 435/368

ABSTRACT:

The present invention features methods and compositions for treating a patient who has a neurological deficit. The method can be carried out, for example, by contacting (in vivo or in culture) a neural progenitor cell of the patient's central nervous system (CNS) with a polypeptide that binds the epidermal growth factor (EGF) receptor and directing progeny of the proliferating progenitor cells to migrate en masse to a region of the CNS in which they will reside and function in a manner sufficient to reduce the neurological deficit. The method may include a further step in which the progeny of the neural precursor cells are contacted with a compound that stimulates differentiation.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Drawi Desc

☐ 24. Document ID: US 20010049143 A1

L2: Entry 24 of 53 File: PGPB Dec 6, 2001

PGPUB-DOCUMENT-NUMBER: 20010049143
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010049143 A1

TITLE: Human cell-lines

PUBLICATION-DATE: December 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Stringer, Bradley Michael John	Cyncoed		GB	

US-CL-CURRENT: 435/455; 435/366, 435/456

ABSTRACT:

A method for producing human cell lines by immortalizing a precursor or undifferentiated cell with a controllable immortalizing agent, culturing the cell to provide a cell population, and terminating immobilization to allow differentiation.

h e b b g e e e f e b ef b e

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 25. Document ID: US 20010007657 A1

L2: Entry 25 of 53 File: PGPB Jul 12, 2001

PGPUB-DOCUMENT-NUMBER: 20010007657
PGPUB-FILING-TYPE: new-utility
DOCUMENT-IDENTIFIER: US 20010007657 A1

TITLE: Compositions and methods for manipulating glial progenitor cells and treating neurological deficits

PUBLICATION-DATE: July 12, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Reid, James Steven	Berkeley	CA	US	
Fallon, James H.	Irvine	CA	US	

US-CL-CURRENT: 424/93.7

ABSTRACT:

The invention provides compositions and methods for attracting glial and neuronal progenitor cells and their progeny to desired sites within the central nervous system tissue. These compositions and methods can also be used to induce directed differentiation of these cells. By providing various ways to generate new glial and neuronal cells from endogenous progenitor cells, the invention also provides methods for inducing regeneration of tissues and neurological function, and, indeed, generating new phenotypes and capabilities. Thus, the invention features methods and compositions for ameliorating neurological deficits, including inherited disorders, trauma, infections and the like.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 26. Document ID: US 6764683 B1

L2: Entry 26 of 53 File: USPT Jul 20, 2004

US-PAT-NO: 6764683
DOCUMENT-IDENTIFIER: US 6764683 B1

TITLE: Loop peptide and TGF.alpha. for stimulating stem cell proliferation and migration

DATE-ISSUED: July 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Twardzik; Daniel R.	Bainbridge Island	WA		
Paskell; Stefan	Bainbridge Island	WA		

h e b b g e e e f e b ef b e

Felker; Thomas S. Vashon WA

US-CL-CURRENT: 424/198.1; 514/15, 514/2, 530/300, 530/317, 530/324, 530/327, 530/402, 930/120

ABSTRACT:

There is disclosed a novel genus of small peptides, much smaller than human TGF.alpha., was discovered as having TGF.alpha. biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGF.alpha. polypeptide. There is further disclosed that TGF.alpha. and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.

5 Claims, 11 Drawing figures
Exemplary Claim Number: 5
Number of Drawing Sheets: 10

☐ 27. Document ID: US 6677307 B2

L2: Entry 27 of 53 File: USPT Jan 13, 2004

US-PAT-NO: 6677307
DOCUMENT-IDENTIFIER: US 6677307 B2

TITLE: TGF-.alpha. polypeptides, functional fragments and methods of use therefor

DATE-ISSUED: January 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Twardzik; Daniel R.	Bainbridge Island	WA		
Pernet; Andre	Lake Forest	IL		
Felker; Thomas S.	Vashon	WA		
Paskell; Stefan	Bainbridge Island	WA		
Reno; John M.	Brier	WA		

US-CL-CURRENT: 514/12; 530/300, 530/402

ABSTRACT:

Disclosed are TGF-60 mimetics that PEGylated TGF-.alpha. polypeptides and PEGylated TGF-60 related polypetides or fragments thereof.

5 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

h e b b g e e e f e b ef b e

☐ 28. Document ID: US 6599695 B2

L2: Entry 28 of 53 File: USPT Jul 29, 2003

US-PAT-NO: 6599695
DOCUMENT-IDENTIFIER: US 6599695 B2

TITLE: Method for assaying for early gene expression in neuroblasts

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gage; Fred H.	La Jolla	CA	92037	
Ray; Jasodhara	San Diego	CA	92130	

US-CL-CURRENT: 435/4; 435/29, 435/6, 435/7.1, 435/7.2, 435/7.21

ABSTRACT:

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

4 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 29. Document ID: US 6588431 B1

L2: Entry 29 of 53 File: USPT Jul 8, 2003

US-PAT-NO: 6588431
DOCUMENT-IDENTIFIER: US 6588431 B1

TITLE: Apparatus for simulating traumatic brain injury and method for inducing spinal cord injury

DATE-ISSUED: July 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Meythaler; Jay M.	Birmingham	AL		
Peduzzi; Jean	Chelsea	AL		
Eleftheriou; Evangelos	Hoover	AL		

US-CL-CURRENT: 128/897

ABSTRACT:

h e b b g e e e f e b ef b e

An apparatus for simulating human traumatic brain injury in an animal, said apparatus comprising a support having an aperture having end walls and side walls disposed therein; a sliding element slidingly engaged with said side walls of said aperture, said sliding element having a retainer disposed thereon for receiving an animal holder therein; and a crank arm operatively connected to both said sliding element and an actuator mechanism. There is also disclosed a method of simulating human traumatic brain injury in an animal which includes the steps of providing an animal and repeatedly laterally displacing the animal in a reciprocal manner in order to cause acceleration and deceleration of the animal laterally to cause the animal's brain to be correspondingly accelerated and decelerated thereby causing traumatic brain injury. A method of simulating human spinal cord injury in an animal, said method comprising the steps of providing a vertebrate animal having an invertebral space and a spinal cord; causing an opening in the animal at the invertebral space to the interior surface of the spinal cord; inserting a deflated balloon embolectomy catheter into the opening, and rapidly inflating the balloon catheter to cause the balloon catheter to expand and contact the spinal cord whereby the contact causes injury to the spinal cord.

14 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 30. Document ID: US 6514707 B1

L2: Entry 30 of 53 File: USPT Feb 4, 2003

US-PAT-NO: 6514707
DOCUMENT-IDENTIFIER: US 6514707 B1

TITLE: Methods for detection of prion protein as an indication of transmissible spongiform encephalophathies

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Rourke; Katherine I.	Pullman	WA		
Knowles; Donald P.	Pullman	WA		
Baszler; Timothy V.	Moscow	ID		
Parish; Steven M.	Pullman	WA		

US-CL-CURRENT: 435/7.1; 435/40.5, 435/40.52, 435/7.9, 435/7.92

ABSTRACT:

Methods to detect prion or PrP-Sc protein as an indication of transmissible spongiform encephalopathies (TSEs), including preclinical detection of infected live animals, and postmortem detection methods, are described. In one aspect, the invention is directed to a non-invasive diagnostic assay using third eyelid-associated lymphoid tissue. In another aspect, the invention is directed to monoclonal antibodies that specifically bind a conserved epitope of PrP-Sc protein in fixed or frozen treated tissue.

12 Claims, 0 Drawing figures

h e b b g e e e f e b ef b e

Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 31. Document ID: US 6486122 B1

L2: Entry 31 of 53 File: USPT Nov 26, 2002

US-PAT-NO: 6486122
DOCUMENT-IDENTIFIER: US 6486122 B1

TITLE: Methods of increasing body weight in a subject by administering TGF-.alpha.

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Twardzik; Daniel R.	Bainbridge Island	WA		
Paskell; Stefan	Bainbridge Island	WA		
Felker; Thomas S.	Vashon	WA		

US-CL-CURRENT: 514/2; 530/300, 530/324

ABSTRACT:

Disclosed are peptides related to human TGF-.alpha., having TGF-.alpha. biological activity, which are useful for many of the indications that full-length TGF-.alpha. polypeptide is useful. Also provided are methods of use of such peptides, as well as human TGF-.alpha. and biologically related polypeptides. For example, methods for treating or preventing cachexia in subjects are provided as well as methods for stimulating hematopoiesis in patients undergoing cytotoxic chemotherapy. In addition, the use of TGF-.alpha. related peptides to related neurodengenerative diseases is also provided. Methods of the invention also provide protection for patients undergoing cytotoxic therapy from side effects such as gastrointestinal (GI) mucositis.

12 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 32. Document ID: US 6444205 B2

L2: Entry 32 of 53 File: USPT Sep 3, 2002

US-PAT-NO: 6444205
DOCUMENT-IDENTIFIER: US 6444205 B2
**** See image for Certificate of Correction ****

TITLE: Transplantation of neural cells for the treatment of chronic pain or spasticity

DATE-ISSUED: September 3, 2002

h e b b g e e e f e b ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA		
Siegan; Julie	Boston	MA		

US-CL-CURRENT: 424/93.7

ABSTRACT:

Methods for using neural cells to treat chronic pain and/or spasticity are described. The neural cells can be derived from any mammal, and are preferably human or porcine in origin. The neural cells preferably are serotonergic cells or are gamma-aminobutryic acid (GABA)--producing cells. Neural cells can be obtained from adult, juvenile, embryonic or fetal donors. Neural cells can be modified to be suitable for transplantation into a subject. For example, the neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject or can be genetically modified to produce a factor. In one embodiment, the neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The neural cells of the present invention can be used to treat chronic pain and/or spasticity by delivering the cells into the spinal cord of a subject.

25 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

33. Document ID: US 6340592 B1

L2: Entry 33 of 53 File: USPT Jan 22, 2002

US-PAT-NO: 6340592
DOCUMENT-IDENTIFIER: US 6340592 B1
**** See image for Certificate of Correction ****

TITLE: Human cell lines

DATE-ISSUED: January 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stringer; Bradley Michael John	Cardiff			GB

US-CL-CURRENT: 435/372; 435/325, 435/366, 435/375, 435/440, 435/455, 435/467, 536/23.1, 536/23.7, 536/23.72

ABSTRACT:

The invention relates to a method for producing human cell lines and cell and cell-lines produced by such a method. The method comprising the use of precursor or undifferentiated cells treated with an immortalising agent which is susceptible to environmental conditions so as to provide for selective activation/deactivation of said immortalising agent and so selective activation of differentiation.

h e b b g e e e f e b ef b e

21 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 34. Document ID: US 6312949 B1

L2: Entry 34 of 53 File: USPT Nov 6, 2001

US-PAT-NO: 6312949
DOCUMENT-IDENTIFIER: US 6312949 B1

TITLE: Regulation of tyrosine hydroxylase expression

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sakurada; Kazuhiro	San Diego	CA		
Palmer; Theo	San Diego	CA		
Gage; Fred H.	La Jolla	CA		

US-CL-CURRENT: 435/325; 435/183, 435/189, 435/368, 435/455, 435/6, 435/69.1, 536/23.1

ABSTRACT:

The invention relates to methods and materials involved in the regulation of tyrosine hydroxylase expression as well as the treatment of catecholamine-related diseases. Specifically, the invention provides cells that contain exogenous nucleic acid having a nucleic acid sequence that encodes Nurr1 as well as methods and materials for inducing tyrosine hydroxylase expression, treating catecholamine-related deficiencies, and identifying tyrosine hydroxylase-related deficiencies.

10 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 35. Document ID: US 6294383 B1

L2: Entry 35 of 53 File: USPT Sep 25, 2001

US-PAT-NO: 6294383
DOCUMENT-IDENTIFIER: US 6294383 B1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: September 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

h e b b g e e e f e b ef b e

Isacson; Ole	Cambridge	MA
Dinsmore; Jonathan	Brookline	MA

US-CL-CURRENT: 435/379; 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

8 Claims, 49 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

☐ 36. Document ID: US 6277372 B1

L2: Entry 36 of 53 File: USPT Aug 21, 2001

US-PAT-NO: 6277372
DOCUMENT-IDENTIFIER: US 6277372 B1
**** See image for Certificate of Correction ****

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: August 21, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fraser; Thomas	Newton	MA		
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 424/93.7; 424/93.1, 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be

h e b b g e e e f e b ef b e

modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

10 Claims, 43 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 37. Document ID: US 6265175 B1

L2: Entry 37 of 53 File: USPT Jul 24, 2001

US-PAT-NO: 6265175
DOCUMENT-IDENTIFIER: US 6265175 B1

TITLE: Method for production of neuroblasts

DATE-ISSUED: July 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gage; Fred H.	La Jolla	CA		
Ray; Jasodhara	San Diego	CA		

US-CL-CURRENT: 435/7.21; 435/29, 435/4, 435/7.1, 435/7.2

ABSTRACT:

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblast and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

4 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 38. Document ID: US 6261790 B1

L2: Entry 38 of 53 File: USPT Jul 17, 2001

US-PAT-NO: 6261790

h e b b g e e e f e b ef b e

DOCUMENT-IDENTIFIER: US 6261790 B1

TITLE: Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Rourke; Katherine I.	Albion	WA		

US-CL-CURRENT: 435/7.72; 424/130.1, 424/139.1, 424/141.1, 424/145.1, 424/152.1, 424/9.1, 435/7.1, 435/70.1, 435/70.21, 436/503, 436/518, 436/547, 436/548, 530/388.1

ABSTRACT:

Methods to detect prion or PrP-Sc protein as an indication of transmissible spongiform encephalopathies (TSEs) are described. In one aspect, the invention is directed to monoclonal antibodies that specifically bind a conserved epitope of prion proteins and use of the antibodies in immunoassays to detect PrP-Sc, in fixed or unfixed tissue, as an indication of the presence of TSE infection. In another aspect, the invention is directed to a monoclonal antibody cocktail having the monoclonal antibody in combination with a second monoclonal antibody which specifically binds to a second conserved epitope of prion proteins. One or both monoclonal antibodies of the cocktail can recognize epitopes found in all mammalian species in which a natural TSE has been reported and in a number of closely related species. Thus, the antibody cocktail provides high sensitivity, defined specificity, and broad reactivity to PrP proteins in spite of interspecies and intraspecies variation of species such as ruminant livestock, cats, mink, humans, and non-human primates.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 39. Document ID: US 6258353 B1

L2: Entry 39 of 53 File: USPT Jul 10, 2001

US-PAT-NO: 6258353
DOCUMENT-IDENTIFIER: US 6258353 B1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: July 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Isacson; Ole	Cambridge	MA		
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 424/93.1; 424/130.1, 424/143.1, 424/809, 424/93.7, 435/325, 435/368

ABSTRACT:

h e b b g e e e f e b ef b e

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

26 Claims, 62 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 24

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

---

☐ 40. Document ID: US 6204053 B1

L2: Entry 40 of 53 File: USPT Mar 20, 2001

US-PAT-NO: 6204053
DOCUMENT-IDENTIFIER: US 6204053 B1
**** See image for Certificate of Correction ****

TITLE: Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: March 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 435/325; 424/93.7, 435/374

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma,

stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

16 Claims, 49 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 19

☐ 41. Document ID: US 6197585 B1

L2: Entry 41 of 53 File: USPT Mar 6, 2001

US-PAT-NO: 6197585
DOCUMENT-IDENTIFIER: US 6197585 B1

TITLE: Human cell-lines

DATE-ISSUED: March 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stringer; Bradley Michael John	Cardiff			GB

US-CL-CURRENT: 435/368; 435/325, 435/366, 435/375, 435/440, 435/455, 435/467, 536/23.1, 536/23.7, 536/23.72

ABSTRACT:

The invention relates to a method for producing human cell lines and cell and cell-lines produced by such a method. The method comprising the use of precursor or undifferentiated cells treated with an immortalising agent which is susceptible to environmental conditions so as to provide for selective activation/deactivation of said immortalising agent and so selective activation of differentiation.

22 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 42. Document ID: US 6165784 A

L2: Entry 42 of 53 File: USPT Dec 26, 2000

US-PAT-NO: 6165784
DOCUMENT-IDENTIFIER: US 6165784 A

TITLE: Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

DATE-ISSUED: December 26, 2000

INVENTOR-INFORMATION:

h e b b g e e e f e b ef b e

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Rourke; Katherine I.	Albion	WA		
Knowles; Donald P.	Pullman	WA		
Baszler; Timothy V.	Moscow	ID		
Parish; Steven M.	Pullman	WA		

US-CL-CURRENT: 435/326; 435/329, 435/331, 530/388.2, 530/388.85

ABSTRACT:

Methods to detect prion or PrP-Sc protein as an indication of transmissible spongiform encephalopathies (TSEs), including preclinical detection of infected live animals, and postmortem detection methods, are described. In one aspect, the invention is directed to a non-invasive diagnostic assay using third eyelid-associated lymphoid tissue. In another aspect, the invention is directed to monoclonal antibodies that specifically bind a conserved epitope of PrP-Sc protein in fixed or frozen treated tissue.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 43. Document ID: US 6140116 A

L2: Entry 43 of 53 File: USPT Oct 31, 2000

US-PAT-NO: 6140116
DOCUMENT-IDENTIFIER: US 6140116 A
**** See image for Certificate of Correction ****

TITLE: Isolated and modified porcine cerebral cortical cells

DATE-ISSUED: October 31, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 435/325; 424/93.7, 435/374

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration

h e b b g e e e f e b ef b e

in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

27 Claims, 40 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

☐ 44. Document ID: US 6045807 A

L2: Entry 44 of 53 File: USPT Apr 4, 2000

US-PAT-NO: 6045807
DOCUMENT-IDENTIFIER: US 6045807 A

TITLE: Method for production of neuroblasts

DATE-ISSUED: April 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gage; Fred H.	La Jolla	CA		
Ray; Jasodhara	San Diego	CA		

US-CL-CURRENT: 424/93.21; 424/93.7, 435/325, 435/366, 435/395, 435/402, 435/404, 536/23.1

ABSTRACT:

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

9 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 45. Document ID: US 6020197 A

L2: Entry 45 of 53 File: USPT Feb 1, 2000

US-PAT-NO: 6020197
DOCUMENT-IDENTIFIER: US 6020197 A

TITLE: Method for production of neuroblasts

DATE-ISSUED: February 1, 2000

h e b b g e e e f e b ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gage; Fred H.	La Jolla	CA		
Ray; Jasodhara	San Diego	CA		

US-CL-CURRENT: 435/368; 435/325, 435/366, 435/395, 435/402, 435/404

ABSTRACT:

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

10 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 46. Document ID: US 6013521 A

L2: Entry 46 of 53 File: USPT Jan 11, 2000

US-PAT-NO: 6013521
DOCUMENT-IDENTIFIER: US 6013521 A

TITLE: Method for production of neuroblasts

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gage; Fred H.	La Jolla	CA		
Ray; Jasodhara	San Diego	CA		

US-CL-CURRENT: 435/368; 435/325, 435/363, 435/366, 435/384, 435/387, 435/395, 435/402, 435/405, 435/406, 536/23.1

ABSTRACT:

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

14 Claims, 34 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

h e b b g e e e f e b ef b e

☐ 47. Document ID: US 5850001 A

L2: Entry 47 of 53 File: USPT Dec 15, 1998

US-PAT-NO: 5850001
DOCUMENT-IDENTIFIER: US 5850001 A

TITLE: Transgenic mouse for the neuronal expression of HIV gp160

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kessous-Elbaz; Allegria	Cote-St-Luc			CA
Michaud; Jean	Montreal			CA
Berrada; Fouad	Montreal			CA

US-CL-CURRENT: 800/11; 536/23.1, 800/18

ABSTRACT:

The present invention relates to a transgenic non-human mammal, whose germ cells and somatic cells contain a recombinant env gene sequence which is operably linked to a promoter effective for the expression of the gene in the neuronal tissues of the mammal and effective for the simulation of neurological syndromes associated with HIV-1, the gene being introduced into the mammal, or an ancestor of the mammal, at an embryonic stage. The transgenic non-human mammal is such that transcription of the env gene may be under the control of a promoter sequence, such as a neuron specific promoter of human neurofilament heavy gene (NFH). The promoter can be synthetic or inducible. The transgenic non-human mammal can be a rodent, such as a mouse.

1 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

☐ 48. Document ID: US 5766948 A

L2: Entry 48 of 53 File: USPT Jun 16, 1998

US-PAT-NO: 5766948
DOCUMENT-IDENTIFIER: US 5766948 A

TITLE: Method for production of neuroblasts

DATE-ISSUED: June 16, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gage; Fred H.	La Jolla	CA		
Ray; Jasodhara	San Diego	CA		

US-CL-CURRENT: 435/368; 435/325, 435/366, 435/395, 435/402, 435/404

h e b b g e e e f e b ef b e

ABSTRACT:

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

7 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 49. Document ID: US RE35653 E

L2: Entry 49 of 53 File: USPT Nov 4, 1997

US-PAT-NO: RE35653
DOCUMENT-IDENTIFIER: US RE35653 E

TITLE: In vivo delivery of neurotransmitters by implanted, encapsulated cells

DATE-ISSUED: November 4, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aebischer; Patrick	Providence	RI		
Winn; Shelley R.	Providence	RI		
Galletti; Pierre M.	Providence	RI		

US-CL-CURRENT: 604/891.1; 128/898, 128/899, 424/424

ABSTRACT:

Methods and devices are disclosed for the delivery of a neurotransmitter from an implanted, neurotransmitter-secreting cell culture to a target region in a subject. The cell culture is maintained within a biocompatible, semipermeable membrane which permits the diffusion of the neurotransmitter therethrough while excluding viruses, antibodies, and other detrimental agents present in the external environment from gaining access. Implantable cell culture devices are disclosed, some of which may be retrieved from the subject, replaced or recharged with new, neurotransmitter-secreting cell cultures, and reimplanted.

24 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 50. Document ID: US 5569827 A

L2: Entry 50 of 53 File: USPT Oct 29, 1996

h e b b g e e e f e b ef b e

US-PAT-NO: 5569827
DOCUMENT-IDENTIFIER: US 5569827 A

TITLE: Transgenic mouse for the neuronal expression of HIV gp160

DATE-ISSUED: October 29, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kessous-Elbaz; Allegria	Cote St-Luc			CA
Michaud; Jean	Montreal			CA
Berrada; Fouad	Montreal			CA

US-CL-CURRENT: 800/11; 536/23.1, 800/18

ABSTRACT:

The present invention relates to a transgenic non-human mammal, whose germ cells and somatic cells contain a recombinant env gene sequence which is operably linked to a promoter effective for the expression of the gene in the neuronal tissues of the mammal and effective for the simulation of neurological syndromes associated with HIV-1, the gene being introduced into the mammal, or an ancestor of the mammal, at an embryonic stage. The transgenic non-human mammal is such that transcription of the env gene may be under the control of a promoter sequence, such as a neuron specific promoter of human neurofilament light gene (NFL). The promoter can be synthetic or inducible. The transgenic non-human mammal can be a rodent, such as a mouse.

1 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

☐ 51. Document ID: US 5512661 A

L2: Entry 51 of 53 File: USPT Apr 30, 1996

US-PAT-NO: 5512661
DOCUMENT-IDENTIFIER: US 5512661 A

TITLE: Multitrophic and multifunctional chimeric neurotrophic factors

DATE-ISSUED: April 30, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shooter; Eric M.	Portola Valley	CA		
Suter; Ulrich	Menlo Park	CA		
Ip; Nancy P.	Hong Kong			HK
Squinto; Stephen P.	Irvington	NY		
Furth; Mark E.	Chapel Hill	NC		
Lindsay; Ronald M.	Briarcliff Manor	NY		

US-CL-CURRENT: 530/399; 530/350, 530/839, 930/120

h e b b g e e e f e b ef b e

ABSTRACT:

The present invention relates to chimeric neurotrophic factors which comprise at least a portion of a naturally occurring cellular factor and a portion of at least one other molecule such that the resulting chimeric molecule has neurotrophic activity. It is based, in part, on the discovery that chimeric molecules comprising portions of both NGF and BDNF are likely to possess neurotrotrophic activity, and in some cases exhibit a spectrum of activity larger than that of either parent molecule. It is further based on the discovery that chimeric molecules comprising neurotrophic factor sequences as well as additional peptide sequences may retain neurotrophic activity, and in some cases may exhibit a more potent activity than the parent factor. The chimeric neurotrophic factor molecules of the invention provide a number of advantages relative to naturally occurring neurotrophic factors. Chimeric neurotrophic factors may be used to provide, for example, the activity of two neurotrophic factors in a single molecule, or may serve as superagonists of an endogenous neurotrophic factor, thereby enabling an increased biological response at lower doses.

32 Claims, 28 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 25

☐ 52. Document ID: US 5169764 A

L2: Entry 52 of 53 File: USPT Dec 8, 1992

US-PAT-NO: 5169764
DOCUMENT-IDENTIFIER: US 5169764 A

TITLE: Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras

DATE-ISSUED: December 8, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shooter; Eric M.	Portola Valley	CA		
Suter; Ulrich	Menlo Park	CA		
Ip; Nancy	Stamford	CT		
Squinto; Stephen P.	Irvington	NY		
Furth; Mark E.	Pelham	NY		
Lindsay; Ronald M.	Briarcliff Manor	NY		
Yancopoulos; George D.	Briarcliff Manor	NY		

US-CL-CURRENT: 435/69.7; 435/320.1, 514/12, 530/399, 530/402, 530/839

ABSTRACT:

The present invention relates to chimeric neurotrophic factors which comprise at least a portion of a naturally occurring cellular factor and a portion of at least one other molecule such that the resulting chimeric molecule has neurotrophic activity. It is based, in part, on the discovery that chimeric molecules comprising portions of both NGF and BDNF are likely to possess neurotrotrophic activity, and in some cases exhibit a spectrum of activity larger than that of either parent molecule. It is further based on the discovery that chimeric molecules comprising neurotrophic

h e b b g e e e f e b ef b e

factor sequences as well as additional peptide sequences may retain neurotrophic activity, and in some cases may exhibit a more potent activity than the parent factor. The chimeric neurotrophic factor molecules of the invention provide a number of advantages relative to naturally occurring neurotrophic factors. Chimeric neurotrophic factors may be used to provide, for example, the activity of two neurotrophic factors in a single molecule, or may serve as superagonists of an endogenous neurotrophic factor, thereby enabling an increased biological response at lower doses. Nucleic acids and plasmids encoding the chimeras are disclosed.

34 Claims, 26 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 25

☐ 53. Document ID: US 4892538 A

L2: Entry 53 of 53 File: USPT Jan 9, 1990

US-PAT-NO: 4892538
DOCUMENT-IDENTIFIER: US 4892538 A
**** See image for Certificate of Correction ****

TITLE: In vivo delivery of neurotransmitters by implanted, encapsulated cells

DATE-ISSUED: January 9, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aebischer; Patrick	Providence	RI		
Winn; Shelley R.	Providence	RI		
Galletti; Pierre M.	Providence	RI		

US-CL-CURRENT: 604/891.1; 128/898, 128/899, 424/424

ABSTRACT:

Methods and devices are disclosed for the delivery of a neurotransmitter from an implanted, neurotransmitter-secreting cell culture to a target region in a subject. The cell culture is maintained within a biocompatible, semipermeable membrane which permits the diffusion of the neurotransmitter therethrough while excluding viruses, antibodies, and other detrimental agents present in the external environment from gaining access. Implantable cell culture devices are disclosed, some of which may be retrieved from the subject, replaced or recharged with new, neurotransmitter-secreting cell cultures, and reimplanted.

24 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

h e b b g e e e f e b ef b e

Terms	Documents
L1 AND mesencephalon	53

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Display Summary Show: 500 Sort Send to Text

Items 1-2 of 2

One page.

1: Larsson LC, Anderson P, Widner H, Korsgrent O. Related Articles, Links

Enhanced survival of porcine neural xenografts in mice lacking CD1d1, but no effect of NK1.1 depletion.
Cell Transplant. 2001;10(3):295-304.
PMID: 11437075 [PubMed - indexed for MEDLINE]

2: Brevig T, Kristensen T, Zimmer J. Related Articles, Links

Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain.
Exp Neurol. 1999 Oct;159(2):474-83.
PMID: 10506518 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for mesencephalon AND porcine AND monocyte Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-2 of 2 One page.

1: Larsson LC, Anderson P, Widner H, Korsgrent O. Related Articles, Links

Enhanced survival of porcine neural xenografts in mice lacking CD1d1, but no effect of NK1.1 depletion.
Cell Transplant. 2001;10(3):295-304.
PMID: 11437075 [PubMed - indexed for MEDLINE]

2: Brevig T, Kristensen T, Zimmer J. Related Articles, Links

Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain.
Exp Neurol. 1999 Oct;159(2):474-83.
PMID: 10506518 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for mesencephalon AND porcine Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-148 of 148 One page.

1: Pirone A, Lenzi C, Betti L, Giannaccini G, Lucacchini A, Marroni P, Fabiani O. Related Articles, Links

Immunohistochemical distribution of neuropeptide Y in the mesencephalon and rhombencephalon of carp, Cyprinus carpio L. (Cyprinidae: Teleostei).
Comp Biochem Physiol A Mol Integr Physiol. 2004 Jun;138(2):175-85.
PMID: 15275652 [PubMed - in process]

2: Rosa-Neto P, Olsen AK, Gjedde A, Watanabe H, Cumming P. Related Articles, Links

MDMA-evoked changes in cerebral blood flow in living porcine brain: Correlation with hyperthermia.
Synapse. 2004 Sep 15;53(4):214-21.
PMID: 15266553 [PubMed - in process]

3: Brust P, Walter B, Hinz R, Fuchtner F, Muller M, Steinbach J, Bauer R. Related Articles, Links

Developmental changes in the activities of aromatic amino acid decarboxylase and catechol-O-methyl transferase in the porcine brain: a positron emission tomography study.
Neurosci Lett. 2004 Jul 8;364(3):159-63.
PMID: 15196667 [PubMed - in process]

4: Niblock MM, Kinney HC, Luce CJ, Belliveau RA, Filiano JJ. Related Articles, Links

The development of the medullary serotonergic system in the piglet.
Auton Neurosci. 2004 Feb 27;110(2):65-80.
PMID: 15046730 [PubMed - indexed for MEDLINE]

5: Zwiener U, Walter B, Kratzsch B, Bauer R. Related Articles, Links

Marked reduction of brainstem blood flow in artificially ventilated newborn piglets during normoxia and normocapnic hypoxia.
Intensive Care Med. 2003 Dec;29(12):2277-84. Epub 2003 Oct 16.
PMID: 14564376 [PubMed - indexed for MEDLINE]

6: Larsson LC, Corbascio M, Pearson TC, Larsen CP, Ekberg H, Widner H. Related Articles, Links

Induction of operational tolerance to discordant dopaminergic porcine xenografts.
Transplantation. 2003 May 15;75(9):1448-54.
PMID: 12792495 [PubMed - indexed for MEDLINE]

7: Armstrong RJ, Tyers P, Jain M, Richards A, Dunnett SB, Rosser AE, Barker RA. Related Articles, Links

Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease.
Exp Brain Res. 2003 Jul;151(2):204-17. Epub 2003 Jun 03.
PMID: 12783147 [PubMed - indexed for MEDLINE]

8: Jensen SB, Smith DF, Bender D, Jakobsen S, Peters D, Nielsen EO, Olsen GM, Scheel-Kruger J, Wilson A, Cumming P. Related Articles, Links

h cb hg e e e fcg e ch b e

[11C]-NS 4194 versus [11C]-DASB for PET imaging of serotonin transporters in living porcine brain.
Synapse. 2003 Sep 1;49(3):170-7.
PMID: 12774301 [PubMed - indexed for MEDLINE]

9: Prado WA, Pelegrini-da-Silva A, Martins AR. Related Articles, Links

Microinjection of renin-angiotensin system peptides in discrete sites within the rat periaqueductal gray matter elicits antinociception.
Brain Res. 2003 May 16;972(1-2):207-15.
PMID: 12711094 [PubMed - indexed for MEDLINE]

10: Brachet P, Damier P. Related Articles, Links

[Repair]
Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S49-55. Review. French.
PMID: 12690664 [PubMed - indexed for MEDLINE]

11: Brachet P, Damier P. Related Articles, Links

[Repair]
Rev Neurol (Paris). 2002;158(122):49-55. French.
PMID: 12690315 [PubMed - as supplied by publisher]

12: Dall AM, Danielsen EH, Sorensen JC, Andersen F, Moller A, Zimmer J, Gjedde AH, Cumming P; Danish Neuronal Xenografting Group. Related Articles, Links

Quantitative [18F]fluorodopa/PET and histology of fetal mesencephalic dopaminergic grafts to the striatum of MPTP-poisoned minipigs.
Cell Transplant. 2002;11(8):733-46.
PMID: 12588105 [PubMed - indexed for MEDLINE]

13: Bauer M, Meyer M, Brevig T, Gasser T, Widmer HR, Zimmer J, Ueffing M. Related Articles, Links

Lipid-mediated glial cell line-derived neurotrophic factor gene transfer to cultured porcine ventral mesencephalic tissue.
Exp Neurol. 2002 Sep;177(1):40-9.
PMID: 12429209 [PubMed - indexed for MEDLINE]

14: Cicchetti F, Costantini L, Belizaire R, Burton W, Isacson O, Fodor W. Related Articles, Links

Combined inhibition of apoptosis and complement improves neural graft survival of embryonic rat and porcine mesencephalon in the rat brain.
Exp Neurol. 2002 Oct;177(2):376-84.
PMID: 12429184 [PubMed - indexed for MEDLINE]

15: Messier ML, Li A, Nattie EE. Related Articles, Links

Muscimol inhibition of medullary raphe neurons decreases the CO2 response and alters sleep in newborn piglets.
Respir Physiol Neurobiol. 2002 Nov 19;133(3):197-214.
PMID: 12425968 [PubMed - indexed for MEDLINE]

16: Jacoby DB, Lindberg C, Ratliff J, Wetzel K, Stewart GR, Dinsmore J. Related Articles, Links

Comparison of fresh and cryopreserved porcine ventral mesencephalon cells transplanted in A rat model of Parkinson's disease.
J Neurosci Res. 2002 Aug 1;69(3):382-96.
PMID: 12125079 [PubMed - indexed for MEDLINE]

17: Barker RA. Related Articles, Links

Repairing the brain in Parkinson's disease: where next?
Mov Disord. 2002 Mar;17(2):233-41. Review. No abstract available.

PMID: 11921107 [PubMed - indexed for MEDLINE]

18: Lindvall O. Related Articles, Links

Parkinson disease. Stem cell transplantation.
Lancet. 2001 Dec;358 Suppl:S48. No abstract available.
PMID: 11784596 [PubMed - indexed for MEDLINE]

19: Bellido I, Diaz-Cabiale Z, Jimenez-Vasquez PA, Andbjer B, Mathe AA, Fuxe K. Related Articles, Links

Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression.
Neurosci Lett. 2002 Jan 11;317(2):101-5.
PMID: 11755250 [PubMed - indexed for MEDLINE]

20: Koopmans J, HogenEsch I, Copray S, Middel B, van Dijk H, Go KG, Staal M. Related Articles, Links

Cryopreservation of porcine fetal ventral mesencephalic tissue for intrastriatal transplantation in Parkinson's disease.
Cell Transplant. 2001;10(7):573-81.
PMID: 11714191 [PubMed - indexed for MEDLINE]

21: Larsson LC, Frielingsdorf H, Mirza B, Hansson SJ, Anderson P, Czech KA, Strandberg M, Widner H. Related Articles, Links

Porcine neural xenografts in rats and mice: donor tissue development and characteristics of rejection.
Exp Neurol. 2001 Nov;172(1):100-14.
PMID: 11681844 [PubMed - indexed for MEDLINE]

22: Brevig T, Meyer M, Kristensen T, Zimmer J, Holgersson J. Related Articles, Links

Xenotransplantation for brain repair: reduction of porcine donor tissue immunogenicity by treatment with anti-Gal antibodies and complement.
Transplantation. 2001 Jul 27;72(2):190-6.
PMID: 11477337 [PubMed - indexed for MEDLINE]

23: Larsson LC, Anderson P, Widner H, Korsgrent O. Related Articles, Links

Enhanced survival of porcine neural xenografts in mice lacking CD1d1, but no effect of NK1.1 depletion.
Cell Transplant. 2001;10(3):295-304.
PMID: 11437075 [PubMed - indexed for MEDLINE]

24: Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, Lejeune F, Rivet JM, Brocco M, Duqueyroix D, Nicolas JP, Boutin JA, Newman-Tancredi A Related Articles, Links

Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
J Pharmacol Exp Ther. 2001 Jun;297(3):876-87.
PMID: 11356907 [PubMed - indexed for MEDLINE]

25: Subramanian T. Related Articles, Links

Cell transplantation for the treatment of Parkinson's disease.
Semin Neurol. 2001;21(1):103-15. Review.
PMID: 11346020 [PubMed - indexed for MEDLINE]

26: Brevig T, Meyer M, Kristensen T, Zimmer J. Related Articles, Links

Neural xenotransplantation: pretreatment of porcine embryonic nigral tissue with anti-Gal antibodies and complement is not toxic for the dopaminergic neurons.
Cell Transplant. 2001 Jan-Feb;10(1):25-30.

PMID: 11294468 [PubMed - indexed for MEDLINE]

27: Bauer R, Walter B, Vorwieger G, Bergmann R, Fuchtner F, Brust P. Related Articles, Links

Intrauterine growth restriction induces up-regulation of cerebral aromatic amino acid decarboxylase activity in newborn piglets: [18F]fluorodopa positron emission tomographis study.
Pediatr Res. 2001 Apr;49(4):474-80.
PMID: 11264429 [PubMed - indexed for MEDLINE]

28: Kalman M, Pritz MB. Related Articles, Links

Glial fibrillary acidic protein-immunopositive structures in the brain of a Crocodilian, Caiman crocodilus, and its bearing on the evolution of astroglia.
J Comp Neurol. 2001 Mar 19;431(4):460-80.
PMID: 11223815 [PubMed - indexed for MEDLINE]

29: Pedersen EB, Widner H. Related Articles, Links

Xenotransplantation.
Prog Brain Res. 2000;127:157-88. Review. No abstract available.
PMID: 11142027 [PubMed - indexed for MEDLINE]

30: Innis SM. Related Articles, Links

The role of dietary n-6 and n-3 fatty acids in the developing brain.
Dev Neurosci. 2000 Sep-Dec;22(5-6):474-80. Review.
PMID: 11111165 [PubMed - indexed for MEDLINE]

31: Dinsmore JH, Manhart C, Raineri R, Jacoby DB, Moore A. Related Articles, Links

No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells.
Transplantation. 2000 Nov 15;70(9):1382-9.
PMID: 11087157 [PubMed - indexed for MEDLINE]

32: Armstead WM. Related Articles, Links

Role of nociceptin/orphanin FQ in age-dependent cerebral hemodynamic effects of brain injury.
J Neurotrauma. 2000 Sep;17(9):751-64.
PMID: 11011815 [PubMed - indexed for MEDLINE]

33: HogenEsch RI, Koopmans J, Copray JC, van Roon WM, Kema I, Molenaar G, Go KG, Staal MJ. Related Articles, Links

Fetal porcine ventral mesencephalon graft. Determination of the optimal gestational age for implantation in parkinsonian patients.
Exp Brain Res. 2000 Jun;132(3):345-50.
PMID: 10883382 [PubMed - indexed for MEDLINE]

34: Meyer M, Johansen J, Gramsbergen JB, Johansen TE, Zimmer J. Related Articles, Links

Improved survival of embryonic porcine dopaminergic neurons in coculture with a conditionally immortalized GDNF-producing hippocampal cell line.
Exp Neurol. 2000 Jul;164(1):82-93.
PMID: 10877918 [PubMed - indexed for MEDLINE]

35: Fabre V, Boutrel B, Hanoun N, Lanfumey L, Fattaccini CM, Demeneix B, Adrien J, Hamon M, Martres MP. Related Articles, Links

Homeostatic regulation of serotonergic function by the serotonin transporter as revealed by nonviral gene transfer.
J Neurosci. 2000 Jul 1;20(13):5065-75.
PMID: 10864964 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

☐ **36:** Larsson LC, Czech KA, Brundin P, Widner H. Related Articles, Links

Intrastriatal ventral mesencephalic xenografts of porcine tissue in rats: immune responses and functional effects.
Cell Transplant. 2000 Mar-Apr;9(2):261-72.
PMID: 10811398 [PubMed - indexed for MEDLINE]

☐ **37:** Danielsen EH, Cumming P, Andersen F, Bender D, Brevig T, Falborg L, Gee A, Gillings NM, Hansen SB, Hermansen F, Johansen J, Johansen TE, Dahl-Jorgensen A, Jorgensen HA, Meyer M, Munk O, Pedersen EB, Poulsen PH, Rodell AB, Sakoh M, Simonsen CZ, Smith DF, Sorensen JC, Ostergard L, Zimmer J, Gjedde A. Related Articles, Links

The DaNeX study of embryonic mesencephalic, dopaminergic tissue grafted to a minipig model of Parkinson's disease: preliminary findings of effect of MPTP poisoning on striatal dopaminergic markers.
Cell Transplant. 2000 Mar-Apr;9(2):247-59.
PMID: 10811397 [PubMed - indexed for MEDLINE]

☐ **38:** Barker RA, Ratcliffe E, McLaughlin M, Richards A, Dunnett SB. Related Articles, Links

A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease.
J Neurosci. 2000 May 1;20(9):3415-24.
PMID: 10777804 [PubMed - indexed for MEDLINE]

☐ **39:** Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, Fischman AJ, Thomas C, Feldman RG, Kassissieh S, Raineri R, Manhart C, Penney D, Fink JS, Isacson O. Related Articles, Links

Transplantation of embryonic porcine mesencephalic tissue in patients with PD.
Neurology. 2000 Mar 14;54(5):1042-50.
PMID: 10720272 [PubMed - indexed for MEDLINE]

☐ **40:** Sumitran S, Anderson P, Widner H, Holgersson J. Related Articles, Links

Porcine embryonic brain cell cytotoxicity mediated by human natural killer cells.
Cell Transplant. 1999 Nov-Dec;8(6):601-10.
PMID: 10701489 [PubMed - indexed for MEDLINE]

☐ **41:** Barker RA, Ratcliffe E, Richards A, Dunnett SB. Related Articles, Links

Fetal porcine dopaminergic cell survival in vitro and its relationship to embryonic age.
Cell Transplant. 1999 Nov-Dec;8(6):593-9.
PMID: 10701488 [PubMed - indexed for MEDLINE]

☐ **42:** Larsson LC, Czech KA, Widner H, Korsgren O. Related Articles, Links

Discordant neural tissue xenografts survive longer in immunoglobulin deficient mice.
Transplantation. 1999 Oct 27;68(8):1153-60.
PMID: 10551645 [PubMed - indexed for MEDLINE]

☐ **43:** Brevig T, Kristensen T, Zimmer J. Related Articles, Links

Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain.
Exp Neurol. 1999 Oct;159(2):474-83.
PMID: 10506518 [PubMed - indexed for MEDLINE]

☐ **44:** Sumitran S, Liu J, Czech KA, Christensson B, Widner H, Holgersson J. Related Articles, Links

Human natural antibodies cytotoxic to pig embryonic brain cells recognize novel non-Galalpha1,3Gal-based xenoantigens.
Exp Neurol. 1999 Oct;159(2):347-61.
PMID: 10506507 [PubMed - indexed for MEDLINE]

45: Donald JA, Toop T, Evans DH. Related Articles, Links

Natriuretic peptide binding sites in the brain of the Atlantic hagfish, Myxine glutinosa.
J Exp Zool. 1999 Sep 1;284(4):407-13.
PMID: 10451418 [PubMed - indexed for MEDLINE]

46: Lange D, Funa K, Ishisaki A, Bauer R, Wollina U. Related Articles, Links

Autocrine endothelial regulation in brain stem vessels of newborn piglets.
Histol Histopathol. 1999 Jul;14(3):821-5.
PMID: 10425552 [PubMed - indexed for MEDLINE]

47: Piekarzewska A, Sadowski B, Rosochacki SJ. Related Articles, Links

Alterations of brain monoamine levels in pigs exposed to acute immobilization stress.
Zentralbl Veterinarmed A. 1999 May;46(4):197-207.
PMID: 10399478 [PubMed - indexed for MEDLINE]

48: McLeod JL, Donald JA. Related Articles, Links

Relationship between arginine vasotocin-like and natriuretic peptide-like immunoreactive structures in the brain of the toad Bufo marinus.
Cell Tissue Res. 1999 Jul;297(1):47-55.
PMID: 10398882 [PubMed - indexed for MEDLINE]

49: St-John WM, St Jacques R, Li A, Darnall RA. Related Articles, Links

Modulation of hypoxic depressions of ventilatory activity in the newborn piglet by mesencephalic mechanisms.
Brain Res. 1999 Feb 20;819(1-2):147-9.
PMID: 10082870 [PubMed - indexed for MEDLINE]

50: Chiba A. Related Articles, Links

Immunohistochemical distribution of neuropeptide Y-related substance in the brain and hypophysis of the arctic lamprey, Lethenteron japonica.
Brain Behav Evol. 1999;53(2):102-9.
PMID: 9933786 [PubMed - indexed for MEDLINE]

51: Itakura T, Nakai E, Nakao N, Nakai K. Related Articles, Links

Transplantation of neural tissue into the brain--a new therapeutic modality for the 21st century.
Neurol Med Chir (Tokyo). 1998 Nov;38(11):756-62. Review. No abstract available.
PMID: 9919910 [PubMed - indexed for MEDLINE]

52: Martres MP, Demeneix B, Hanoun N, Hamon M, Giros B. Related Articles, Links

Up- and down-expression of the dopamine transporter by plasmid DNA transfer in the rat brain.
Eur J Neurosci. 1998 Dec;10(12):3607-16.
PMID: 9875340 [PubMed - indexed for MEDLINE]

53: Schwippert WW, Rottgen A, Ewert JP. Related Articles, Links

Neuropeptide Y (NPY) or fragment NPY 13-36, but not NPY 18-36, inhibit retinotectal transfer in cane toads Bufo marinus.
Neurosci Lett. 1998 Aug 28;253(1):33-6.
PMID: 9754798 [PubMed - indexed for MEDLINE]

54: Othberg AI, Willing AE, Saporta S, Cameron DF, Sanberg PR. Related Articles, Links

Preparation of cell suspensions for co-transplantation: methodological considerations.
Neurosci Lett. 1998 May 15;247(2-3):111-4.
PMID: 9655605 [PubMed - indexed for MEDLINE]

55: Othberg AI, Willing AE, Cameron DF, Anton A, Saporta S, Freeman TB, Sanberg PR. Related Articles, Links

Trophic effect of porcine Sertoli cells on rat and human ventral mesencephalic cells and hNT neurons in vitro.
Cell Transplant. 1998 Mar-Apr;7(2):157-64. Erratum in: Cell Transplant 1998 Sep-Oct;7 (5):497.
PMID: 9588597 [PubMed - indexed for MEDLINE]

56: Dreshaj IA, Haxhiu MA, Martin RJ. Related Articles, Links

Role of the medullary raphe nuclei in the respiratory response to CO2.
Respir Physiol. 1998 Jan;111(1):15-23.
PMID: 9496468 [PubMed - indexed for MEDLINE]

57: Ostergaard K. Related Articles, Links

The nigrostriatal system. An experimental slice culture study of the postnatal rat with a description of the pig mesencephalon.
Acta Neurol Scand Suppl. 1997;171:1-36. No abstract available.
PMID: 9406618 [PubMed - indexed for MEDLINE]

58: Molenaar GJ, Hogenesch RI, Sprengers ME, Staal MJ. Related Articles, Links

Ontogenesis of embryonic porcine ventral mesencephalon in the perspective of its potential use as a xenograft in Parkinson's disease.
J Comp Neurol. 1997 May 26;382(1):19-28.
PMID: 9136809 [PubMed - indexed for MEDLINE]

59: Wolfla CE, Luerssen TG, Bowman RM. Related Articles, Links

Regional brain tissue pressure gradients created by expanding extradural temporal mass lesion.
J Neurosurg. 1997 Mar;86(3):505-10.
PMID: 9046308 [PubMed - indexed for MEDLINE]

60: Galpern WR, Burns LH, Deacon TW, Dinsmore J, Isacson O. Related Articles, Links

Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology.
Exp Neurol. 1996 Jul;140(1):1-13.
PMID: 8682173 [PubMed - indexed for MEDLINE]

61: Jimenez AJ, Mancera JM, Pombal MA, Perez-Figares JM, Fernandez-Llebrez P. Related Articles, Links

Distribution of galanin-like immunoreactive elements in the brain of the adult lamprey Lampetra fluviatilis.
J Comp Neurol. 1996 Apr 29;368(2):185-97.
PMID: 8725301 [PubMed - indexed for MEDLINE]

62: Hau SK, Mytilineou C, Cohen G. Related Articles, Links

L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress.
J Neurochem. 1996 Feb;66(2):501-10.
PMID: 8592119 [PubMed - indexed for MEDLINE]

63: Pearson PL, Anderson LL, Jacobson CD. Related Articles, Links

The prepubertal ontogeny of neuropeptide Y-like immunoreactivity in the

male Meishan pig brain.
Brain Res Dev Brain Res. 1996 Jan 22;91(1):41-69.
PMID: 8821478 [PubMed - indexed for MEDLINE]

64: Illing RB. Related Articles, Links

The mosaic architecture of the superior colliculus.
Prog Brain Res. 1996;112:17-34.
PMID: 8979818 [PubMed - indexed for MEDLINE]

65: Holtzman D, Mulkern R, Tsuji M, Cook C, Meyers R. Related Articles, Links

Phosphocreatine and creatine kinase in piglet cerebral gray and white matter in situ.
Dev Neurosci. 1996;18(5-6):535-41.
PMID: 8940629 [PubMed - indexed for MEDLINE]

66: García AR, Deacon TW, Dinsmore J, Isacson O. Related Articles, Links

Extensive axonal and glial fiber growth from fetal porcine cortical xenografts in the adult rat cortex.
Cell Transplant. 1995 Sep-Oct;4(5):515-27.
PMID: 8520835 [PubMed - indexed for MEDLINE]

67: Vallarino M, Tranchand-Bunel D, Thoumas JL, Masini MA, Conlon JM, Fournier A, Pelletier G, Vaudry H. Related Articles, Links

Neuropeptide tyrosine in the brain of the African lungfish, Protopterus annectens: immunohistochemical localization and biochemical characterization.
J Comp Neurol. 1995 Jun 12;356(4):537-51.
PMID: 7560265 [PubMed - indexed for MEDLINE]

68: Jimenez AJ, Mancera JM, Perez-Figares JM, Fernandez-Llebrez P. Related Articles, Links

Distribution of galanin-like immunoreactivity in the brain of the turtle Mauremys caspica.
J Comp Neurol. 1994 Nov 1;349(1):73-84.
PMID: 7531723 [PubMed - indexed for MEDLINE]

69: Caffe AR. Related Articles, Links

Light microscopic distribution of some cholinergic markers in the rat and rabbit locus coeruleus and the nucleus angularis grisea periventricularis of the domestic pig (Sus scrofa): a correlative electron microscopic investigation of cholinergic receptor proteins in the rabbit.
Microsc Res Tech. 1994 Oct 15;29(3):186-99.
PMID: 7849322 [PubMed - indexed for MEDLINE]

70: Klosen P, Van den Bosch de Aguilar P. Related Articles, Links

Phosphorylated neurofilament epitopes in neuronal perikarya in the septum, mesencephalon and dorsal root ganglia of mammals and birds.
J Neurocytol. 1994 May;23(5):297-311.
PMID: 7522268 [PubMed - indexed for MEDLINE]

71: Benedetti F, Ferro I. Related Articles, Links

Implantation of artificial whiskers on the ears of newborn mice induces visual re-mapping in the superior colliculus.
Neurosci Lett. 1994 Feb 28;168(1-2):45-8.
PMID: 8028792 [PubMed - indexed for MEDLINE]

72: Spector DH, Boss BD, Strecker RE. Related Articles, Links

A model three-dimensional culture system for mammalian dopaminergic

precursor cells: application for functional intracerebral transplantation.
Exp Neurol. 1993 Dec;124(2):253-64.
PMID: 7904568 [PubMed - indexed for MEDLINE]

73: Beer MS, Stanton JA, Bevan Y, Heald A, Reeve AJ, Street LJ, Matassa VG, Hargreaves RJ, Middlemiss DN. Related Articles, Links

L-694,247: a potent 5-HT1D receptor agonist.
Br J Pharmacol. 1993 Nov;110(3):1196-200.
PMID: 8298808 [PubMed - indexed for MEDLINE]

74: Barnes K, Turner AJ, Kenny AJ. Related Articles, Links

Co-localisation of substance P and endopeptidase-24.11 in pig substantia nigra: an ultrastructural study.
Biochem Soc Trans. 1993 Aug;21 (Pt 3)(3):246S. No abstract available.
PMID: 7693520 [PubMed - indexed for MEDLINE]

75: Barnes K, Turner AJ, Kenny AJ. Related Articles, Links

An immunoelectron microscopic study of pig substantia nigra shows co-localization of endopeptidase-24.11 with substance P.
Neuroscience. 1993 Apr;53(4):1073-82.
PMID: 7685069 [PubMed - indexed for MEDLINE]

76: Donald JA, Vomachka AJ, Evans DH. Related Articles, Links

Immunohistochemical localisation of natriuretic peptides in the brains and hearts of the spiny dogfish Squalus acanthias and the Atlantic hagfish Myxine glutinosa.
Cell Tissue Res. 1992 Dec;270(3):535-45.
PMID: 1486606 [PubMed - indexed for MEDLINE]

77: Ostergaard K, Holm IE, Zimmer J. Related Articles, Links

Tyrosine hydroxylase and acetylcholinesterase in the domestic pig mesencephalon: an immunocytochemical and histochemical study.
J Comp Neurol. 1992 Aug 8;322(2):149-66.
PMID: 1355778 [PubMed - indexed for MEDLINE]

78: Barnes K, Turner AJ, Kenny AJ. Related Articles, Links

Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase A (angiotensin converting enzyme) in the pig brain: a study using subcellular fractionation and electron microscopic immunocytochemistry.
J Neurochem. 1992 Jun;58(6):2088-96.
PMID: 1315375 [PubMed - indexed for MEDLINE]

79: Kopyov OV, Polzik ES, Jacques DB, Kimble HJ, Rand RW, Craft J. Related Articles, Links

Effect of coherent blue light on fetal pig xenotransplants.
Transplant Proc. 1992 Apr;24(2):549-50. No abstract available.
PMID: 1566425 [PubMed - indexed for MEDLINE]

80: Kopyov OV, Jacques DB, Rand RW, Craft J, Buckwalter JG. Related Articles, Links

Fetal human and pig mesencephalon xenografts have equal effectiveness in behavioral restoration of damaged rat brain.
Transplant Proc. 1992 Apr;24(2):547-8. No abstract available.
PMID: 1566424 [PubMed - indexed for MEDLINE]

81: Crick DC, Rush JS, Waechter CJ. Related Articles, Links

Characterization and localization of a long-chain isoprenyltransferase activity in porcine brain: proposed role in the biosynthesis of dolichyl phosphate.

h cb h g e e e fcg e ch b e

J Neurochem. 1991 Oct;57(4):1354-62.
PMID: 1895109 [PubMed - indexed for MEDLINE]

☐ **82:** Lazar GY, Liposits ZS, Toth P, Trasti SL, Maderdrut JL, Merchenthaler I. Related Articles, Links

Distribution of galanin-like immunoreactivity in the brain of Rana esculenta and Xenopus laevis.
J Comp Neurol. 1991 Aug 1;310(1):45-67.
PMID: 1719037 [PubMed - indexed for MEDLINE]

☐ **83:** Cheung R, Ferreira LC, Youson JH. Related Articles, Links

Distribution of two forms of somatostatin and peptides belonging to the pancreatic polypeptide family in tissues of larval lampreys, Petromyzon marinus L.: an immunohistochemical study.
Gen Comp Endocrinol. 1991 Apr;82(1):93-102.
PMID: 1678724 [PubMed - indexed for MEDLINE]

☐ **84:** Olivereau M, Olivereau JM. Related Articles, Links

Corticotropin-like immunoreactivity in the brain and pituitary of three teleost species (goldfish, trout and eel).
Cell Tissue Res. 1990 Oct;262(1):115-23.
PMID: 2175252 [PubMed - indexed for MEDLINE]

☐ **85:** Ganz JC, Hall C, Zwetnow NN. Related Articles, Links

Cerebral blood flow during experimental epidural bleeding in swine.
Acta Neurochir (Wien). 1990;103(3-4):148-57.
PMID: 2399842 [PubMed - indexed for MEDLINE]

☐ **86:** Madsen FF, Jensen FT, Vaeth M, Djurhuus JC. Related Articles, Links

Regional cerebral blood flow in pigs estimated by microspheres.
Acta Neurochir (Wien). 1990;103(3-4):139-47.
PMID: 2399841 [PubMed - indexed for MEDLINE]

☐ **87:** Plogmann D, Kruska D. Related Articles, Links

Volumetric comparison of auditory structures in the brains of European wild boars (Sus scrofa) and domestic pigs (Sus scrofa f. dom.).
Brain Behav Evol. 1990;35(3):146-55.
PMID: 2375973 [PubMed - indexed for MEDLINE]

☐ **88:** Leffler CW, Busija DW, Mirro R, Armstead WM, Beasley DG. Related Articles, Links

Effects of ischemia on brain blood flow and oxygen consumption of newborn pigs.
Am J Physiol. 1989 Dec;257(6 Pt 2):H1917-26.
PMID: 2513731 [PubMed - indexed for MEDLINE]

☐ **89:** Waeber C, Schoeffter P, Palacios JM, Hoyer D. Related Articles, Links

5-HT1D receptors in guinea-pig and pigeon brain. Radioligand binding and biochemical studies.
Naunyn Schmiedebergs Arch Pharmacol. 1989 Nov;340(5):479-85.
PMID: 2533324 [PubMed - indexed for MEDLINE]

☐ **90:** Schoeffter P, Hoyer D. Related Articles, Links

Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?
Naunyn Schmiedebergs Arch Pharmacol. 1989 Jun;339(6):675-83.
PMID: 2770889 [PubMed - indexed for MEDLINE]

☐ **91:** Jaworska-Adamu J, Cybulska R. Related Articles, Links

h cb hg e e e fcg e ch b e

The development of activity of succinate dehydrogenase (EC.1.3.99.1) in the areas of the nigro-striatal pathway during the ontogenesis of a pig.
Folia Histochem Cytobiol. 1989;27(2):97-106.
PMID: 2767284 [PubMed - indexed for MEDLINE]

92: Jaworska-Adamu J. Related Articles, Links

The development of activity of lactate dehydrogenase (EC 1.1.1.27) in the areas of nigro-striatal pathway during the ontogenesis of pig.
Folia Histochem Cytobiol. 1989;27(3):131-40.
PMID: 2612692 [PubMed - indexed for MEDLINE]

93: Huffaker TK, Boss BD, Morgan AS, Neff NT, Strecker RE, Spence MS, Miao R. Related Articles, Links

Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease.
Exp Brain Res. 1989;77(2):329-36.
PMID: 2571515 [PubMed - indexed for MEDLINE]

94: Chiriboga CA, Pranzatelli MR, De Vivo DC. Related Articles, Links

Chronic ACTH treatment increases striatal dopamine D-2 receptor binding in developing rat brain.
Brain Dev. 1989;11(3):197-200.
PMID: 2546461 [PubMed - indexed for MEDLINE]

95: Nona SN, Shehab SA, Stafford CA, Cronly-Dillon JR. Related Articles, Links

Glial fibrillary acidic protein (GFAP) from goldfish: its localisation in visual pathway.
Glia. 1989;2(3):189-200.
PMID: 2526081 [PubMed - indexed for MEDLINE]

96: Perroteau I, Danger JM, Biffo S, Pelletier G, Vaudry H, Fasolo A. Related Articles, Links

Distribution and characterization of neuropeptide Y-like immunoreactivity in the brain of the crested newt.
J Comp Neurol. 1988 Sep 15;275(3):309-25.
PMID: 3225341 [PubMed - indexed for MEDLINE]

97: Hoyer D, Schoeffter P. Related Articles, Links

5-HT1D receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in calf substantia nigra.
Eur J Pharmacol. 1988 Feb 16;147(1):145-7. No abstract available.
PMID: 3371410 [PubMed - indexed for MEDLINE]

98: Freeman TB, Wojak JC, Brandeis L, Michel JP, Pearson J, Flamm ES. Related Articles, Links

Cross-species intracerebral grafting of embryonic swine dopaminergic neurons.
Prog Brain Res. 1988;78:473-7. No abstract available.
PMID: 3247444 [PubMed - indexed for MEDLINE]

99: Merchenthaler I, Maderdrut JL, Lazar G, Gulyas J, Petrusz P. Related Articles, Links

Immunocytochemical analysis of proenkephalin-derived peptides in the amphibian hypothalamus and optic tectum.
Brain Res. 1987 Jul 28;416(2):219-27.
PMID: 3113668 [PubMed - indexed for MEDLINE]

100: O'Byrne KT, Eltringham I, Summerlee AJ. Related Articles, Links

Central inhibitory effects of relaxin on the milk ejection reflex of the rat depends upon the site of injection into the cerebroventricular system.

h cb h g e e e fcg e ch b e

Brain Res. 1987 Mar 3;405(1):80-3.
PMID: 3567598 [PubMed - indexed for MEDLINE]

101: Ekstrom P. Related Articles, Links

Distribution of choline acetyltransferase-immunoreactive neurons in the brain of a cyprinid teleost (Phoxinus phoxinus L.).
J Comp Neurol. 1987 Feb 22;256(4):494-515.
PMID: 3549797 [PubMed - indexed for MEDLINE]

102: Hummel G. Related Articles, Links

[Structure and function of the central nervous system of domestic animals]
Tierarztl Prax. 1987;15(1):1-10. German.
PMID: 3590162 [PubMed - indexed for MEDLINE]

103: Konradi C, Riederer P, Jellinger K, Denney R. Related Articles, Links

Cellular action of MAO inhibitors.
J Neural Transm Suppl. 1987;25:15-25.
PMID: 3480938 [PubMed - indexed for MEDLINE]

104: Johnston KM, Connolly JA, van der Kooy D. Related Articles, Links

Inhibition of axonal transport 'in vivo' by a tubulin-specific antibody.
Brain Res. 1986 Oct 15;385(1):38-45.
PMID: 2429735 [PubMed - indexed for MEDLINE]

105: Kalivas PW, Richardson-Carlson R, Duffy P. Related Articles, Links

Neuromedin N mimics the actions of neurotensin in the ventral tegmental area but not in the nucleus accumbens.
J Pharmacol Exp Ther. 1986 Sep;238(3):1126-31.
PMID: 3755755 [PubMed - indexed for MEDLINE]

106: Johnson CD, Epstein ML. Related Articles, Links

Monoclonal antibodies and polyvalent antiserum to chicken choline acetyltransferase.
J Neurochem. 1986 Mar;46(3):968-76.
PMID: 3512775 [PubMed - indexed for MEDLINE]

107: Danger JM, Guy J, Benyamina M, Jegou S, Leboulenger F, Cote J, Tonon MC, Pelletier G, Vaudry H. Related Articles, Links

Localization and identification of neuropeptide Y (NPY)-like immunoreactivity in the frog brain.
Peptides. 1985 Nov-Dec;6(6):1225-36.
PMID: 3914637 [PubMed - indexed for MEDLINE]

108: Kalivas PW. Related Articles, Links

Interactions between neuropeptides and dopamine neurons in the ventromedial mesencephalon.
Neurosci Biobehav Rev. 1985 Winter;9(4):573-87. Review.
PMID: 2417173 [PubMed - indexed for MEDLINE]

109: Kanazawa I, Ogawa T, Kimura S, Munekata E. Related Articles, Links

Regional distribution of substance P, neurokinin alpha and neurokinin beta in rat central nervous system.
Neurosci Res. 1984 Dec;2(1-2):111-20.
PMID: 6085650 [PubMed - indexed for MEDLINE]

110: Jeserich G. Related Articles, Links

Protein analysis of myelin isolated from the CNS of fish: developmental

and species comparisons.
Neurochem Res. 1983 Aug;8(8):957-70.
PMID: 6621780 [PubMed - indexed for MEDLINE]

111: Bauer HJ. Related Articles, Links

[Controversial MS therapy]
Nervenarzt. 1983 Aug;54(8):400-5. German. No abstract available.
PMID: 6194441 [PubMed - indexed for MEDLINE]

112: Kolata G. Related Articles, Links

Monkey model of Parkinson's disease.
Science. 1983 May 13;220(4598):705. No abstract available.
PMID: 6403987 [PubMed - indexed for MEDLINE]

113: Christofides ND, McGregor GP, Woodhams PL, Yiangou Y, Aarons E, Tatemoto K, Bloom SR. Related Articles, Links

Ontogeny of PHI in the rat brain.
Brain Res. 1983 Apr 4;264(2):359-61.
PMID: 6687824 [PubMed - indexed for MEDLINE]

114: Hallberg JW, Draper DD, Topel DG, Altrogge DM. Related Articles, Links

Neural catecholamine deficiencies in the porcine stress syndrome.
Am J Vet Res. 1983 Mar;44(3):368-71.
PMID: 6838032 [PubMed - indexed for MEDLINE]

115: Higgins RJ, Rings DM, Fenner WR, Stevenson S. Related Articles, Links

Spontaneous lower motor neuron disease with neurofibrillary accumulation in young pigs.
Acta Neuropathol (Berl). 1983;59(4):288-94.
PMID: 6683455 [PubMed - indexed for MEDLINE]

116: Xie GX, Han JS, Hollt V. Related Articles, Links

Electroacupuncture analgesia blocked by microinjection of anti-beta-endorphin antiserum into periaqueductal gray of the rabbit.
Int J Neurosci. 1983;18(3-4):287-91.
PMID: 6305863 [PubMed - indexed for MEDLINE]

117: Wawrzyniak M, Cybulska R, Radymska-Wawrzyniak K. Related Articles, Links

Activity of acetylcholine hydrolase (EC 3.1.1.7) in the pig brain; spectrophotometric and histochemical studies in the light and electron microscope.
Folia Histochem Cytochem (Krakow). 1980;18(2):113-22.
PMID: 7450601 [PubMed - indexed for MEDLINE]

118: Stoeter P, Schmidt-Lademann S, Voigt K. Related Articles, Links

Embryonal and fetal development of capillaries: microangiographic investigations. I. The brain stem.
Diagn Imaging. 1980;49(3):131-40.
PMID: 7389571 [PubMed - indexed for MEDLINE]

119: Bosin TR, Jonsson G, Beck O. Related Articles, Links

On the occurrence of 5-methoxytryptamine in brain.
Brain Res. 1979 Sep 7;173(1):79-88.
PMID: 290404 [PubMed - indexed for MEDLINE]

120: Stoeter P, Schmidt-Lademann S, Voigt K. Related Articles, Links

Comparative microangiographic and histologic studies of the embryonal development of intracerebral capillaries.

Neuroradiology. 1978;16:620-4.
PMID: 745777 [PubMed - indexed for MEDLINE]

121: Opolon P, Rapin JR, Huguet C, Granger A, Delorme ML, Boschat M, Sausse A. Related Articles, Links

Hepatic failure coma (HFC) treated by polyacrylonitrile membrane (PAN) hemodialysis (HD).
Trans Am Soc Artif Intern Organs. 1976;22:701-10. No abstract available.
PMID: 781986 [PubMed - indexed for MEDLINE]

122: Monlux VS, McKercher PD, Graves JH. Related Articles, Links

Brain and spinal cord lesions in pigs inoculated with swine vesicular disease (UKG strain) virus and coxsackievirus B5.
Am J Vet Res. 1975 Dec;36(12):1745-9.
PMID: 128305 [PubMed - indexed for MEDLINE]

123: Knutsen P, Stanton HC, Shirachi DY. Related Articles, Links

A regional study of acetylcholinesterase in pig brain.
Proc West Pharmacol Soc. 1975;18:78-80. No abstract available.
PMID: 1178713 [PubMed - indexed for MEDLINE]

124: Kuzemensky J. Related Articles, Links

Contribution to the structure of the subthalamic nucleus in the rat.
Folia Morphol (Praha). 1975;23(3):182-96. No abstract available.
PMID: 808462 [PubMed - indexed for MEDLINE]

125: Kruska D, Rohrs M. Related Articles, Links

Comparative--quantitative investigations on brains of feral pigs from the Galapagos Islands and of European domestic pigs.
Z Anat Entwicklungsgesch. 1974 Jul 5;144(1):61-73. No abstract available.
PMID: 4851103 [PubMed - indexed for MEDLINE]

126: Haas E, Goldblatt H, Rowland V, Vrtunski P. Related Articles, Links

Neurogenic pressor response due to mesencephalic electrical stimulation--effect of blockade of renin-angiotensin system.
Am J Physiol. 1974 Apr;226(4):771-5. No abstract available.
PMID: 4362802 [PubMed - indexed for MEDLINE]

127: Polak JM, Pearse AG, Le Lievre C, Fontaine J, Le Douarin NM. Related Articles, Links

Immunocytochemical confirmation of the neural crest origin of avian calcitonin-producing cells.
Histochemistry. 1974;40(3):209-14. No abstract available.
PMID: 4604566 [PubMed - indexed for MEDLINE]

128: Freund E. Related Articles, Links

[Myeloarchitecture of the mesencephalon in the domestic swine (Sus scrofa domestica)]
Anat Anz. 1973;134(5):445-59. German. No abstract available.
PMID: 4207344 [PubMed - indexed for MEDLINE]

129: Karamanlidis AN, Magras J. Related Articles, Links

Retinal projections in domestic ungulates. I. The retinal projections in the sheep and the pig.
Brain Res. 1972 Sep 15;44(1):127-45. No abstract available.
PMID: 5056972 [PubMed - indexed for MEDLINE]

130: Cheng KW, Martin JB, Friesen HG. Related Articles, Links

Studies of neurophysin release.

Endocrinology. 1972 Jul;91(1):177-84. No abstract available.
PMID: 5063542 [PubMed - indexed for MEDLINE]

131: Gootman N, Gootman PM, Buckley NM, Cohen MI, Levine M, Spielberg R. Related Articles, Links

Central vasomotor regulation in the newborn piglet Sus scrofa.
Am J Physiol. 1972 Apr;222(4):994-9. No abstract available.
PMID: 5027111 [PubMed - indexed for MEDLINE]

132: Khalaf F, Robinson DW. Related Articles, Links

Aphagia and adipsia in pigs with induced hypothalamic lesions.
Res Vet Sci. 1972 Jan;13(1):5-7. No abstract available.
PMID: 5017824 [PubMed - indexed for MEDLINE]

133: Kruska D. Related Articles, Links

[Volumetric comparison of various visual centers in the brains of wild boars and domestic pigs]
Z Anat Entwicklungsgesch. 1972;138(3):265-82. German. No abstract available.
PMID: 4659110 [PubMed - indexed for MEDLINE]

134: Srebro Z. Related Articles, Links

Gomori positive glia and ependymosecretion in mammals.
Folia Biol (Krakow). 1972;20(4):363-8. No abstract available.
PMID: 4122650 [PubMed - indexed for MEDLINE]

135: George RE, Chaput RL, Verrelli DM, Barron EL. Related Articles, Links

The relative effectiveness of fission neutrons for miniature pig performance decrement.
Radiat Res. 1971 Nov;48(2):332-45. No abstract available.
PMID: 5115772 [PubMed - indexed for MEDLINE]

136: Swiatek KR, Streeter DG, Simon LN. Related Articles, Links

Transfer ribonucleic acid methylase activity in the developing pig brain.
Biochemistry. 1971 Jun 22;10(13):2563-7. No abstract available.
PMID: 4934114 [PubMed - indexed for MEDLINE]

137: Bortolami R, Palmieri G, Callegari E. Related Articles, Links

Degenerated nerve fibres within trigeminal branches following trigeminal root cutting in some mammals.
Sperimentale. 1971 Jan-Feb;121(1):39-47. No abstract available.
PMID: 5172998 [PubMed - indexed for MEDLINE]

138: Campos-Ortega JA. Related Articles, Links

The distribution of retinal fibres in the brain of the pig.
Brain Res. 1970 Apr 14;19(2):306-12. No abstract available.
PMID: 5432213 [PubMed - indexed for MEDLINE]

139: Philippu A, Heyd W. Related Articles, Links

Release of dopamine from subcellular particles of the striatum.
Life Sci. 1970 Apr;9(7):361-73. No abstract available.
PMID: 5444014 [PubMed - indexed for MEDLINE]

140: Otabe JS, Horowitz A. Related Articles, Links

Morphology and cytoarchitecture of the red nucleus of the domestic pig (Sus scrofa).
J Comp Neurol. 1970 Mar;138(3):373-89. No abstract available.
PMID: 4986159 [PubMed - indexed for MEDLINE]

Mikulski T. Related Articles, Links

h cb h g e e e fcg e ch b e

141:

[Electron spin resonance (ESR) and infrared spectra of eye melanin and of the pigment in substantia nigra]
Acta Physiol Pol. 1970 Mar-Apr;21(2):219-25. Polish. No abstract available.
PMID: 4319204 [PubMed - indexed for MEDLINE]

142: Kruska D. Related Articles, Links

[Comparative cytoarchitectonic investigations in brains of wild and domestic pigs]
Z Anat Entwicklungsgesch. 1970;131(4):291-324. German. No abstract available.
PMID: 5471597 [PubMed - indexed for MEDLINE]

143: Wong PY, Fritze K. Related Articles, Links

Determination by neutron activation of copper, manganese, and zinc in the pineal body and other areas of brain tissue.
J Neurochem. 1969 Aug;16(8):1231-4. No abstract available.
PMID: 5803798 [PubMed - indexed for MEDLINE]

144: Engler E, Urbaneck D. Related Articles, Links

[The diagnostic significance of histopathologic changes in the central nervous system in runted store swine after swine fever infection]
Arch Exp Veterinarmed. 1969;23(6):1163-82. German. No abstract available.
PMID: 5384473 [PubMed - indexed for MEDLINE]

145: Freund E. Related Articles, Links

[Topography of various nuclear areas in the mesencephalon of Sus scrofa domestica]
Verh Anat Ges. 1969;63:649-54. German. No abstract available.
PMID: 5378557 [PubMed - indexed for MEDLINE]

146: Freund E. Related Articles, Links

[Ctyoarchitecture of sagittal sections of the mesencephalon of domestic swines (Sus scrofa domestica)]
Anat Anz. 1969;125(5):539-48. German. No abstract available.
PMID: 4913397 [PubMed - indexed for MEDLINE]

147: Freund E. Related Articles, Links

[Cytoarchitectonics of the mesencephalon and pons in the domestic pig (Sus scrofa domestica)]
Anat Anz. 1969;125(4):345-62. German. No abstract available.
PMID: 4903679 [PubMed - indexed for MEDLINE]

148: Neims AH, Zieverink WD, Smilack JD. Related Articles, Links

Distribution of D-amino acid oxidase in bovine and human nervous tissues.
J Neurochem. 1966 Mar;13(3):163-8. No abstract available.
PMID: 4380208 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

1: Exp Brain Res. 1989;77(2):329-36.

Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease.

Huffaker TK, Boss BD, Morgan AS, Neff NT, Strecker RE, Spence MS, Miao R.

Hana Biologics, Inc., Alameda, CA 94501.

A suspension of cells from embryonic day 21 fetal pig ventral mesencephalon was transplanted into the striatum of 20 immunosuppressed rats with 6-hydroxydopamine-induced lesions of the nigrostriatal dopamine pathway. Of these rats, 15 showed reduction of amphetamine-induced ipsilateral rotation by 9 weeks and complete reversal of rotation by 14-17 weeks. Animals maintained stable reversal of rotations (contralateral direction) until cessation of Cyclosporin A (CyA) treatment at 15-20 weeks. Within 4-9 weeks after CyA removal, these rats showed exclusively ipsilateral rotations during behavioral testing which were comparable to pre-transplant levels, suggesting that the grafts were rejected upon cessation of CyA treatment. Rats were sacrificed and tyrosine hydroxylase (TH) immunohistochemistry was performed at several time points, both on and off CyA, to examine a possible correlation between the degree of rotational behavior and the number of TH-positive surviving grafted cells. Staining showed large numbers (230-12,329) of TH-positive surviving cells in animals displaying a high degree of rotational correction (1.6 to -9.6 net ipsilateral rotations/min) after cessation of CyA treatment. Two control groups, those transplanted with non-neuronal cells from the pig ventral mesencephalon (n = 5) and those receiving only daily CyA injections (n = 4) showed no significant reduction of net ipsilateral rotations throughout the experiment. No TH-positive surviving cells were seen in the one non-neuronal transplant analyzed. This data demonstrates long-term retention of xenografted tissue with immunosuppression and its concomitant restoration of normal motor behavior in the rat model of Parkinson's disease.

PMID: 2571515 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg c e e e b b e b c

1: Exp Neurol. 1996 Jul;140(1):1-13.

Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology.

Galpern WR, Burns LH, Deacon TW, Dinsmore J, Isacson O.

Neurogeneration Laboratory, McLean Hospital, Harvard Medical School, Massachusetts 02178, USA.

Neurotransplantation of human fetal dopamine (DA) neurons is currently being investigated as a therapeutic modality for Parkinson's disease (PD). However, the practical limitations of human fetal transplantation indicate a need for alternative methodologies. Using the 6-hydroxydopamine rat model of PD, we transplanted dopaminergic neurons derived from Embryonic Day 27 porcine fetuses into the denervated striatum of cyclosporine-A (CyA)-treated or non-CyA-treated rats. Functional recovery was assessed by amphetamine-induced rotation, and graft survival and morphology were analyzed using neuronal and glial immunostaining as well as in situ hybridization with a porcine repeat element DNA probe. A significant, sustained reduction in amphetamine-induced rotational asymmetry was present in the CyA-treated rats whereas the non-CyA-treated rats showed a transient behavioral recovery. The degree of rotational recovery was highly correlated to the number of surviving transplanted porcine dopaminergic neurons. TH+ neuronal survival and graft volume were significantly greater in the CyA-treated group as compared to the non-CyA group. By donor-specific neuronal and glial immunostaining as well as donor-specific DNA labeling, we demonstrate that porcine fetal neuroblasts are able to survive in the adult brain of immunosuppressed rats, mediate functional recovery, and extensively reinnervate the host striatum. These findings suggest that porcine DA neurons may be a suitable alternative to the use of human fetal tissue in neurotransplantation for PD.

PMID: 8682173 [PubMed - indexed for MEDLINE]

Ontogenesis of embryonic porcine ventral mesencephalon in the perspective of its potential use as a xenograft in Parkinson's disease.

Molenaar GJ, Hogenesch RI, Sprengers ME, Staal MJ.

Department of Functional Morphology, Faculty of Veterinary Medicine, University of Utrecht, The Netherlands. w.a.weijs@pobox.ruu.nl

Human fetal neural dopaminergic tissue can be transplanted and can ameliorate neurological deficiencies in patients with Parkinson's disease (PD). Donor tissue from other species has been used experimentally for several years in animal experiments and is now being considered an attractive alternative, particularly from a donor species that breeds in large litters, e.g., the pig. We have studied the early ontogenetic development of the mesencephalic dopaminergic system in the pig, utilising an anti-tyrosine hydroxylase (TH) immunocytochemical technique, and demonstrated the earliest appearance of its cell bodies at embryonic day 20 (E20). We compared the porcine data with those of human fetal development, as revealed by the same technique. Embryonic dopaminergic cell groups resembling the A8, A9, and A10 of the rat are present in the pig and differentiate into the homologous cell groups of human, although interesting quantitative differences are apparent. In the pig, prolonged presence of immature characteristics of TH-immunoreactive (TH-i.r.) cell bodies was observed, notwithstanding the early outgrowth of TH-i.r. axons into the ganglionic eminence. In the human, on the other hand, cell divisions and maturation of dendrites have progressed to a further degree than in the pig, before such distinct outgrowth of axons takes place. In pig embryos of 28 days, cells in the ventral mesencephalon had differentiated into TH containing neurons, which indicates their potential to synthesize dopamine. In spite of their differentiation, these cells still showed immature morphological features (rounded cell bodies with undifferentiated, short processes). Dopamine synthesis by these cells was demonstrated in previous studies by the high performance liquid chromatographic technique (HogenEsch et al. [1993] Can. J. Neurol. Sci. 20(suppl. 4):P.S. 235). In a separate paper, we have described that these porcine 28-day dopaminergic cells retain their potential for development and outgrowth in culture (van Roon et al. [1995] Res. Neurol. Neurosci. 7:199-205). We conclude that the ventral mesencephalon in pig embryos of 28 days is a potential source of dopaminergic neurons to be used as a xenograft in PD.

Items 1-81 of 81 One page.

1: Wiegrebe L, Meddis R. Related Articles, Links

The representation of periodic sounds in simulated sustained chopper units of the ventral cochlear nucleus.
J Acoust Soc Am. 2004 Mar;115(3):1207-18.
PMID: 15058342 [PubMed - indexed for MEDLINE]

2: Larsson LC, Corbascio M, Pearson TC, Larsen CP, Ekberg H, Widner H. Related Articles, Links

Induction of operational tolerance to discordant dopaminergic porcine xenografts.
Transplantation. 2003 May 15;75(9):1448-54.
PMID: 12792495 [PubMed - indexed for MEDLINE]

3: Armstrong RJ, Tyers P, Jain M, Richards A, Dunnett SB, Rosser AE, Barker RA. Related Articles, Links

Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease.
Exp Brain Res. 2003 Jul;151(2):204-17. Epub 2003 Jun 03.
PMID: 12783147 [PubMed - indexed for MEDLINE]

4: Dall AM, Danielsen EH, Sorensen JC, Andersen F, Moller A, Zimmer J, Gjedde AH, Cumming P; Danish Neuronal Xenografting Group. Related Articles, Links

Quantitative [18F]fluorodopa/PET and histology of fetal mesencephalic dopaminergic grafts to the striatum of MPTP-poisoned minipigs.
Cell Transplant. 2002;11(8):733-46.
PMID: 12588105 [PubMed - indexed for MEDLINE]

5: Bauer M, Meyer M, Brevig T, Gasser T, Widmer HR, Zimmer J, Ueffing M. Related Articles, Links

Lipid-mediated glial cell line-derived neurotrophic factor gene transfer to cultured porcine ventral mesencephalic tissue.
Exp Neurol. 2002 Sep;177(1):40-9.
PMID: 12429209 [PubMed - indexed for MEDLINE]

6: Cicchetti F, Costantini L, Belizaire R, Burton W, Isacson O, Fodor W. Related Articles, Links

Combined inhibition of apoptosis and complement improves neural graft survival of embryonic rat and porcine mesencephalon in the rat brain.
Exp Neurol. 2002 Oct;177(2):376-84.
PMID: 12429184 [PubMed - indexed for MEDLINE]

7: Jacoby DB, Lindberg C, Ratliff J, Wetzel K, Stewart GR, Dinsmore J. Related Articles, Links

Comparison of fresh and cryopreserved porcine ventral mesencephalon cells transplanted in A rat model of Parkinson's disease.
J Neurosci Res. 2002 Aug 1;69(3):382-96.
PMID: 12125079 [PubMed - indexed for MEDLINE]

8: Chen BT, Rice ME. Related Articles, Links

Synaptic regulation of somatodendritic dopamine release by glutamate and GABA differs between substantia nigra and ventral tegmental area.
J Neurochem. 2002 Apr;81(1):158-69.
PMID: 12067228 [PubMed - indexed for MEDLINE]

9: Koopmans J, HogenEsch I, Copray S, Middel B, van Dijk H, Go KG, Staal M. Related Articles, Links

Cryopreservation of porcine fetal ventral mesencephalic tissue for intrastriatal transplantation in Parkinson's disease.
Cell Transplant. 2001;10(7):573-81.
PMID: 11714191 [PubMed - indexed for MEDLINE]

10: Larsson LC, Frielingsdorf H, Mirza B, Hansson SJ, Anderson P, Czech KA, Strandberg M, Widner H. Related Articles, Links

Porcine neural xenografts in rats and mice: donor tissue development and characteristics of rejection.
Exp Neurol. 2001 Nov;172(1):100-14.
PMID: 11681844 [PubMed - indexed for MEDLINE]

11: Neuert V, Pressnitzer D, Patterson RD, Winter IM. Related Articles, Links

The responses of single units in the inferior colliculus of the guinea pig to damped and ramped sinusoids.
Hear Res. 2001 Sep;159(1-2):36-52.
PMID: 11520633 [PubMed - indexed for MEDLINE]

12: Larsson LC, Anderson P, Widner H, Korsgrent O. Related Articles, Links

Enhanced survival of porcine neural xenografts in mice lacking CD1d1, but no effect of NK1.1 depletion.
Cell Transplant. 2001;10(3):295-304.
PMID: 11437075 [PubMed - indexed for MEDLINE]

13: Subramanian T. Related Articles, Links

Cell transplantation for the treatment of Parkinson's disease.
Semin Neurol. 2001;21(1):103-15. Review.
PMID: 11346020 [PubMed - indexed for MEDLINE]

14: Brevig T, Meyer M, Kristensen T, Zimmer J. Related Articles, Links

Neural xenotransplantation: pretreatment of porcine embryonic nigral tissue with anti-Gal antibodies and complement is not toxic for the dopaminergic neurons.
Cell Transplant. 2001 Jan-Feb;10(1):25-30.
PMID: 11294468 [PubMed - indexed for MEDLINE]

15: Cragg SJ, Nicholson C, Kume-Kick J, Tao L, Rice ME. Related Articles, Links

Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake.
J Neurophysiol. 2001 Apr;85(4):1761-71.
PMID: 11287497 [PubMed - indexed for MEDLINE]

16: Dinsmore JH, Manhart C, Raineri R, Jacoby DB, Moore A. Related Articles, Links

No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells.
Transplantation. 2000 Nov 15;70(9):1382-9.
PMID: 11087157 [PubMed - indexed for MEDLINE]

17: HogenEsch RI, Koopmans J, Copray JC, van Roon WM, Kema I, Molenaar G, Go KG, Staal MJ. Related Articles, Links

Fetal porcine ventral mesencephalon graft. Determination of the optimal gestational age for implantation in parkinsonian patients.
Exp Brain Res. 2000 Jun;132(3):345-50.
PMID: 10883382 [PubMed - indexed for MEDLINE]

18: Meyer M, Johansen J, Gramsbergen JB, Johansen TE, Zimmer J. Related Articles, Links

Improved survival of embryonic porcine dopaminergic neurons in coculture with a conditionally immortalized GDNF-producing hippocampal cell line.
Exp Neurol. 2000 Jul;164(1):82-93.
PMID: 10877918 [PubMed - indexed for MEDLINE]

19: Mihaly A, Endresz V. Related Articles, Links

Neuronal expression of Raf protooncogene in the brain stem of adult guinea pig.
Acta Histochem. 2000 May;102(2):203-17.
PMID: 10824613 [PubMed - indexed for MEDLINE]

20: Larsson LC, Czech KA, Brundin P, Widner H. Related Articles, Links

Intrastriatal ventral mesencephalic xenografts of porcine tissue in rats: immune responses and functional effects.
Cell Transplant. 2000 Mar-Apr;9(2):261-72.
PMID: 10811398 [PubMed - indexed for MEDLINE]

21: Barker RA, Ratcliffe E, McLaughlin M, Richards A, Dunnett SB. Related Articles, Links

A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease.
J Neurosci. 2000 May 1;20(9):3415-24.
PMID: 10777804 [PubMed - indexed for MEDLINE]

22: Sumitran S, Anderson P, Widner H, Holgersson J. Related Articles, Links

Porcine embryonic brain cell cytotoxicity mediated by human natural killer cells.
Cell Transplant. 1999 Nov-Dec;8(6):601-10.
PMID: 10701489 [PubMed - indexed for MEDLINE]

23: Barker RA, Ratcliffe E, Richards A, Dunnett SB. Related Articles, Links

Fetal porcine dopaminergic cell survival in vitro and its relationship to embryonic age.
Cell Transplant. 1999 Nov-Dec;8(6):593-9.
PMID: 10701488 [PubMed - indexed for MEDLINE]

24: Larsson LC, Czech KA, Widner H, Korsgren O. Related Articles, Links

Discordant neural tissue xenografts survive longer in immunoglobulin deficient mice.
Transplantation. 1999 Oct 27;68(8):1153-60.
PMID: 10551645 [PubMed - indexed for MEDLINE]

25: Sumitran S, Liu J, Czech KA, Christensson B, Widner H, Holgersson J. Related Articles, Links

Human natural antibodies cytotoxic to pig embryonic brain cells recognize novel non-Galalpha1,3Gal-based xenoantigens.
Exp Neurol. 1999 Oct;159(2):347-61.
PMID: 10506507 [PubMed - indexed for MEDLINE]

26: Larsson LC, Duan WM, Widner H. Related Articles, Links

Discordant xenografts: different outcome after mouse and rat neural tissue

transplantation to guinea-pigs.
Brain Res Bull. 1999 Jul 15;49(5):367-76.
PMID: 10452358 [PubMed - indexed for MEDLINE]

27: McLeod JL, Donald JA. Related Articles, Links

Relationship between arginine vasotocin-like and natriuretic peptide-like immunoreactive structures in the brain of the toad Bufo marinus.
Cell Tissue Res. 1999 Jul;297(1):47-55.
PMID: 10398882 [PubMed - indexed for MEDLINE]

28: Gueudet C, Santucci V, Soubrie P, Le Fur G. Related Articles, Links

Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs.
Synapse. 1999 Jul;33(1):71-9.
PMID: 10380852 [PubMed - indexed for MEDLINE]

29: Suneja SK, Benson CG, Potashner SJ. Related Articles, Links

Glycine receptors in adult guinea pig brain stem auditory nuclei: regulation after unilateral cochlear ablation.
Exp Neurol. 1998 Dec;154(2):473-88.
PMID: 9878183 [PubMed - indexed for MEDLINE]

30: Marco N, Thirion A, Mons G, Bougault I, Le Fur G, Soubrie P, Steinberg R. Related Articles, Links

Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig.
Neuropeptides. 1998 Oct;32(5):481-8.
PMID: 9845011 [PubMed - indexed for MEDLINE]

31: Othberg AI, Willing AE, Saporta S, Cameron DF, Sanberg PR. Related Articles, Links

Preparation of cell suspensions for co-transplantation: methodological considerations.
Neurosci Lett. 1998 May 15;247(2-3):111-4.
PMID: 9655605 [PubMed - indexed for MEDLINE]

32: Othberg AI, Willing AE, Cameron DF, Anton A, Saporta S, Freeman TB, Sanberg PR. Related Articles, Links

Trophic effect of porcine Sertoli cells on rat and human ventral mesencephalic cells and hNT neurons in vitro.
Cell Transplant. 1998 Mar-Apr;7(2):157-64. Erratum in: Cell Transplant 1998 Sep-Oct;7 (5):497.
PMID: 9588597 [PubMed - indexed for MEDLINE]

33: Shore SE, Moore JK. Related Articles, Links

Sources of input to the cochlear granule cell region in the guinea pig.
Hear Res. 1998 Feb;116(1-2):33-42.
PMID: 9508026 [PubMed - indexed for MEDLINE]

34: Cragg SJ, Hawkey CR, Greenfield SA. Related Articles, Links

Comparison of serotonin and dopamine release in substantia nigra and ventral tegmental area: region and species differences.
J Neurochem. 1997 Dec;69(6):2378-86.
PMID: 9375669 [PubMed - indexed for MEDLINE]

35: Molenaar GJ, Hogenesch RI, Sprengers ME, Staal MJ. Related Articles, Links

Ontogenesis of embryonic porcine ventral mesencephalon in the

perspective of its potential use as a xenograft in Parkinson's disease.
J Comp Neurol. 1997 May 26;382(1):19-28.
PMID: 9136809 [PubMed - indexed for MEDLINE]

36: Cameron DL, Wessendorf MW, Williams JT. Related Articles, Links

A subset of ventral tegmental area neurons is inhibited by dopamine, 5-hydroxytryptamine and opioids.
Neuroscience. 1997 Mar;77(1):155-66.
PMID: 9044383 [PubMed - indexed for MEDLINE]

37: Cragg S, Rice ME, Greenfield SA. Related Articles, Links

Heterogeneity of electrically evoked dopamine release and reuptake in substantia nigra, ventral tegmental area, and striatum.
J Neurophysiol. 1997 Feb;77(2):863-73.
PMID: 9065855 [PubMed - indexed for MEDLINE]

38: Rice ME, Cragg SJ, Greenfield SA. Related Articles, Links

Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmental area in vitro.
J Neurophysiol. 1997 Feb;77(2):853-62.
PMID: 9065854 [PubMed - indexed for MEDLINE]

39: Caicedo A, d'Aldin C, Puel JL, Eybalin M. Related Articles, Links

Distribution of calcium-binding protein immunoreactivities in the guinea pig auditory brainstem.
Anat Embryol (Berl). 1996 Nov;194(5):465-87.
PMID: 8905014 [PubMed - indexed for MEDLINE]

40: Galpern WR, Burns LH, Deacon TW, Dinsmore J, Isacson O. Related Articles, Links

Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology.
Exp Neurol. 1996 Jul;140(1):1-13.
PMID: 8682173 [PubMed - indexed for MEDLINE]

41: Malmierca MS, Le Beau FE, Rees A. Related Articles, Links

The topographical organization of descending projections from the central nucleus of the inferior colliculus in guinea pig.
Hear Res. 1996 Apr;93(1-2):167-80.
PMID: 8735077 [PubMed - indexed for MEDLINE]

42: Suneja SK, Benson CG, Gross J, Potashner SJ. Related Articles, Links

Evidence for glutamatergic projections from the cochlear nucleus to the superior olive and the ventral nucleus of the lateral lemniscus.
J Neurochem. 1995 Jan;64(1):161-71.
PMID: 7798910 [PubMed - indexed for MEDLINE]

43: Monassi CR, Hoffmann A, Menescal-de-Oliveira L. Related Articles, Links

Participation of the periaqueductal gray matter in the modulation of tonic immobility in the guinea pig.
Braz J Med Biol Res. 1994 May;27(5):1243-8.
PMID: 8000346 [PubMed - indexed for MEDLINE]

44: Rice ME, Richards CD, Nedergaard S, Hounsgaard J, Nicholson C, Greenfield SA. Related Articles, Links

Direct monitoring of dopamine and 5-HT release in substantia nigra and ventral tegmental area in vitro.
Exp Brain Res. 1994;100(3):395-406.
PMID: 7813678 [PubMed - indexed for MEDLINE]

45: Spector DH, Boss BD, Strecker RE. Related Articles, Links

A model three-dimensional culture system for mammalian dopaminergic precursor cells: application for functional intracerebral transplantation.
Exp Neurol. 1993 Dec;124(2):253-64.
PMID: 7904568 [PubMed - indexed for MEDLINE]

46: Thompson AM, Thompson GC. Related Articles, Links

Relationship of descending inferior colliculus projections to olivocochlear neurons.
J Comp Neurol. 1993 Sep 15;335(3):402-12.
PMID: 8227527 [PubMed - indexed for MEDLINE]

47: Turcotte JC, Blaustein JD. Related Articles, Links

Immunocytochemical localization of midbrain estrogen receptor- and progestin receptor-containing cells in female guinea pigs.
J Comp Neurol. 1993 Feb 1;328(1):76-87.
PMID: 8429127 [PubMed - indexed for MEDLINE]

48: Shneiderman A, Chase MB, Rockwood JM, Benson CG, Potashner SJ. Related Articles, Links

Evidence for a GABAergic projection from the dorsal nucleus of the lateral lemniscus to the inferior colliculus.
J Neurochem. 1993 Jan;60(1):72-82.
PMID: 8380198 [PubMed - indexed for MEDLINE]

49: Ostergaard K, Holm IE, Zimmer J. Related Articles, Links

Tyrosine hydroxylase and acetylcholinesterase in the domestic pig mesencephalon: an immunocytochemical and histochemical study.
J Comp Neurol. 1992 Aug 8;322(2):149-66.
PMID: 1355778 [PubMed - indexed for MEDLINE]

50: Schofield BR, Cant NB. Related Articles, Links

Organization of the superior olivary complex in the guinea pig: II. Patterns of projection from the periolivary nuclei to the inferior colliculus.
J Comp Neurol. 1992 Mar 22;317(4):438-55.
PMID: 1578006 [PubMed - indexed for MEDLINE]

51: Corvisier J, Hardy O. Related Articles, Links

Possible excitatory and inhibitory feedback to the superior colliculus: a combined retrograde and immunocytochemical study in the prepositus hypoglossi nucleus of the guinea pig.
Neurosci Res. 1991 Dec;12(4):486-502.
PMID: 1724558 [PubMed - indexed for MEDLINE]

52: Arai R, Winsky L, Arai M, Jacobowitz DM. Related Articles, Links

Immunohistochemical localization of calretinin in the rat hindbrain.
J Comp Neurol. 1991 Aug 1;310(1):21-44.
PMID: 1939729 [PubMed - indexed for MEDLINE]

53: Staiger JF, Nurnberger F. Related Articles, Links

The efferent connections of the lateral septal nucleus in the guinea pig: projections to the diencephalon and brainstem.
Cell Tissue Res. 1991 Jun;264(3):391-413.
PMID: 1868517 [PubMed - indexed for MEDLINE]

54: Benson CG, Chase MC, Potashner SJ. Related Articles, Links

Decreased release of D-aspartate in the guinea pig spinal cord after lesions

h cb h g e e e fcg e ch b e

of the red nucleus.
J Neurochem. 1991 Apr;56(4):1174-83.
PMID: 2002335 [PubMed - indexed for MEDLINE]

55: Shore SE, Helfert RH, Bledsoe SC Jr, Altschuler RA, Godfrey DA. Related Articles, Links

Descending projections to the dorsal and ventral divisions of the cochlear nucleus in guinea pig.
Hear Res. 1991 Mar;52(1):255-68.
PMID: 1648060 [PubMed - indexed for MEDLINE]

56: Sanchez D, Ribas J. Related Articles, Links

Properties and ionic basis of the action potentials in the periaqueductal grey neurones of the guinea-pig.
J Physiol. 1991;440:167-87.
PMID: 1804959 [PubMed - indexed for MEDLINE]

57: Schalling M, Friberg K, Seroogy K, Riederer P, Bird E, Schiffmann SN, Mailleux P, Vanderhaeghen JJ, Kuga S, Goldstein M, et al. Related Articles, Links

Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia.
Proc Natl Acad Sci U S A. 1990 Nov;87(21):8427-31.
PMID: 1978324 [PubMed - indexed for MEDLINE]

58: Ciofi P, Tramu G. Related Articles, Links

Distribution of cholecystokinin-like-immunoreactive neurons in the guinea pig forebrain.
J Comp Neurol. 1990 Oct 1;300(1):82-112.
PMID: 2229489 [PubMed - indexed for MEDLINE]

59: Smits RP, Steinbusch HW, Mulder AH. Related Articles, Links

Distribution of dopamine-immunoreactive cell bodies in the guinea-pig brain.
J Chem Neuroanat. 1990 Mar-Apr;3(2):101-23.
PMID: 2340115 [PubMed - indexed for MEDLINE]

60: Sharif NA, Hughes J. Related Articles, Links

Discrete mapping of brain Mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors.
Peptides. 1989 May-Jun;10(3):499-522.
PMID: 2550910 [PubMed - indexed for MEDLINE]

61: Millhorn DE, Hokfelt T, Verhofstad AA, Terenius L. Related Articles, Links

Individual cells in the raphe nuclei of the medulla oblongata in rat that contain immunoreactivities for both serotonin and enkephalin project to the spinal cord.
Exp Brain Res. 1989;75(3):536-42.
PMID: 2744110 [PubMed - indexed for MEDLINE]

62: Huffaker TK, Boss BD, Morgan AS, Neff NT, Strecker RE, Spence MS, Miao R. Related Articles, Links

Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease.
Exp Brain Res. 1989;77(2):329-36.
PMID: 2571515 [PubMed - indexed for MEDLINE]

63: Tokunaga A. Related Articles, Links

Superior olivary and lateral lemniscal neurons projecting to the cochlea in the guinea pig.
Neurosci Res. 1988 Oct;6(1):20-30.
PMID: 2462200 [PubMed - indexed for MEDLINE]

64: Obrocki J, Borroni E. Related Articles, Links

Immunocytochemical evaluation of a cholinergic-specific ganglioside antigen (Chol-1) in the central nervous system of the rat.
Exp Brain Res. 1988;72(1):71-82.
PMID: 3169197 [PubMed - indexed for MEDLINE]

65: Carlile S, Pettigrew AG. Related Articles, Links

Distribution of frequency sensitivity in the superior colliculus of the guinea pig.
Hear Res. 1987 Dec;31(2):123-36.
PMID: 3446670 [PubMed - indexed for MEDLINE]

66: Strutz J. Related Articles, Links

[Anatomy of the central auditory pathway. Demonstration with horseradish peroxidase in the guinea pig]
HNO. 1987 Oct;35(10):407-15. German.
PMID: 3679895 [PubMed - indexed for MEDLINE]

67: Thompson GC, Cortez AM, Lam DM. Related Articles, Links

Localization of GABA immunoreactivity in the auditory brainstem of guinea pigs.
Brain Res. 1985 Jul 22;339(1):119-22.
PMID: 3896399 [PubMed - indexed for MEDLINE]

68: Taber-Pierce E, Lichtenstein E, Feldman SC. Related Articles, Links

The somatostatin systems of the guinea-pig brainstem.
Neuroscience. 1985 May;15(1):215-35.
PMID: 2861583 [PubMed - indexed for MEDLINE]

69: Warembourg M, Poulain P. Related Articles, Links

Localization of serotonin in the hypothalamus and the mesencephalon of the guinea-pig. An immunohistochemical study using monoclonal antibodies.
Cell Tissue Res. 1985;240(3):711-21.
PMID: 3893722 [PubMed - indexed for MEDLINE]

70: Palacios JM, Wiederhold KH. Related Articles, Links

Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound producing parkinsonism in humans, stimulates [2-14C]deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains.
Brain Res. 1984 May 28;301(1):187-91.
PMID: 6610458 [PubMed - indexed for MEDLINE]

71: Hayakawa T, Zyo K. Related Articles, Links

Comparative anatomical study of the tegmentomammillary projections in some mammals: a horseradish peroxidase study.
Brain Res. 1984 May 23;300(2):335-49.
PMID: 6428701 [PubMed - indexed for MEDLINE]

72: Harrison RV, Palmer AR. Related Articles, Links

Neurone response latency in the inferior colliculus in relation to the